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FOREWORD 
 
A ROT IN HEAVEN 
A POWERFUL INVESTIGATIVE PARTNERSHIP, 
THE OPIOID CRISIS, PILL PROFITS, AND A 
PULITZER PRIZE 
 
Becky L. Jacobs* 
 
“Almost Heaven, West Virginia” 
Bill Danoff, Taffy Nivert, and John Denver1 
“All the host of heaven shall rot away, and the skies roll up like a 
scroll.” 
Isaiah 34:42 
_________________________________ 
In the spring of 2018, when the Tennessee Journal 
of Law and Policy hosted the “Healing Appalachia: The 
Role of Professionals in Solving the Opioid Crisis” 
symposium, there were more than 400 lawsuits pending 
against corporations that manufacture, distribute, and 
retail opioids in just one consolidated case in the federal 
                                               
* Waller Lansden Distinguished Professor of Law, The 
University of Tennessee College of Law. Email: 
jacobs@utk.edu. 
1 Bill Danoff, Taffy Nivert & John Denver, Take Me Home, 
Country Roads (April 12, 1971).  
2 Isaiah 34:4 (English Standard Version). 
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district court for the Northern District of Ohio.3 This 
single, consolidated case initially involved only claims 
brought by governmental entities, but the Judicial Panel 
on Multidistrict Litigation consolidating the cases 
acknowledged that the action potentially could include 
claims brought by individuals, consumers, hospitals, and 
third party payors, as well as additional categories of 
defendants.4  
It is not hyperbole to say that we can thank Eric 
Eyre of the Charleston Gazette-Mail, of Charleston, West 
Virginia, for these lawsuits and for the momentum that 
we now are experiencing in support of a response to the 
national opioid crisis. The government, the legal 
community, and many media outlets seemingly were 
willing to ignore the opiate plague that was infecting our 
communities, but Eric’s Pulitzer Prize-winning series of 
articles5 made it impossible for anyone to profess 
ignorance any longer.  
As lawyers, we also should take pride in the role 
that our colleagues from WVU College of Law, Pat 
McGinley and Suzanne Weise, played in supporting 
Eric’s efforts to uncover the shocking data that appeared 
                                               
3 In re Nat’l Prescription Opiate Litig., MDL No. 1:17-MD-2804 
(N.D. Ohio 2017) [hereinafter “MDL Litigation”]; see also Jan 
Hoffman, Can This Judge Solve the Opioid Crisis?, N.Y. TIMES 
(Mar. 7, 2018), https://www.nytimes.com/2018/03/05/health/ 
opioid-crisis-judge-lawsuits.html [https://perma.cc/H87X-UYN 
W]. 
4 Transfer Order, In re Nat’l Prescription Opiate Litig., MDL 
No. 1:17-MD-2804 (N.D. Ohio Dec. 12, 2017). 
5 Eric also won the Scripps Howard First Amendment Award, 
was a finalist for the Selden Ring awards, and won a first-place 
award for investigative reporting from the Association for 
Healthcare Journalists. See Susan Heavey, Reporter’s Work 
Pushes Regulators, Legislators to Act on Opioids, ASS’N HEALTH 
CARE JOURNALISTS: COVERING HEALTH (May 8, 2017), 
https://healthjournalism.org/blog/2017/05/reporters-work-
pushes-regulators-legislators-to-act-on-opioids/ [https://perma. 
cc/MDV6-FF6W]. 
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in his articles. Without their tireless efforts, Eric may not 
have been able to prevail against the well-financed 
political and industry resistance to accessing the data 
that so starkly revealed the appalling opiate prescription 
and distribution patterns in West Virginia. 
To put the importance of Eric’s contribution, and 
that of Pat and Suzanne, in perspective, consider the 
odds against which they were fighting - and it is critical 
to remember that, at the time Eric, Pat, and Suzanne 
were seeking the distribution data, the only litigation 
pending against any entity or individual involved in the 
opioid distribution chain was the groundbreaking lawsuit 
filed by then-West Virginia Attorney General Darrell 
McGraw in 2012 against Cardinal Health.6 Eric’s 
newspaper, the Gazette-Mail, was a family-owned, daily 
newspaper with a print circulation of 37,000, and Pat and 
Suzanne were providing their services pro bono.  
Thus, the odds were enormous, considering the 
Goliath-like financial resources of their opposition. 
Opioid painkillers are a nearly $9 billion-a-year market 
in the U.S. alone,7 and pharmaceutical companies such 
as Purdue Pharma L.P., Johnson & Johnson, Teva, 
Allergan PLC, and the Endo Health Solutions unit of 
Endo International PLC have all earned billions over the 
years from the sale of these drugs.8 Wholesale 
distributors like McKesson Corp., Cardinal Health, and 
AmerisourceBergen also have profited,9 as have the 
                                               
6 See Records: Company Shipped Millions of Pills to West 
Virginia, ASSOCIATED PRESS (Oct. 09, 2016), https:// 
www.apnews.com/20ed75eba921466aba2155f4a846dc75 
[https://perm a.cc/P624-LN5W]. 
7 Haley Sweetland Edwards, The Drug Cascade, TIME (June 22, 
2017), http://time.com/4828108/the-drug-cascade/ [https://per 
ma.cc/Q9L5-A84S]. 
8 Stock Review: Two-Bagger Collegium Pharmaceutical Surges 
108%, GLOBAL ROUND UP - STOCKS, Mar. 23, 2018. 
9 Katie Tabeling, County Files Lawsuit Against Opioid 
Manufacturers, CECIL WHIG (Elkton, Md.) (Jan. 9, 2018), 
http://www.cecildaily.com/spotlight/county-files-lawsuit-
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physicians, pain clinics, and pharmacies prescribing and 
dispensing these medications - some legitimately, some 
not.10  
These profits, though, have had a very high public 
health cost, as Eric’s articles helped to expose. Here is 
just a snapshot of the scale of what is being called an 
epidemic11 and what President Trump declared, in 
August of 2017, to be a “national emergency.”12 According 
                                               
against-opioid-manufacturers/article_9be21338-13aa-5855-
b8be-caf98167bf5f.html [https://perma.cc/Y2PV-RXFU] 
(“Among the lawsuit’s 20 manu-facturing defendants, 14 are 
subsidiaries of six pharmaceutical giants, including Endo, 
Purdue, Johnson & Johnson, Teva, Allegran [sic] and 
Mallinckrodt Pharmaceuticals. The remaining defendants are 
McKesson, Cardinal Health and AmerisourceBergen -
characterized in the complaint as ‘the big three’ drug wholesale 
distributors.”); see also Joey Garrison, Nashville Sues Opioid 
Makers, THE TENNESSEAN, Dec. 23, 2017, at A5, 
https://www.tennessean. com/story/news/2017/12/23/nashville-
sues-opioid-manufacturers-recoup-costs-fighting-epidemic/ 
978861001/ [https://perma.cc/3CYT-3L8N] (“Cities like 
Nashville and their taxpayers have borne the cost of the opioid 
epidemic for far too long while the pharmaceutical 
manufacturing industry, consisting of manufacturers and 
distributors, has reaped astronomical profits[.]”). 
10 Chris McGreal, ‘It was a Conspiracy’: Recovering Addicts 
Wage Legal Battle over Prescription Use, GUARDIAN (UK) (Aug. 
28, 2016), https://www.theguardian.com/us-news/2016/aug/ 
28/opioid-addiction-west-virginia-lawsuit [https://perma.cc/Z2 
QP-HCJU] (“29 survivors of opioid addiction or relatives of 
those who overdosed on painkillers . . . accuse doctors, 
pharmacies and distributors in a rural corner of West Virginia 
of pushing the powerful and highly addictive drugs, which have 
properties similar to heroin.”). 
11 U.S. DRUG ENF’T AGENCY, 2015 NATIONAL DRUG THREAT 
ASSESSMENT SUMMARY, at iii (2015), https://www.dea.gov/ 
docs/2015%20NDTA%20Report.pdf [https://perma.cc/5USM-
JQJS]. 
12 Joel Achenbach, John Wagner & Lenny Bernstein, Trump 
Says Opioid Crisis is a National Emergency, Pledges More 
10
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to the CDC, more than 200,000 people in the U.S. died 
from overdoses related to prescription opioids from 1999 
to 2016.13 In 2016 alone, more than 46 people died every 
day from overdoses involving prescription opioids.14 Also, 
in 2016, three of the six states with the highest rates of 
death due to drug overdose were located in close 
geographic proximity to Tennessee: West Virginia (52.0 
per 100,000), Ohio (39.1 per 100,000), and Kentucky (33.5 
per 100,000).15 Tennessee’s rate was 24.5.16  
These death rates are startling, but perhaps not 
as surprising as one might first imagine given that 
doctors prescribed enough opioids in 2016 to provide 
every man, woman, and child in the U.S. with 36 pills 
each.17 The highest prescribing rates, however, 
reportedly were concentrated in the more rural states 
that year, primarily in the South; in Tennessee, with the 
second highest prescribing rate in the nation, every 
resident could have had 70 pills each in 2016.18  
The West Virginia numbers were even more 
alarming. Eric’s research revealed that, “[i]n six years, 
                                               
Money and Attention, WASH. POST (Aug. 10, 2017), 
https://www.washingtonpost.com/politics/trump-declares-
opioid-crisis-is-a-national-emergency-pledges-more-money-
and-attention/2017/08/10/5aaaae32-7dfe-11e7-83c7-5bd5460f0 
d7e_story.html [https://perma.cc/GTU6-EMRN]. 
13 CTRS. FOR DISEASE CONTROL & PREVENTION, PRESCRIPTION 
OPIOID OVERDOSE DATA, https://www.cdc.gov/drugoverdose/ 
data/overdose.html [https://perma.cc/6HVX-YYKV]. 
14 Id.  
15 CTRS. FOR DISEASE CONTROL & PREVENTION, Rates, DRUG 
OVERDOSE DEATH DATA, https://www.cdc.gov/drugoverdose/ 
data/statedeaths.html [https://perma.cc/Y7SX-YVZK]. 
16 Id. 
17 PACIRA PHARM., INC., UNITED STATES FOR NON-
DEPENDENCE: AN ANALYSIS OF THE IMPACT OF OPIOID 
OVERPRESCRIBING IN AMERICA 11 (2017), https://www. 
pacira.com/sites/default/files/inline-files/USND_Stats_FINAL. 
pdf [https://perma.cc/JAS3-WDWP]. 
18 Id. at Slides 11-12.  
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drug wholesalers showered the state with 780 million 
hydrocodone and oxycodone pills, while 1,728 West 
Virginians fatally overdosed on those two painkillers[.]”19 
Proportionately, in terms of geographical distribution 
and in terms of population, that “amount[s] to 433 pain 
pills for every man, woman and child in West Virginia.”20 
In that state, the data that Eric secured uncovered a 
dismaying pattern of distribution: small, independent 
pharmacies received a disproportionate percentage of the 
shipments of prescription opioids, e.g., wholesale 
distributors delivered 1.4 million to 4.7 million 
hydrocodone pills each year to locally-owned pharmacies 
in Mingo and Logan counties when one of the busiest 
Wal-Mart’s in West Virginia received only about 5,000 
oxycodone and 9,500 hydrocodone pills annually.21 
The companies involved in the opioid distribution 
chain fought tooth-and-nail to keep these data from being 
released, relying upon an impressive array of legal talent 
to defend them on this issue22 and on the other claims of, 
inter alia, negligence, public nuisance, violations of West 
Virginia’s consumer act, etc. that arose in that ground-
                                               
19 Eric Eyre, Drug Firms Poured 780M Painkillers into WV 
amid Rise of Overdoses, W.V. GAZETTE-MAIL (Dec. 16, 2016), 
https://www.wv gazettemail.com/news/cops_and_courts/drug-
firms-poured-m-painkillers-into-wv-amid-rise-of/article_99026 
dad-8ed5-5075-90fa-adb906a36214.html [https://perma.cc/R38 
M-FFSP].  
20 Id. 
21 Id. 
22 AmerisourceBergen Drug Corp.’s Objection to Hearing Date 
and Opposition to Motion on Behalf of the Charleston Gazette 
to Intervene for the Limited Purpose of Moving the Circuit 
Court to Unseal the Plaintiff’s Second Amended Complaint at 
5, State ex rel. Morrissey v. AmerisourceBergen Drug Corp., 
Civil Action No. 12-C-141 (W. Va. Cir. Ct. 2016) (“And if [the 
DEA] protect[s] any of that information from the intrusive 
journalistic nose of the Gazette, then its confidential nature 
must be respected.”).   
12
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breaking case filed against them in West Virginia.23 
Highly regarded national and West Virginia firms such 
as Jones Day; Morgan Lewis; Steptoe & Johnson; 
Jackson Kelly; Bowles Rice; and Spilman Thomas & 
Battle were involved as defense counsel in the West 
Virginia litigation.24   
Pat, Suzanne, and Boone County, West Virginia 
lawyer Tim Conaway provided essential, legal support to 
the Gazette-Mail to force disclosure of the court records 
that revealed these staggering distribution figures.25 The 
sealed complaint in the State’s lawsuit contained 
shipment data supplied by defendants and the U.S. DEA 
during discovery in the case, and the West Virginia 
Attorney General at that time, Patrick Morrisey,26 and 
                                               
23 Complaint, State ex rel. McGraw v. AmerisourceBergen Drug 
Corp., Civil Action No. 12-C-141, 2012 WL 2544646 (W. Va. Cir. 
Ct. 2012).   
24 See, e.g., Docket, West Virginia v. AmerisourceBergen, Civil 
Action No.  2:12-CV-03760 (Closed Mar. 27, 2013). 
25 See supra note 22. A conversation about these events 
between Pat and Eric took place at an event at Washington & 
Lee at https://livestream.com/wlu/wv-opioid/videos/165654080. 
26 It is not without irony that Morrisey, who is running for the 
U.S. Senate as an anti-opioid warrior, see Ken Blackwell, A 
Clear Choice in WV Senate Battle: Conservative Patrick 
Morrisey, TOWNHALL: OPINION (July 14, 2017), 
https://townhall.com/columnists/kenblackwell/ 2017/07/14/a-
clear-choice-in-wv-senate-battle-conservative-patrick-
morrisey-n2354783 [https://perma.cc/9LD5-JD55], lobbied for 
the Healthcare Distribution Management Association, a group 
that represents drug wholesalers, in Washington, D.C. before 
taking office as West Virginia Attorney General in 2013; 
Cardinal Health is a member of this group. Louis Jacobson, A 
Closer Look at Patrick Morrisey’s Family Ties to ‘Big Pharma’, 
POLITIFACT (Mar. 27, 2018), http://www.politifact.com/truth-o-
meter/article/2018/mar/27/closer-look-patrick-morriseys-
family-ties-big-phar/ [https: //perma.cc/S59G-3MBS]. His wife, 
Denise Henry Morrisey, is a partner with a Washington 
lobbying firm retained by a number of major pharmaceutical 
13
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other plaintiffs apparently agreed with the defendants’ 
arguments that the data were proprietary.27 Pat et al. 
filed a motion on behalf of the Gazette-Mail to unseal the 
complaint, and, despite a vigorous and lengthy fight to 
maintain the confidentiality of the records, the judge 
ordered the first ever public release of these previously-
undisclosed data.28  
The import of this legal event cannot be 
overstated - these data shifted the public discourse on the 
opioid crisis. Opioid abuse was of course on the public 
radar, but opinion did not appear to have moved much 
beyond the “blame the addict” and “those damn pill mills” 
mentality. The data in the lawsuit, however, told stories 
of predatory practices and suffering people in pain, and 
they inspired a sense of outrage and urgency that 
prompted enforcement and reform efforts by regulators 
and legislators.29     
In West Virginia alone, for example, Cardinal 
Health and AmerisourceBergen, two of the nation’s “big 
three” drug wholesalers, agreed to pay the State a 
combined $36 million to settle their lawsuits, and at least 
one county commission has filed suit against all of the 
“big three” to recover costs associated with prescription 
drug abuse, with other West Virginia counties and cities 
declaring their intentions to follow suit.30 Beyond West 
                                               
clients, including several involved in the opioid industry, such 
as Allergan, Johnson & Johnson, Janssen, Purdue Pharma, 
and the membership of the Healthcare Leadership Council; 
e.g., Cardinal, Sanofi, Johnson & Johnson, and Pfizer. Id.  
27 Eric Eyre, Drug Firms Fueled ‘Pill Mills’ in Rural WV, W.V. 
GAZETTE-MAIL (May 23, 2016), https://www.wvgazette 
mail.com/news/cops_and_courts/drug-firms-fueled-pill-mills-
in-rural-wv/article_14c8e1a5-19b1-579d-9ed5-770f09589a22. 
html [https://perma.cc/2B SG-3TFD].  
28 See id. 
29 See Heavey, supra note 5. 
30 Eric Eyre, 2 Drug Distributors to Pay $36M to Settle WV 
Painkiller Lawsuits, W.V. GAZETTE-MAIL (Jan. 9, 2017), 
https://www.wvgazettemail.com/news/health/drug-
14
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Virginia’s borders, nearly every state Attorney General 
has either filed a lawsuit against an opioid manufacturer 
or distributor or is involved in an investigation and has 
issued subpoenas for records.31 The MDL litigation 
consolidated in the Northern District of Ohio currently 
involves 400 cases filed by cities, counties, and states 
against manufacturers and distributors of opiates, but 
those involved have publicly acknowledged the 
possibility that individuals, consumers, hospitals, and 
third party payors might be added as plaintiffs.32 The 
                                               
distributors-to-pay-m-to-settle-wv-painkiller-lawsuits/article_ 
b43534bd-b020-5f56-b9f3-f74270a54c07.html [https://perma. 
cc/AVK9-TB9E].  
31 Jerry Mitchell, Judge: Stop the Legal Fights and Curb the 
Opioid Epidemic, CLARION LEDGER (Jan. 26, 2018), 
https://www.clarion ledger.com/story/news/2018/01/26/opioid-
epidemic-litigation-dan-polster/1014046001/ [https://perma.cc/ 
C7J6-82E9]. Tennessee Attorney General Herbert H. Slatery, 
III, for example, filed a 270-page complaint in the Knox County 
Circuit Court in May of 2018 alleging that Purdue Pharma, 
L.P. violated the Tennessee Consumer Protection Act vis-à-vis 
false, deceptive, and/or unsubstantiated claims about its opioid 
products or opioids in general including OxyContin; that it 
breached a 2007 Agreed Final Judgment with the State 
involving the cessation of sales promotions to prescribers 
whose practices showed indications of abuse or diversion; and 
that it created a public nuisance in Tennessee by significantly 
interfering with the commercial marketplace and endangered 
the life and health of the State's residents. See Tennessee’s 
Motion, Memorandum in Support, and Order Granting Leave 
to File Complaint under Seal, State ex rel. Slatery v. Purdue 
Pharma, L.P., No. 1-173-18 (Tenn. Knox Co. Cir. Ct. 2018), 
https://www.tn.gov/content/dam/tn/attorneygeneral/documents/ 
foi/purdue/purdue-motion-5-15-2018.pdf [https://perma.cc/ 
S8E2-QDQC]. 
32 See supra note 4. The Tennessee Attorney General was not, 
at the time of the publication of this Foreword, a party to the 
federal multidistrict litigation pending in Cleveland, Ohio, but 
that Office has publicly stated that it is “voluntarily engaging 
in settlement discussions” in connection therewith. See Press 
15
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lawsuits involve claims as widely divergent as public 
nuisance, negligence, negligent misrepresentation, 
fraud, and unjust enrichment as well as violations of 
consumer protection laws and the state versions of the 
Controlled Substances Act and RICO statute(s).33  
The pool of defendants is also expanding. For 
example, attributing blame and seeking recovery even 
further afield, several cities in West Virginia brought a 
class action suit against the Joint Commission on 
Accreditation of Health Care Organizations on behalf of 
all U.S. cities and towns.34 The Joint Commission is the 
entity that certifies U.S. health care organizations and 
programs. The suit alleges that the Joint Commission’s 
Pain Management Standards “grossly misrepresented 
the addictive qualities of opioids and fostered dangerous 
pain control practices[.]”35  
Outside of the civil context, prosecutors have 
begun to bring charges against individuals for crimes 
involving opioid abuse and distribution. In 2015, the 
Obama-era U.S. Department of Justice issued a memo 
directing federal prosecutors to pursue charges against 
individual defendants.36 As an example of its use of this 
policy, the DOJ charged John Kapoor, former CEO of 
Insys Therapeutics, with conspiracy to commit 
racketeering and mail and wire fraud in connection with 
a bribe and kickback scheme associated with Subsys, the 
                                               
Release No. 18-10, Tenn. Attorney Gen., No. 18-10:  Tennessee 
Attorney General Sues Purdue Pharma (May 15, 2018), 
https://www.tn.gov/attorneygeneral/news/2018/5/15/pr18-
10.html [https://perma.cc/R459-5ZP4].  
33 Id. 
34 Complaint, City of Charleston v. The Joint Commission, No. 
2:17-cv-04267 (S.D.W.V. Nov. 2, 2017).  
35 Id. at 2.  
36 Memorandum from Deputy Att’y Gen. Sally Q. Yates on 
Individual Accountability for Corporate Wrongdoing (Sept. 9, 
2015), https://www.justice.gov/archives/dag/file/769036/download 
[https://perma.cc/8ARN-NPCS].  
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company’s powerful synthetic opioid fentanyl in spray 
form.37 Closer to home, in early 2017, a Maryville doctor 
received a 10-year federal prison sentence for serving as 
the supervising and prescribing doctor at a notorious 
Maryville pain clinic.38 
Legislative activity is also taking place in 
response to the momentum generated in the wake of 
Eric’s articles. That activity, however, is focused 
primarily at the state level. As of April 2018, twenty-
eight states had enacted legislation that either limited, 
offered guidance, or listed requirements related to opioid 
prescribing practices.39 Further, every state except 
Missouri has enacted monitoring program legislation 
“designed to reduce doctor shopping and identify patients 
at risk for substance use disorders.”40 In addition to these 
                                               
37 Cynthia McFaddin, Billionaire Charged with Bribing 
Doctors to Prescribe Opioids, NBC NEWS: HEALTH (Oct. 26, 
2017), https://www.nbcnews.com/storyline/americas-heroin-
epidemic/billionaire-charged-bribing-doctors-prescribe-
opioids-n814686 [https://perma.cc/W3D3-L62U] (“The 
corporation is not facing criminal charges and is still selling 
Subsys - some $240 million worth of Subsys just last year.”).  
38 Jamie Satterfield, Doctor for Maryville Pill Mill Draws 10-
year Prison Term, KNOXVILLE NEWS SENTINEL (Feb. 22, 2017), 
https://www.knoxnews.com/story/news/crime/2017/02/22/doctor
-maryville-pill-mill-draws-10-year-prison-term/98268716/ 
[https://perma.cc/437L-KJ5V].  
39 Prescribing Policies: States Confront Opioid Overdose 
Epidemic, NAT’L CONF. ST. LEGISLATURES: STATE ACTION (Apr. 
5, 2018), http://www.ncsl.org/research/health/prescribing-
policies-states-confront-opioid-overdose-epidemic.aspx 
[https://perma.cc/VR62-LA4U].  
40 Chris Elkins, The Opioid Epidemic: What Caused the Heroin 
Epidemic?, DRUGREHAB.COM, https://www.drugrehab.com/ 
opioid-epidemic-causes/ [https://perma.cc/ZX2U-NZ7J]. The 
Prescription Safety Act of 2016 is Tennessee’s version - 
legislation that revised or made permanent existing regulation 
of controlled substances and enacted several other provisions. 
Tennessee Prescription Safety Act of 2016, 2016 Tenn. Pub. 
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legislative initiatives, states have considered, proposed, 
and/or adopted opioid-related legislation in a number of 
other categories, including opioid taxes, pain clinic 
licensure, training and education plans, and pill “take-
back” programs.41 
At the federal level, one hears numerous claims 
that actions are being taken to “combat the opioid 
crisis[,]”42 including President Trump’s plan to use the 
death penalty as an option for drug dealers in fatal opioid 
overdose cases.43 Not all have been deemed to be a 
success. For example, an earlier piece of federal 
legislation, the Ensuring Patient Access and Effective 
Drug Enforcement Act of 2016, has been subjected to 
scathing criticism, with even its title described as 
“misleading.”44 According to a report resulting from a 
joint investigation by The Washington Post and “60 
Minutes,” an ex-DEA lawyer working for a 
pharmaceutical company drafted an early version of the 
                                               
Acts 1002 (codified at TENN. CODE ANN. §§ 53-10-301 to -312 
(2016)). 
41 Kate Blackman & Amber Widgery, Summer Progress in 
Opioid Misuse Prevention Legislation, NAT’L CONF. ST. 
LEGISLATURES: NCSL BLOG (Aug. 31, 2017), 
http://www.ncsl.org/blog/2017/08/31/summer-progress-in-
opioid-misuse-prevention-legislation.aspx [https://perma.cc/P 
NT2-ZBM4]. 
42 See, e.g., Combatting the Opioid Crisis, HOUSE COMM. ON 
ENERGY & COM.: ISSUE IN FOCUS, https://energycommerce. 
house.gov/opioids/ [https://perma.cc/V9DA-VNW9].  
43  Louise Radnofsky, Trump’s Opioid Battle Plan Includes 
Seeking More Death-Penalty Prosecutions, WALL ST. J. (Mar. 
18, 2018), https://www.wsj.com/articles/trumps-opioid-battle-
plan-includes-seeking-more-death-penalty-prosecutions-
1521414347 [https://perma.cc/D2JW-N3R6].  
44 Scott Higham & Lenny Bernstein, New Drug Law Makes It 
‘Harder for Us to Do Our Jobs,’ Former DEA Officials Say, 
WASH. POST (Dec. 15, 2017), https://www.washington 
post.com/graphics/2017/investigations/dea-law/?utm_term=.6c 
c2264b1f35 [https://perma.cc/X 8YA-XEXH]. 
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law.45 The final version dramatically curtailed the DEA’s 
enforcement powers: the agency now must demonstrate 
that a company’s actions represent “a substantial 
likelihood of an immediate threat” before it can halt drug 
shipments, whereas previously it needed only to show 
that they posed an “imminent danger” to the 
community.46 The law also allows companies to submit 
“corrective action plans” before they can be sanctioned by 
the DEA,47 which one former DEA investigator called a 
“get out of jail free card[.]”48 
More recently, the new two-year budget deal 
passed in early 2018 promised funding for the epidemic, 
the details of which were not specified.49 Additionally, a 
bipartisan group of senators introduced a follow-up bill to 
2016’s Comprehensive Addiction and Recovery Act, 
commonly referred to as CARA 2.0.50 A version of the bill 
was introduced in the House of Representatives by 
Tennessee Representative Marsha Blackburn.51 If 
passed, CARA 2.0 would, among other things, commit 
more funding to the fight against the opioid crisis, 
restrict access to opioid painkillers, improve access for 
medication-assisted treatment, and increase civil and 
criminal penalties for opioid manufacturers if they fail to 
report suspicious orders or fail to prevent diversion.52 
The impact of Eric’s articles and its aftermath can 
be seen far beyond the nation’s courtrooms and 
                                               
45 Id.  
46 Ensuring Patient Access and Effective Drug Enforcement 
Act of 2016, Pub. L. No. 114-145, § 2(a)(1), 130 Stat. 354 (2016) 
(codified as amended at 21 U.S.C. § 823 (2017)). 
47 Ensuring Patient Access and Effective Drug Enforcement 
Act of 2016, Pub. L. No. 114-145, § 2(a)(2), 130 Stat. 354 
(codified as amended at 21 U.S.C. § 824 (2016)). 
48 See Higham & Bernstein, supra note 44. 
49 See, e.g., Bipartisan Budget Act of 2018, H.R. 1892, 115th 
Cong. § 50723 (2018). 
50 CARA 2.0 Act of 2018, S. 2456, 115th Cong. (2018). 
51 CARA 2.0 Act of 2018, H.R. 5311, 115th Cong. (2018). 
52 Id. 
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legislatures, with some good results and some not as 
positive. Eric discussed some of these results at the 
symposium. For example, while he was relieved that 
many of the opioid “pill mills” in West Virginia had been 
shut down or had voluntarily closed their doors, he 
suspected that a number of them had simply changed the 
signs on their doors and morphed into “treatment 
centers” that use medication to treat the opioid addicts 
that they helped to create.  
Medication-assisted treatment for opioid 
addiction is still very controversial.53 The main criticism 
of using medication in this context is that it is just 
replacing one drug - whether an opioid painkiller or 
heroin - with another, such as methadone, 
buprenorphine, and naltrexone.54 Research clearly 
demonstrates, however, that medication improves 
outcomes for patients with opioid use disorders.55  
Along with the success of these treatments, 
several tag-along legal issues have arisen which are 
worthy of monitoring. One involves claims by the 
Attorneys General of 35 states and the District of 
Columbia that British pharmaceutical manufacturer 
Indivior Inc. and U.S. company MonoSol Rx “product 
hopped” in order to delay less expensive generic versions 
                                               
53 See, e.g., Sameer Hassamal et al., Overcoming Barriers to 
Initiating Medication-Assisted Treatment for Heroin Use 
Disorder in a General Medical Hospital: A Case Report and 
Narrative Literature Review, J. PSYCHOL. PRAC. 221 (2017).  
54 Medication and Counseling Treatment, SUBSTANCE ABUSE & 
MENTAL HEALTH ADMIN. (APR. 8, 2018), https://www. 
samhsa.gov/medication-assisted-treatment/treatment 
[https://perma.cc/5VC4-LULF]. Buprenorphine (Subutex) and 
Buprenorphine-naloxone (Suboxone) were approved by the 
U.S. FDA in 2002 to treat opiate dependence. Naloxone is the 
drug used to revive overdose victims. 
55 Mollie Durkin, Primary Care Takes on Opioid Addiction, 
ACP INTERNIST: OPIOIDS (Oct. 2017), https://acpinternist.org/ 
archives/2017/10/primary-care-takes-on-opioid-addiction.htm 
[https: //perma.cc/L49U-BM2H]. 
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of Suboxone, Indivior’s opioid addiction treatment drug.56 
The defendants in that case are accused of conspiring to 
create a sublingual film version of its Suboxone drug 
shortly before its license expired in order to extend its 
patent; of incrementally increasing the price of its tablets 
and engaging in potentially misleading marketing to 
encourage patients and doctors to switch to the new film 
version; and of then announcing its intent to remove the 
tablets from the market entirely.57 
Another pharmaceutical manufacturer in the 
ever-growing opioid treatment market has drawn fire for 
its marketing practices. Alkermes, a Massachusetts 
company, makes a monthly injectable treatment 
medication called Vivitrol that blocks the effects of 
opioids and reduces cravings, and the company has taken 
its aggressive marketing pitch directly to drug court 
judges, prosecutors, and other officials in the criminal 
justice system who appear receptive to the “nonaddictive” 
qualities of its product.58 According to medical 
professionals, this approach is misleading and 
contributes to the “existing stigma on the use of opioid 
[methadone or buprenorphine] therapy in the treatment 
of opioid addiction, despite a large and robust evidence 
base showing [its] effectiveness . . . for opioid addiction.”59 
In addition to the potentially predatory practices 
of the companies and individuals seeking to exploit the 
market for opioid addiction treatment, there are other 
                                               
56 See Wisconsin v. Indivior Inc., Civ. No. 16-5073, 2017 WL 
3967911 (E.D. Pa. Sept. 8, 2017). 
57 Id. 
58 See, e.g., Press Release, U.S. Senator Kamala Harris, 
Senator Harris Launches Investigation into Pharmaceutical 
Manufacturer Alkermes Regarding Opioid Addiction 
Treatment Manipulation (Nov. 6, 2017), https://www. 
harris.senate.gov/news/press-releases/senator-harris-
launches-investigation-into-pharmaceutical-manufacturer-
alkermes-regarding-opioid-addiction-treatment-manipulation 
[https://perma.cc/G5C7-YFKP]. 
59 Id.  
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obvious downsides to the successful closure of many of 
the unethical pill mills that blighted our rural 
communities. Some of the poor souls who are no longer 
able to access opioid prescriptions have turned to heroin 
or to the very deadly synthetic opioid, fentanyl. According 
to the CDC, “illicitly manufactured fentanyl is now a 
major cause of opioid overdose deaths in multiple 
states.”60 One law enforcement officer compared it to a 
community weapon of mass destruction: “[i]t’s 
manufactured death.”61 
Hopefully, no one will be discouraged from 
seeking to combat the opioid crisis in all of its forms, 
whether the drug has been produced legally or illegally. 
We should look to Eric’s efforts, and those of our 
colleagues whose legal work supported him, for courage 
and inspiration. The unsealed data that Eric and Pat et 
al. secured in West Virginia are still among the only such 
data that are publicly-available. The industry, with 
support from the U.S. Department of Justice and the U.S. 
DEA, is still demanding that its data be protected on the 
grounds that disclosure could violate privacy rights, 
breach trade secrets, interfere with law enforcement 
investigations, and encourage criminal activity.62 This is 
                                               
60 Maggie Fox, Synthetic Fentanyl Deaths Rise in Americans 
Opioid Epidemic, NBC NEWS: HEALTH (Oct. 27, 2017), 
https://www.nbcnews.com/storyline/americas-heroin-epidemic/ 
synthetic-fentanyl-deaths-rise-americans-opioid-epidemic-
n814956 [https://perma.cc/S42J-CTEH].    
61 Nicole Lewis et al., Fentanyl Linked to Thousands of Urban 
Overdose Deaths, WASH. POST: NAT’L (Aug. 17. 2017), 
https://www.washingtonpost.com/graphics/2017/national/fent
anyl-overdoses/?utm_term=.d64447b619c9 [https://perma.cc/ 
ZRV4-N57W].   
62 Letter from David A. Sierleja, First Assistant U.S. Attorney, 
N. Dist. of Ohio, to Paul T. Ferrell, Jr., Partner, Green, 
Ketchum, Farrell, Bailey & Tweel LLP (Feb. 26, 2018), 
https://images.law.com/contrib/content/uploads/documents/39
8/11419/Critical-Mass-opioid-DOJ-letter.pdf [https://perma.cc/ 
EQ9L-FBGV].  
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despite the Justice Department’s request to participate 
in the settlement talks in the large MDL pending in the 
Northern District of Ohio.63  
This reluctance is understandable. The publicly-
available raw numbers in Tennessee are sobering. In 
Knox County alone, there were 294 suspected drug 
overdose deaths in 2017 and 84 so far in 2018. Those are 
not just numbers: those are our children, mothers, 
fathers, siblings, and friends, and each leaves behind 
grieving loved ones, all of whom deserve the best of our 
combined professional efforts. As painful as the truth 
may be, lawyers and journalists should be working to 
uncover it, individually and as partners. Eric and his 
legal support may be a tough, if not an impossible, act to 
follow, but it is one to which I hope that we all will aspire.  
 
 
  
                                               
63 United States’ Motion to Participate in Settlement 
Discussions and as Friend of the Court, In re National 
Prescription Opiate Litigation, MDL No. 1:17-MD-2804 (N.D. 
Ohio April 2, 2018). This apparent cognitive dissonance 
appears to be an issue amongst the manufacturing community, 
too. OxyContin manufacturer Purdue Pharma recently 
announced that it would stop promoting opioids to physicians, 
see OxyContin Maker Purdue Pharma Stops Promoting 
Opioids, Cuts Sales Staff, WASH. POST: HEALTH SCIENCE (Feb. 
10, 2018), https://www.washingtonpost.com/national/health-
science/oxycontin-maker-purdue-pharma-to-stop-promoting-
the-drug-to-doctors/2018/02/10/c59be118-0ea7-11e8-95a5-
c396801049ef_story.html [https://perma.cc/9FR5-4WSP], 
while at the same time “funneling $4.7 million to organizations 
and physicians from 2012 through last year” that promoted the 
use of opioid painkillers. Associated Press, Opioid Makers Gave 
$10 Million to Drug Advocacy Groups Amid Epidemic, NBC 
NEWS: NEWS (Feb. 18, 2018), https://www.nbcnews.com/storyline/ 
americas-heroin-epidemic/opioid-makers-gave-10m-advocacy-
groups-amid-epidemic-n849211 [https://perma.cc/LW39-63UK].  
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HEALING APPALACHIA: KEYNOTE 
DISCUSSION 
 
Eric Eyre 
Patrick C. McGinley 
Becky Jacobs, Moderator 
 
 
INTRODUCTION:  Welcome to "Healing 
Appalachia, The Role of Professionals in Solving the 
Opioid Crisis."  My name is Michael Deel.  On behalf of 
the Tennessee Journal of Law and Policy and the 
University of Tennessee College of Law, thank you for 
attending.   
Today we have gathered experts who are working 
to find legal and political solutions to this public health 
crisis while also working with individuals who are 
suffering on a day-to-day basis. I invite you to not only 
listen to their stories but to learn from them and to 
remember their efforts when you make your own 
everyday decisions, decisions like how to help a friend, 
how to effect policy, how to find hidden information, or 
simply how to vote in the next election.  
I would like to thank all the panelists and 
moderators that are participating today and also thank 
everyone who helped put this event together.  So many 
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people gave their time and energy to make this 
symposium possible.   
Mr. Eric Eyre and Professor Patrick McGinley will 
deliver our keynote address which will be followed by two 
panel discussions and a documentary viewing.  We will 
take a 15-minute break between each session and there 
will be a transcript available after we get it published in 
the next issue of TJLP.  
Mr. Eyre won the Pulitzer Prize for investigative 
reporting for his articles regarding the distribution of 750 
million prescription pills in West Virginia and the tragic 
overdoses that followed those pills.  He currently works 
as a statehouse reporter for the Charleston Gazzette-
Mail. 
Professor McGinley is a Charles H. Hayden II 
Professor of Law at West Virginia College of Law. 
Professor McGinley teaches administrative law, 
environmental law, and appellate advocacy.  He also 
represented the Charleston Gazzette-Mail in a lawsuit 
that resulted in a court order unsealing the documents 
that led to Mr. Eyre's articles.   
Professor Becky Jacobs from the University of 
Tennessee College of Law will moderate this discussion. 
Please join me in welcoming them. 
 
MS. JACOBS:    So just to like frame our 
discussion this afternoon, I want to give you just a few 
facts.  So opioid painkillers are a nine-billion-dollar-a-
year market in the U.S. alone.  In pharmaceutical 
companies such as Purdue Pharma, Johnson & Johnson, 
Teva, and Allergan have all earned many billions over 
the years from the sale of these drugs.  Wholesaler 
distributors like McKesson, Cardinal Health, and 
AmerisourceBergen also have profited, as have the 
physicians and pain clinics that prescribe these 
medications, some legitimately, some not so legitimately.   
These profits, though, have had a very, very high 
public health cost as the work of our guests today helped 
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to expose.  According to the CDC, from 1999 to 2016, more 
than 200,000 people have died in the U.S. from overdoses 
related to prescription opioids.  That's just the 
prescription opioids.  In 2016 alone, more than 46 people 
every day have died from overdoses involving 
prescription opioids.  Also in 2016, three of the five states 
with the highest rates of death due to drug overdoses 
were close to us:  West Virginia had 52 per 100,000, Ohio 
had 39.1 per 100,000, and Kentucky had 33.5.  
Tennessee's rate was 24.5.  And our guests today fought 
to make these data public. So I want to thank them very 
much for being here. 
I want to start by asking you, for those who aren't 
familiar with kind of what these drugs are, can you 
describe the specific painkillers that we're talking about 
and which ones are the focus of this investigation? 
 
MR. EYRE:      Sure.  The two that we primarily 
focused on, because we got the DEA data on were 
hydrocodone, which is Lortab and Vicodin, and 
oxycodone, which is OxyContin.  And there's plenty of 
other pills that are distributed, but those were the two 
that we focused on primarily. 
 
MS. JACOBS:    Okay.  So how you did you get 
interested in the topic, and how and when did Pat get 
involved? 
 
MR. EYRE:      I kind of wound up in it in a 
different way.  I covered the legislature for West Virginia, 
so I'm based at the Capitol, and we had a new attorney 
general elected in our state.  There had been a lawsuit 
filed about six months prior to his win by our former 
attorney general, and that lawsuit was against the drug 
wholesalers.  When our new attorney general got elected, 
I got this phone call that this woman wanted to meet with 
me outside the Capitol; she had some information for me.   
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She brought this envelope of stuff.  She had— I 
remember it was crazy because she had a dog with her 
named Bernard the Pekinese.  So she's literally handing 
stuff out and I'm worried I'm going to get bit by this dog, 
Bernard the Pekinese.  What it was was information 
about the new incoming attorney general's ties to these 
drug wholesalers.  The one company that you mentioned, 
Cardinal Health, had paid for his inauguration, and then 
when we also looked back at contributions, a lot of these 
drug wholesalers after the lawsuit was filed in July of 
2012 had given money to the attorney general.  And so 
we did a story about that and he said over and over that 
he had recused himself from the case at the beginning of 
when we assume he took office, but we had heard from 
staff that that wasn't the case.  So we actually filed a 
number of Freedom of Information Act requests and that 
wound up in court.   
This photo here is— the attorney general is on the 
right there.  This was a photo taken by a New York Times 
reporter, Eric Lipton, who actually won the Pulitzer Prize 
two or three years ago and he was writing about both the 
Republican Attorneys General Association and the 
Democratic Attorneys General Association wining and 
dining various attorneys general to get them— to try to 
persuade them to drop lawsuits or not file lawsuits.  And 
the woman there is Pam Bondi. I believe she's still the 
attorney general in Florida. 
And the story was about her being pushed— this 
was in the Hotel del Coronado in San Diego, a beautiful 
resort there— she was being pushed to drop a lawsuit 
against 5-hour ENERGY.  And these guys are lobbyists.  
I think it was something like three thousand dollars a 
night to stay there.  I met the reporter at the Pulitzer 
ceremony.  And eventually when they found out what he 
was doing, he got kicked out of course but . . .  So the next 
step was the FOIA lawsuit, and maybe Pat can talk a 
little bit about that.  This is back in 2013, 2014. 
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MR. MCGINLEY:  Yeah.  So— 
 
MS. JACOBS:    Before you do that, step back a 
little bit and— 
 
MR. EYRE:      The lawsuit— 
 
MS. JACOBS:    —the first lawsuit that Darrell 
McGraw filed. 
 
MR. MCGINLEY:  So in was it 2012 a long-time 
West Virginia attorney general, Darrell McGraw, filed 
the first case against drug distributors of opioid drugs, 
recognizing the impact of opioids in West Virginia, and, 
really, the first public official to take some kind of action.  
The lawsuit, the cause of action, was new and it was 
suggested that this is a looser, the attorney general's 
office is up against Big Pharma, billion-dollar 
enterprises, lawyers from New York and Philadelphia 
and Cleveland.  But that lawsuit was filed.  And then in 
a very narrow election, Attorney General McGraw lost to 
Patrick Morrisey.  He's pictured there in blue jeans with 
a lobbyist and the attorney general of Florida.  And so 
within six months of the time that these "pill mill" cases, 
that's what they were referred to, were filed in the 
summer of 2012, a new attorney general who had 
formerly been a lobbyist for trade associations from the 
pharmaceutical industry took office. 
 
MR. EYRE:      And what I forgot to mention, his 
wife was the lead lobbyist for Cardinal Health in 
Washington D.C. and made millions of dollars. 
 
MR. MCGINLEY:  Cardinal Health being one of 
the three leading opioid drug distributors in the country.  
And she continued to be a lobbyist until after our lawsuit.  
There was an ethics complaint filed against the attorney 
general at some point and said, well, I don't have to do 
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this but I won't have my fingers on any of these cases.  
But that took a couple of years.  In the meantime, Eric 
and the Gazzette-Mail are interested in what this new 
attorney general was going to do in terms of supervising 
these "pill mill" cases, considering his former relationship 
with the industry.  And Eric filed several FOIA requests 
and he was basically stonewalled, the responses didn't 
meet the requirements of the West Virginia Freedom of 
Information Act.  I think the first one, they said, well, if 
we had these documents you're requesting that relate to 
whether the attorney general is supervising the "pill mill" 
cases, if we have them, they would be exempt.   
And, you know, at that point the Gazzette asked 
me to be of assistance, because I've done a lot of FOIA 
stuff, and so I wrote to the attorney general and I said, 
well, that's not good enough, you've got to look for it, you 
can't just say if you have it.  And then there was a series 
of back and forth with nonresponsive answers from the 
attorney general, and I would say, well, let's read the law, 
you know, you must have something.  And then, 
ultimately, after about six months, they said— they 
called Eric and said, okay, you can come and look at the 
documents but they are totally redacted and you can't 
take photographs, and they set a time for it.  And we 
talked and we responded, that's not what the law 
requires, no, we're not doing that.  And they said, we'll 
get back to you.   
They didn't get back to us.  We filed a FOIA suit.  
It went on for almost a year.  We did discovery.  We found 
out they had documents that they hadn't mentioned 
before but they claimed were attorney-client privilege, 
work product.  And we thought we had a really good 
paper trail, a good case for joint motions for summary 
judgment, cross motions for summary judgment.  And the 
judge ruled against us and granted summary judgment.  
And I was depressed.  I thought this is a winner.  Eric 
and the others at the Gazzette were taken aback.  And 
then something happened that was interesting. 
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MR. EYRE:  So after we lost the FOIA case, 
somebody— I was not home.  This is a recreated— 
actually I found this— this is actually the envelope that 
it came in but somebody walked up to our house and my 
son texted me at work and said some man just came up 
to our house and dropped something in the mailbox with 
your name on it. 
Go to the next slide. You can't see it there but that 
was one of the e-mails that was being withheld, and what 
it said in the e-mail was that the attorney general has 
specific instructions regarding this case.  So it was hard 
to believe— he had done multiple interviews, not just 
with me but with other media, over and over again saying 
that he was completely recused from the case, he had had 
nothing to do with it since the day he took office.  And 
this countered his assertions for sure.  And then where 
do you want— 
 
MR. MCGINLEY:  Well, so Eric wanted to write 
about this of course— 
 
MR. EYRE:      Oh yeah. 
 
MR. MCGINLEY: —because this is exactly the 
opposite of what the attorney general had stated in court 
proceedings. And so, Eric, you can tell the story.  As 
reporters usually would do, you asked him for comment. 
 
MR. EYRE:      Yeah.  They required all their 
questions to be e-mailed, so I e-mailed a bunch of 
questions about when you said that you recused yourself 
from the case, it would seem this contradicts what you 
are saying.  We also found at around the same time there 
had been some documents saying that a court hearing 
related to this drug distributors lawsuit had to be 
canceled because Attorney General Pat Morrisey can't fit 
it into his schedule and can't make it.  And so if he was 
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recused from the case, why would they be saying he 
couldn't be there and things like that.  So I e-mailed to 
their press person these questions about what's going on. 
And then the next thing you know, their general counsel 
called or e-mailed you, Pat.  
 
MR. MCGINLEY:  Their solicitor general. 
 
MR. EYRE:      Became solicitor general. 
 
MR. MCGINLEY:  We never had a solicitor 
general in West Virginia but it sounds like a good title.  
Yeah, he called me, and I was actually here in Knoxville, 
at the time I was on my way to the Public Interest 
Environmental Law Conference, and I get the call on my 
cell phone from Misha— 
 
MR. EYRE:      Misha Tseytlin. 
 
MR. MCGINLEY:  —Tseytlin. 
 
MR. EYRE:  He's now the solicitor general at 
Wisconsin. 
 
MR. MCGINLEY:  —and there were documents 
that were in the files of the court in our FOIA case that 
were produced by (inaudible) and that were examined by 
the court, quashed by the court in camera before it 
granted summary judgment against us.  And so he called 
me and he said you better tell your client not to publish 
this story about documents that are under seal in the 
court, you're going to be sanctioned, and we're not going 
to tolerate this. And, you know, I'm in the rental car 
and— 
 
MR. EYRE:      And I'm like am I going to jail or . 
. . 
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MR. MCGINLEY:  And I said, Misha, have you 
ever heard of the Pentagon Papers case?  Misha was a 
law clerk to Justice Kennedy, so he knew the story. I said 
you do what you want but I can assure you this is going 
to go to print.  But that wasn't the end of the story.  We 
had to have conversations with the editor and publisher 
and they were concerned with are they going to sue us.  
And I said they can sue you, anybody can sue you, but 
this is a winner.   
And they went ahead and Eric told the story.  It 
didn't have much impact.  He continued to deny and it 
just sort of went over people's heads.  But we knew about 
that, it was clear the relationship there.  The overarching 
concern was that the attorney general would somehow 
dump the "pill mill" cases, that it would settle them cheap 
or make errors, who knew, who knows.  But he certainly 
with the appearance of impropriety with his prior 
relationships and the representations made to the Court, 
he shouldn't have been involved at all. 
 
MS. JACOBS:    Well, in fact, he wasn't very 
aggressive about the data that you guys had to intervene 
to get.  So tell us about that.  Because that's what broke— 
 
MR. EYRE:      That was— that was the next thing.  
So if we sort of flash forward, I kind of kept following the 
story and started seeing stuff in various legal filings.  But 
in I think it was around March 2016 we got wind that 
there had been what was called a second amended 
complaint or a revised complaint.  When they filed the 
original lawsuit back in 2012, the judge in this rural 
county that was handling it said we need some specifics 
here, we need some examples of, you know, this sending 
these larger quantities of drugs, these "pill mill" 
pharmacies. So they had filed an updated complaint 
called the second amended complaint and it was filed 
under seal. So this was the State of West Virginia filing 
a complaint outlining its allegations against the drug 
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distributors and you couldn't see it.  It was just 
completely filed under seal.  And I went to Pat and said, 
is this possible. 
                 
MR. MCGINLEY:  Yeah.  I said, well, that 
certainly violates the West Virginia Constitution, 
violates West Virginia Freedom of Information Act, and 
the West Virginia Rules of Civil Procedure. So the 
general rule is that public documents should be public 
when they are filed with the court.  And here he had a 
complaint on behalf of the State that says on behalf of the 
people of West Virginia against these drug companies, 
but the people don't know what the allegations are.  And 
so the State itself had come around to the point where it 
wanted the second amended complaint to be unsealed, 
but the Court did nothing and they didn't assert that 
aggressively.  So I talked to Eric, and I got other things 
to do at the law school, and I'm thinking well they are 
going to act, nothing happened, so we filed a motion to 
intervene for the purposes of seeking unsealing of the 
second amended complaint, which is in the materials that 
you have.  And we basically argued that there's no law on 
the side of the drug companies.   
Their response, which I think is in the material as 
well, was that these are essentially trade secrets, 
confidential business information about how many pills, 
opioids, that we sell to pharmacies, so our competitors 
would find out who the pharmacies are and how much.  
And, you know, we read that and said, what?  And not 
only that, it was old data.  And we went to Boone County 
Circuit Court for a hearing.  There were lawyers from 
everywhere.  The court was filled. 
 
MR. EYRE:      It's a picture from the courtroom. 
 
MR. MCGINLEY:  That's our co-counsel from 
Boone County, Tim Conaway.  And we were totally 
outnumbered.  There must have been 40 lawyers there 
34
Tennessee Journal of Law and Policy, Vol. 13, Iss. 3 [2018], Art. 1
https://trace.tennessee.edu/tjlp/vol13/iss3/1
HEALING APPALACHIA: KEYNOTE DISCUSSION  
13 TENN. J.L. & POL’Y 285 (2018) 
 
 
[295] 
for the various drug companies and pharmacies. And we 
argued the case. And the judge eventually said he was 
going to rule to unseal the documents, and then one of 
the drug companies filed a motion and wanted to have a 
conference call and— what did they say— 
 
MR. EYRE: There was like this 11th hour try to 
block the release of this— to unseal this complaint and 
what they said was they wanted to redact 18 words. We 
had a conference call about it, and I think they filed 
something too. And they said— and it was probably 70 
pages long. And they said we just want to redact 18 
words. They just kept saying if you can keep these 18 
words out, we're good with that. Well, it turned out— I'm 
making a spoiler alert here, I'm jumping ahead— but it 
turned out the 18 words were 18 numbers and it was 
numbers of pain pills. They said words. 
 
MR. MCGINLEY: Yeah. And, well, the judge 
didn't buy that. He ordered the complaint to be unsealed. 
And then that gave Eric insight into the bigger story, the 
sheer volume of opioids that were being marketed in the 
places they were being marketed. When we saw that first 
information, we were stunned. We're talking about a 
couple hundred million doses over a five-, six-year period. 
But there was more. But Eric wrote a story that was part 
of the Pulitzer recognition in May of 2016. You can 
describe what— 
 
MR. EYRE: That one was some of these numbers 
were— these orders were shipped— you have 20,000 
oxycodone to one pharmacy in a little town of a couple 
hundred people, and then it would say on the following 
week they'd get another 50,000, and then the next week 
they'd get another 20,000. So it was just these large 
shipments over consecutive days or consecutive weeks. 
And what the average hydrocodone I think nationally is 
90,000 per pharmacy per year, and oxycodone is probably 
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like 50,000 doses per year. So these small-town 
pharmacies were getting the equivalent of what they 
should have gotten in a year in a matter of a week or two. 
But what ultimately happened though, where this really 
opened things up, is throughout the complaint that was 
unsealed, they kept referring to DEA data shows, DEA 
data shows, DEA data shows this, that, and the other. So 
I did a FOIA asking the attorney general's office for all 
the DEA data that they used to cite all these various 
figures. And it turns out that there was a 2015 e-mail 
sent from DEA to the attorney general's office outlining 
every shipment to every pharmacy in West Virginia of 
hydrocodone and oxycodone and also it was broken down 
by the name of the company and how many pills they 
distributed to each county in West Virginia. And what 
we— just to sum it up, after we got this DEA data, there 
was a disproportionate number of pills sent to the 
southern part of the state, the coalfield region.  
And you had these situations where you had 
pharmacies with— one town had a pharmacy— 400 
people— and got nearly nine million hydrocodone pills in 
two years, in just two years. There were cases like this all 
over southern West Virginia, Logan County, Boone 
County, Mingo County. They had a town of 3,000 in 
Mingo County, they got 20 million hydrocodone over 
eight years. Just these incredible numbers. And then we 
looked at, you know, we did the (unintelligible) maps and 
looked at where most of the overdose deaths were, and 
they don't line up perfectly, but they match up pretty 
closely. And these counties here, not only are they 
number one for prescription drug overdose deaths in 
West Virginia, but they are I think of the top 10 about six 
or seven of them were all in West Virginia in the country 
for overdose death rates. So it was an incredible thing. 
And, in addition, I don't have a slide to show it, but the 
DEA agent who sent the data to the attorney general's 
office, he also did a— he mapped out the strength of the 
pills of the OxyContin, the milligram levels had 
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increased. So you had in 2007 the most popular milligram 
level of OxyContin was five milligrams, and then the next 
year it was like 10 milligrams. So the strength of the pills 
were actually getting stronger too in terms of— 
 
MR. MCGINLEY: How high did they go? 
 
MR. EYRE: They had OxyContin 80, but that was 
outlawed I believe. 
 
MR. MCGINLEY: But they went beyond 10, it 
went pretty far above it. 
 
MR. EYRE: Yeah, I think it went to like 30. 
 
MS. JACOBS: I know there's a quote from your 
article that there were 433 pain pills for every man, 
woman, and child in West Virginia. 
 
MR. EYRE: Just those two, right. I mean, we're 
not even doing hydromorphone, oxymorphone, Xanax, 
and all the others. 
 
MS. JACOBS: That's astounding. 
 
MR. MCGINLEY: There's one parenthetical that 
Eric was— when he filed actually a Freedom of 
Information Act request with the attorney general 
seeking the DEA data in August of 2016. And under West 
Virginia law, a FOIA law response is required within five 
working days. Well, the attorney general's office kept 
delaying, we're looking for the data, we'll get back to you, 
we'll get back to you. Meantime, there's an election going 
on where the attorney general is running for re-election. 
His opponent has a lot of cash and is running— has spent 
several million dollars on TV ads trumpeting the 
relationship of the attorney general to the drug 
companies and the opioid epidemic. And there was an 
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infusion of cash into Morrisey's campaign in October of—
what was it— six million dollars from the National— the 
Republican Attorneys General Association, more money 
that flowed from that association than any other attorney 
general race. That money is sort of dark money. The 
contributors are the Koch brothers, pharmaceutical 
companies. And so the attorney general continued to 
delay responding. And what happened then? 
 
MR. EYRE: Pat came up with a good idea that we 
should file a FOIA asking them— because they kept 
responding that they are searching for the records, they 
are searching for the records, and they would just keep 
every five days saying we're still searching for the 
records— Pat came up with an idea just to do a FOIA 
saying any documents that would show you're actually 
searching for the records. Of course there were none. And 
then about two or three weeks before the election he did, 
to his credit, he did release the DEA data.  
The backdrop, as Pat was describing, was this 
immense pressure in terms of ads from the democratic 
opponent. Actually, CBS News had picked up on our story 
and came to West Virginia multiple times. And the 
attorney general agreed to do an interview with CBS 
News, which I can't— I don't know who told him to do 
that. But of course they did the things where they are 
asking all these happy questions and then they say what 
about your wife works for Cardinal Health and you have 
this lawsuit and, you know, they zero in on your face and 
you start seeing the twitches and all that. Well, the 
democratic guy that was running against him just kept 
running that interview over and over in his ad. But that 
was countered by all the money from the Republican 
Attorneys General Association who said that the 
democratic opponent was big friends with Hillary Clinton 
and Obama and they pounded that over and over and 
over, which is a simple effective message that worked. 
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MR. MCGINLEY: And Attorney General Morrisey 
won the election. It was close but he prevailed. I don't 
know that I would give him credit because he knew that 
Eric and the Gazzette were going to write stories and we 
were considering a lawsuit against him, a FOIA suit, that 
would have come out right before the election. So I think 
he had some good political counselors in-house that said 
you better get this information out there. And it's really 
a question whether that information should be— should 
not be available to the public because it came from the 
DEA. And that's more the problem, all this information 
the DEA has but it's not shared, the public doesn't have 
access to it. So the public knows because of Eric's 
reporting the volume of prescription opioids that were 
sold in West Virginia. But we don't know, we don't have 
the data at this point, about the sales in Ohio, in New 
Jersey, Tennessee, Kentucky, and so forth. And that's a 
real flaw in the system. But subsequent to Eric's 
reporting there have been numerous lawsuits that have 
been filed here in Tennessee, for example, by 
Municipalities, Indian tribes, Cities, States, against the 
drug manufacturers and distributors seeking 
compensation for the cost of dealing with the opioid 
epidemic, which is enormous.  
The American Enterprise Institute report just 
came out pegging the cost to the gross domestic product 
in West Virginia of eight billion dollars. That sounds high 
to me but I don't know. And the human cost, you can't 
calculate that. And, hopefully, in these cases that are, you 
know, following up on what West Virginia did, that 
litigation and exposure. But the volume— I was looking 
at the audience here, we were talking about how many 
oxycodone, OxyContin pills, and the total is 780 million. 
And when we saw that, I said oh my God. I think that's 
what a jury would do, if you've got a case where you could 
get it to the jury. It's a question of creative lawyering, 
having statute or common law remedies that will make 
these— hold these billion-dollar companies responsible. 
39
et al.: Symposium Issue 2018
Published by Trace: Tennessee Research and Creative Exchange, 2018
TENNESSEE JOURNAL OF LAW AND POLICY 
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION 
 
 
[300] 
And that's one of the grossest things about this whole 
story is the billions of dollars that these companies have 
made and there have been very few repercussions, 
certainly not to the companies. Three of the top 15 
Fortune 500 companies are drug distributors and were 
parties in the "pill mill" litigation in West Virginia. 
McKesson, Cardinal Health, Amerisource Bergen, not 
household names, but they're right up there with Wal-
Mart and Apple. And what do they do? I mean, what— 
 
MR. EYRE: They ship drugs from factories to 
warehouses to pharmacies and hospitals. 
 
MS. JACOBS: Purdue Pharma who produces 
OxyContin— 
 
MR. MCGINLEY: The manufacturer. 
 
MS. JACOBS: —they're the manufacturer, 
privately owned by a family, and they are I think the 
wealthiest, or maybe behind Bill Gates, in the country. 
 
MR. EYRE: Well, like McKesson is the number 
five on the Fortune 500. And that shocked me. I didn't 
even figure that all out until we were in the courtroom 
and I turned around and introduced myself, and 
somebody was telling me they were from D.C. and like 
Cardinal Health or the other companies would have three 
or four lawyers there. We don't have the rankings but I 
think it's Wal-Mart, Apple is number two on the Fortune 
500, or Berkshire Hathaway, Exxon, and then McKesson 
is number five. And then I'm not going to get these 
exactly right but I think AmerisourceBergen is 12 and 
Cardinal Health is 15. And they've actually climbed— 
since my story has come out, they've actually climbed in 
places in the Fortune 500. These are CEOs that are 
making— a guy in McKesson— there's been stories in 
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Fortune or Forbes— Forbes— making over 60 million 
dollars a year in compensation. 
 
MR. MCGINLEY: The McKesson CEO one year 
was the highest paid CEO of any corporation in the 
United States. 
 
MR. EYRE: And nobody had heard anything. 
 
MS. JACOBS: I've heard another topic you've 
done. You were talking about the distribution 
outlets, some of the pharmacies. It wasn't Wal-Mart or 
Walgreens or— tell us about where these pills were being 
distributed in West Virginia. 
 
MR. EYRE: Yeah. That was surprising. Because 
before I covered the— as you guys know a lot about the 
meth epidemic when they're doing the shake and bake 
bottles and making it with Sudafed, and we used to 
identify the pharmacies that were selling the most 
Sudafed in the state and they were typically the Wal-
Marts and the Rite Aids. But in this case it was these 
independent pharmacies, these mom and pop 
pharmacies. They were literally drive-thru pharmacies. 
They didn't sell Band-Aids, they didn't sell Q-tips. They 
literally had names like Meds To Go Express and Larry's 
Drive-thru Pharmacy. And you'd see people lined up up 
and down the block. People would come from all over. You 
know, I've seen recent stories where some of these 
pharmacies are defending themselves saying we just 
didn't serve the town of 400, people came from all over. 
But I think that's more damning than— I mean, they 
were literally coming from Tennessee, Kentucky, Ohio, 
Pennsylvania to these little small towns in the southern 
part of West Virginia. Whitfield, Virginia is another 
place.  
And you had these— you know, I wasn't there— 
but everybody describes these scenes that there's one 
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pharmacy in Kermit, which is this little town of 400 
people, because there were so many people in line, they 
started handing out bags of free popcorn just as a bonus. 
They had bags for the people in town where if it was 
opioids, you'd get it in one color bag, and if not, like if it 
was blood pressure medication, you'd get it in another 
color bag, because they didn't want the senior citizens in 
town getting robbed. Because if the people would see you 
had the color bag that wasn't opioids, then they wouldn't 
rob you. They actually set up a hotdog stand with 
hamburgers and hotdogs while people were waiting in 
line. It was just an unbelievable scene from what's been 
described to me. 
 
MR. MCGINLEY: What about the doctors? I refer 
to this as a legal cartel. You have the Mexican brown 
heroin cartel or Columbian cocaine cartel. You have the 
legal cartel, you've got manufacturers, you've got the 
distributors, you've got the doctors who were writing the 
scripts, you've got the pharmacies who were filling the 
prescriptions, they all had to know. With those numbers, 
all of them knew. And where was the law enforcement? 
Where is the Pharmacy Board? Where was the DEA? And 
this was going on for more than a decade. And I think the 
numbers, when we finally saw the numbers, the light 
went on and the country woke up to realize that this was 
all legal and they had— the defense was of the 
manufacturers, well, we're just making stuff to help 
people with their pain. The distributors, we're just taking 
them to the pharmacies. The pharmacies, we're just 
filling the doctors' prescriptions. And the doctors saying 
we're helping our patients with pain. They are all 
pointing fingers, they didn't do anything wrong. The 
doctor's office, what was that like? 
 
MR. EYRE: Just last week or this week they 
busted what's called The Hope Clinic. I think at one point 
they had— yeah, what a name for a "pill mill" pain clinic, 
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The Hope Clinic, we're giving people hope— I had 
actually written about them. One of the prisms of my 
stories is they only focused on the drug wholesalers. My 
mom called me the day that story came out, when it first 
came out back in December 2016, she said what about the 
doctors. And I said I've been writing about the doctors for 
years. They had these pain clinics where the doctors 
didn't even show up. The one that just got busted that we 
wrote about back in 2014, 2015, they had former cops, 
retired cops, who were taking people's blood pressure, 
doing the weight, doing their charts. They carried guns 
holstered at the site. They had these special machines, I 
can't remember the exact name of them, but they were 
these electronic machines that would crank out 
prescriptions by the hundreds. They would have the 
doctor’s signature on them, but they were just being 
reproduced through the machines. And I would get calls 
back in 2014, 2015 from legitimate pharmacists that 
would call me up and say come up and let me show you 
what they are doing, you know. But they would set up 
special relationships with some pharmacies that were 
disreputable, and they would fill those prescriptions. And 
it was an all cash basis. There was no insurance or 
anything like that. It was just a cash only business. 
 
MS. JACOBS: It's astounding that— where was 
the Board of Pharmacy? In your third article you talked 
about the responsibility to file reports about large 
shipments. What happened with all of that? 
 
MR. EYRE: Well, our Board of Pharmacy is 
almost exclusively made up of independent mom and pop, 
including some that were involved in this "pill mill" stuff. 
Their directors are all appointed by the governor and 
they are all independent pharmacists. So they had some 
rules on the books related to something called "suspicious 
orders" and those are orders of large numbers of drugs 
over consecutive days or massive quantities over one day. 
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MR. MCGINLEY: Those are Federal rules; right? 
 
MR. EYRE: It was a DEA rule that the State had 
copied and put into their rules at the Board of Pharmacy. 
And I asked our executive director of our Pharmacy 
Board, because it was cited in the lawsuit, I said what are 
you doing with that. They said that hasn't been on my 
radar, we just don't enforce that rule. So there had been 
no suspicious order reports filed by any of these drug 
wholesalers before 2012. But when the lawsuit was filed 
by the former attorney general, a couple of them— two of 
them started sending suspicious order reports to the 
Board of Pharmacy, sometimes two or three a day. I went 
and said can I take a look at them. I thought they would 
be cataloged, they'd have a total number or something. 
And they just came— I came into the office and they came 
in with two big bankers boxes full and they dropped them 
on the table and they said here is all our suspicious order 
reports. And I said, well, what have you done with them. 
And they said we haven't done anything with them, we 
just shelve them. And they hadn't cataloged them, so I 
literally had to count through each one to figure out how 
many had been filed. 
 
MS. JACOBS: Were they included in the lawsuit, 
the warrant? 
 
MR. MCGINLEY: Not at that point, no. 
 
MS. JACOBS: That's amazing. So talk a little bit 
about the consequences, like the kind of after-effect. Your 
work had a significant impact on all the lawsuits that 
happened. And what else do you think you have done, 
your work has done? 
 
MR. EYRE: Well, the biggest development is there 
is a congressional investigation in the House Energy and 
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Commerce Committee and what they're doing that we 
hadn't been able to do for the most part is linking up exact 
numbers from each company to each of these pharmacies, 
and many of them were shuttered, a lot of them are still 
open actually, and they've been able to sort of dovetail or 
expand upon our work. They were originally stonewalled 
by the DEA. I think in some respects the Congressional 
Committees were still being stonewalled. But they've 
come out with some more shocking numbers like 
McKesson over a two-year period they figured out of 
those nine million pills like five million were from 
McKesson alone, 76 percent of the business. They've 
gotten some real granular detail. And they've identified 
other regional wholesalers. Another name is Miami-
Luken, H.D. Smith. They're starting to get more 
numbers. But what's frustrating is, we talked a little bit 
about this earlier, the DEA, they have all this data. I get 
calls from all over the country saying can we replicate 
what you did. And I said the DEA in a matter of I can't 
imagine it would take more than an hour to do the 
spreadsheets that we got, it's a simple sort, but they just 
won't do it. They point to there's data available on their 
Web site called ARCOS data but it's broken down by 
grams and by zip code prefixes. Which I tried to look up 
our zip code prefixes in West Virginia and they span 
sometimes four or five counties or they dig into half of a 
county, and it's very complicated to do it that way. There 
are ways to see the overall number of grams by state, 
things like that, but nothing like what we got. 
 
MS. JACOBS: Yeah. So what do— I mean, I've 
noticed— 
 
MR. MCGINLEY: Can I add something there? 
 
MR. EYRE: Yeah. 
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MR. MCGINLEY: With regard to the DEA, some 
of you may have saw the story, the DEA had an official 
that was in charge of checking on the drug distributors, 
you know, for suspicious orders and volumes and was 
trying to organize enforcement actions, at least the story 
that's been told publicly, and wasn't permitted to go 
forward. I think there was pressure from higher up in the 
agency or political pressure in the regional offices. But 
there were people in the DEA enforcement that wanted 
to do something about the enormous volume of opioids 
that were being distributed. And the trade associations 
for the pharmaceutical industry hired a former member 
of the DEA's general counsel's office to draft legislation 
that essentially took away the DEA's enforcement power. 
That's the old revolving door. You know, anybody that's 
been around government knows about that. And that bill 
was written in language that was not penetrable by those 
who don't really understand the legal terminology and 
what the DEA does, and so it was sponsored by a 
congressman from northeast Pennsylvania and it was 
passed on a voice vote in both the House and the Senate 
unanimously. I think the attorney general did raise some 
question about it. President Obama signed it and 
nobody— clearly, no one read it and knew what was in 
there. So here is an effort funded by the industry to talk 
about DEA oversight and enforcement power and it just 
goes totally under the radar until the Washington Post— 
was it— 
 
MS. JACOBS: 60 Minutes. 
 
MR. MCGINLEY: —60 Minutes last fall did this 
exposé. At that time the congressman of Pennsylvania 
had been nominated by President Trump to be the new 
head of the DEA. 
 
MS. JACOBS: Yeah, the drug czar. 
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MR. EYRE: The drug czar. 
 
MR. MCGINLEY: Drug czar. 
 
MS. JACOBS: It's very interesting. It's very 
Orwellian. The name of the legislation was "Ensuring 
Patient Access and Effective Drug Enforcement Act". 
That was the name of the legislation. It sounds really 
great, so if you didn't read it, you would vote for it 
thinking this is great for enforcement. But it basically— 
the DEA, to take any kind of enforcement action, they 
have to show a substantial likelihood of an immediate 
threat. Immediate. So it's a higher bar than they ever 
had. And they also cannot sanction any company unless 
they allow them first to put in place a corrective action 
plan. 
 
MR. MCGINLEY: Which did not exist in the prior 
legislative plan. 
 
MS. JACOBS: Yeah. So it's a very different 
enforcement regime than they had previously. 
 
MR. MCGINLEY: A little bit of good news is the 
congressman's nomination was withdrawn a few days 
after the 60 Minutes show ran. 
 
MS. JACOBS: Well, apparently, there's a lot of 
outrage about it in the House and Senate, so I think 
there's a move to repeal it. So, hopefully, that might 
happen. I think there's a lot on the legal side, and 
hopefully the next panel will talk about some of the legal 
fallout from this, but I think there are over 250 public 
lawsuits, you know, Cities, Counties, and State attorneys 
general. I think every state either has a lawsuit pending 
or they are investigating lawsuits against the opioid 
industry, some faction of it. And they consolidated a lot 
of those in this multi-district lawsuit in Ohio and— but 
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the companies have tried to like get settlement 
discussions going and to seal a lot of the data that's been 
coming out of that. Interesting development I read about 
yesterday, there's some lawsuits in Michigan on RICO, 
which I think is a really great kind of cause of action, a 
really creative theory. Hospitals have begun to sue, 
which is another really interesting— looks like if the 
cities can do it, we should be able to do it. Insurance 
companies are probably next. And legislatively, I think 
people have started— I don't know if it's happened in 
West Virginia— they a resetting prescribing limits, 
which I think should have been— 
 
MR. EYRE: We have a bill pending that was just 
approved by the Senate that's been turned over to the 
House for seven-day. Do you guys have three-day or— 
 
MS. JACOBS: I don't know what Tennessee is, if 
we have one. 
 
MR. EYRE: Some states have three-day, some 
have five-day limits. 
 
MS. JACOBS: And there are other— and just last 
week I think, the OxyContin manufacturer, Purdue 
Pharma, said they are not going to market to doctors 
anymore. I'm not sure at this point that makes any 
difference since they're firmly entrenched but . . . 
 
MR. MCGINLEY: Marketing to doctors often 
means paying doctors large amounts to give a talk at 
some proceeding sometimes in Rome or Paris or resorts, 
and it can be very lucrative for doctors and inroads to 
doctors prescribing particular drugs. It's not only in the 
opioid field but certainly makes a difference. Purdue 
Pharma has one of the worst records in terms of they're 
really marketing their opioids as not being addictive. 
That was the first round. I mean, that's when the opioids 
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really started to kick off, you know, doctors prescribing 
them, manufacturers saying they are not addictive. Am I 
right about that? 
 
MR. EYRE: Yeah, absolutely right. 
 
MS. JACOBS: They said it was something like 
ibuprofen. 
 
MR. EYRE: Our public health commissioner is one 
of the champions at trying to reduce that the opioid 
epidemic— he's really a good guy. He's like— he actually 
came from Tennessee and he's like, you know, we just 
were fed a bill of goods, and he's regressed and he's like I 
was a big prescriber of OxyContin. When I talk about 
these "pill mills", I mean, these were guys that had been 
like disciplined in other states, that lost their license in 
other states, and then show up in southern West 
Virginia. These were bad, bad guys. 
 
MR. MCGINLEY: Can I say just one thing about 
that? 
 
MR. EYRE: Yeah. 
 
MR. MCGINLEY: The legal actions now that have 
multiplied, I mean, they are looking for reliable legal 
theory, might be RICO, might be common law, whatever, 
but the thing that exists is intent and knowledge. You 
can't look at those numbers and believe that this was a 
legal operation. And the doctors made millions. The 
pharmacies made millions. The distributors and the 
manufacturers made billions. So, you know, there's the 
intent, there's the knowledge. It's looking for creative 
lawyers and law that would at least try to bring some 
money back to the communities and try to figure out what 
the solutions are. And I know you're going to be talking 
about that on panels this afternoon. I mean, this is a long 
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road. It's difficult. Money is important and it's just one of 
the parts of the puzzle. 
 
MS. JACOBS: So we don't have tons of time left 
but do you have questions? Anybody have questions? 
 
UNIDENTIFIED SPEAKER: I missed whether or 
not you got that all unsealed or not. 
 
MR. MCGINLEY: Yes. 
 
MR. EYRE: Well, actually, companies that settled 
previously were allowed to keep their numbers under 
seal, who had settled previously with the State. But we 
got most of the larger companies. 
 
MR. MCGINLEY: The complaints in— the second 
amended complaint is in the materials and it does say 
redacted, that was almost wholly redacted, so we have 
some of the ones that settled. The judge let them off the 
hook. I think we could still get that through— 
 
MR. EYRE: Miami-Luken was the one— probably 
the one— the largest of the ones that were nonexempt. 
But a lot of them are real small and didn't have large 
distributions in the state. And I could see from the DEA 
data that I had later which ones were, you know, larger. 
We got Amerisource Bergen, we got Cardinal Health. The 
McKesson case is a separate lawsuit that's still pending. 
 
UNIDENTIFIED SPEAKER: Well, the same way 
that the states sue tobacco companies, is that going on 
yet? 
 
MR. EYRE: Yeah. And one thing we haven't 
talked about yet is that there's been some evidence, in 
particular with McKesson and Miami-Luken, that there 
were concerns brought to higher-ups, to executives, from 
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regional managers, and things like that, that these 
numbers were extraordinarily high. There was 
something with the McKesson, there's a separate action 
against McKesson by shareholders in Delaware and 
there's allegations that there were actually concerns 
brought by certain employees to the Board of Directors 
and they didn't do anything, allegations. 
 
MS. JACOBS: And, interestingly, one of the main 
tobacco lawyers, Mike Moore, is involved in a lot of these 
suits, the pharmaceutical suits, also on the plaintiff's 
side. So they're getting that same coalition together to 
work on these pharmaceutical cases. 
 
MR. MCGINLEY: One of the problems with those 
suits is if the plaintiffs are awarded compensation, will it 
go to deal with the problem. That's one of the problems 
with the tobacco suits and the lawyers— there's a lot of 
good lawyers. Moore is, you know, he's effective but— and 
they will make money. That’s what lawyers do. But will 
the proceeds go to help solve the problem. 
 
UNIDENTIFIED SPEAKER: I have some family 
there, married into family that's from Boone County. So 
I guess what I'm thinking is what now. There's all of this. 
Obviously your work has exposed a lot of this. But what 
is happening in West Virginia to try to help these people? 
 
MR. EYRE: They did take the money from the 
settlements and put it towards treatment beds but the 
sad thing is— 
 
UNIDENTIFIED SPEAKER: The trouble with 
those towns, like when I go to visit my husband's 
grandmother who is in Madison, you know, she's lived 
there— 
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MR. EYRE: That's where all this started, in 
Madison. 
 
UNIDENTIFIED SPEAKER: Yeah. 
 
MR. EYRE: Everything started in Madison. 
 
UNIDENTIFIED SPEAKER: Like I know where 
Larry's is, you know, I've driven past there. There's no 
one hardly left in the town, I mean, they've either moved 
away, died. 
 
MR. MCGINLEY: One of the problems is that, you 
know, people who are disempowered who have lost their 
jobs in the coal industry, you know, they've lived in the 
area, their family has been there for generations, what do 
you do. And, you know, coalminers that were injured, 
they take painkillers, and it just steamrolls. And an 
economy that is already going down is plagued by this 
epidemic. And it's an enormous problem. I would say— I 
mean, there are certainly well-meaning people 
throughout West Virginia who are trying to come up with 
solutions, but there's a lot of talk too and there are people 
who are trying to make a profit off of the solutions. 
 
UNIDENTIFIED SPEAKER: And not enough 
money, right— 
 
MR. MCGINLEY: Right. 
 
UNIDENTIFIED SPEAKER: —to actually help 
all the people that actually have problems? 
 
MR. MCGINLEY: Right. 
 
UNIDENTIFIED SPEAKER: So unless it's on a 
national level— 
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MR. EYRE: And the problem is it keeps shifting, 
you know, it went to heroin, and then it went to Fentanyl. 
And now— I was just a week-and-a-half ago in Madison 
talking to Judge Thompson— you probably knew Judge 
Thompson— he said now I'm seeing all this crystal meth 
and cocaine overdoses. So it keeps shifting when you— 
 
UNIDENTIFIED SPEAKER: What about the 
pharmacists and the doctors, any disciplinary action, 
anything happening to the people who— 
 
MR. MCGINLEY: A little. 
 
MR. EYRE: The pain clinic, they— but that was 
like three years too late— but they finally indicted 12 
doctors that were affiliated with The Hope Clinic for 
something that occurred back in 2012 to 2015. 
 
UNIDENTIFIED SPEAKER: I'm from Tyler 
County. I did my undergraduate at WVU. I just recently 
last summer spent the summer working with the drug 
court of the Circuit of Marshall, Tyler, and Wetzel, so I've 
seen first-hand the experience of the issue. Just kind of 
piggybacking off of her question, it seems like the 
Suboxone is becoming a replacement for the addiction. I 
just wondered if you had looked into or, you know, this 
could speak to that issue that we are replacing a drug 
dependency with another prescription that has a high 
risk of dependency. 
 
MR. EYRE: Well, the Boone County judge has his 
drug court too and he is very upset because he's directed 
to do the treatment with Suboxone and they are diverting 
the Suboxone. Another problem that's cropped up is 
many of these "pill mill" doctors that lost their licenses 
and went to jail, they are out of jail now and now they are 
opening up Suboxone clinics next to legitimate, you know, 
the more corporate Suboxone clinics. They're opening up 
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and they are not doing any counseling, they're not doing 
anything but just handing out the sublingual things that 
they take. 
 
MR. MCGINLEY: That's a really important 
question. I know that there is some discussion in the 
panels this afternoon. I know Suzanne Weise is here and 
she's going to talk about it from her experience with the 
Child & Family Law Clinic at WVU. I want to give 
Suzanne the shoutout too because she was co-counsel in 
the FOIA cases and in our intervention in the "pill mill" 
cases. But I think that's going to come up in discussion 
this afternoon. 
 
MS. JACOBS: That's another interesting legal 
consequence though. Suboxone's maker is a British 
company, Reckitt Benckiser, and they actually are being 
sued by 35 U.S. states for artificially inflating their prices 
and for fraudulently trying to delay their patent 
expiration so to prevent generics coming in. So the kind 
of collateral consequences, again, you know, they are 
making all this money off of the crisis and now you have 
to address their bad actions because they've got a product 
that everybody suddenly needs, so . . . 
 
MR. EYRE: Yeah. The drug money that they 
distributed, they did some new grants for treatment, 
Suboxone people have a very strong lobby down at the 
Legislature, so all faith-based, peer-to-peer type 
programs were excluded from funding because they got it 
written in that you had to do medication-assisted 
treatment in order to qualify for funding into the grants. 
You've probably seen that with the drug courts; right? 
 
UNIDENTIFIED SPEAKER: Yeah. 
 
MS. JACOBS: One more. I think we have time for 
one more. 
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UNIDENTIFIED SPEAKER: Tell us what it's like 
the afternoon you get a telephone call and they tell you 
you've won the Pulitzer Prize. 
 
MR. EYRE: I was in shock for about three months. 
Yeah. We're— unlike the— we're just a little-bitty paper, 
30-some thousand in Charleston, West Virginia. I had 
always thought when you got the Pulitzer Prize that it 
was— if you've ever seen the photos in the New York 
Times and Washington Post, they're standing there with 
champagne bottles like they get tipped off. And then I 
realized later, they didn't really get tipped off but they 
just win one every year. Yeah, it was a bit crazy and . . . 
I don't know. The sad end of this, and I don't want to end 
on a sad note, but the numbers have continued to climb 
of the overdose deaths, as yours has as well. I think yours 
went up by I think 12 or 15 percent, again, because it's a 
moving target. But we at least have good people on the 
ground that are trying to work on it. 
 
MS. JACOBS: Thank you for the work you've 
done, and Suzanne. Thank you, guys. 
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THE OPIOID EPIDEMIC 
REGULATION, RESPONSIBILITY, AND REMEDIES 
 
Tricia Herzfeld 
Gerald Stranch 
Zack Buck 
 
MR. GROVES: My name is Alan Groves. I served 
as the Editor in Chief of the Tennessee Journal of Law 
and Policy from February 2017 until just a few weeks 
ago. My successor Editor in Chief will be moderating our 
second panel this afternoon. Our first panel discussion 
today is going to focus on some of the questions you all 
were asking at the end of the last session about 
regulation, responsibilities and remedies. So, our first 
two panelists to my immediate right come from the firm 
of Branstetter, Stranch and Jennings located in 
Nashville, Tennessee. In the past year, their firm has 
filed three different lawsuits in Tennessee against 
several opioid manufacturers. Tricia Herzfeld is a 2001 
graduate of George Washington University Law School 
and is now a partner at Branstetter, Stranch and 
Jennings. Ms. Herzfeld has previously served as Legal 
Director of the American Civil Liberties Union of 
Tennessee where she successfully litigated dozens of 
high-profile civil rights cases in state and federal courts. 
She has also served as a public defender in Miami where 
she conducted over 80criminal trials. In 2012, she was 
selected as one of the nation’s Super Lawyers, and among 
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those with that honor, she attained Rising Star status in 
2013.  
Her colleague, Gerald Stranch, received his law 
degree from Vanderbilt University. He is now the 
managing member of Branstetter, Stranch and Jennings 
and chairs the firm’s complex litigation team. He 
oversees the firm’s securities, class actions, antitrust, 
shareholder derivative, mass tort and consumer class 
cases. Mr. Stranch also served as an adjunct professor at 
Vanderbilt University School of Law. He was named the 
top 40 under 40 from the National Trial Lawyers 
Association and was named the Mid-South Rising Star by 
Super Lawyers.  
And finally, Professor Zack Buck at the end of the 
table, teaches a variety of health law classes at the 
University of Tennessee College of Law, including a 
bioethics and public health seminar, torts, health care 
finance and organization, health care regulation and 
quality, and health care fraud and abuse. His scholarship 
examines governmental enforcement of laws affecting 
health and health care in the United States. Before 
joining UT, Professor Buck taught at Mercer University 
School of Law, Seton Hall University School of Law and 
the University Pennsylvania School of Law. He also 
practiced complex commercial litigation at Sidley Austin 
in Chicago.  
So, with this distinguished panel now introduced, 
let’s just jump right into our first question, and we are 
going to start off where the last panel ended talking about 
remedies and particularly the search for a cause of action 
in some of these lawsuits that have been filed.  
So, Ms. Herzfeld, I’ll throw this first question to 
you. Can you talk to us a little bit about the suits that 
your firm has filed and particularly why you chose to 
bring those causes of action that you did, the statutory 
and the common law public nuisance claims and then 
also a cause of action under Tennessee’s Drug Dealer 
Liability Act. 
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MS. HERZFELD: Sure. Thanks very much for 
having us. We appreciate the opportunity to talk about 
our lawsuits. Lawyers always like to talk about their 
lawsuits, so we can answer any questions you all have, 
and we happily do so. Our lawsuit that we brought− we 
have actually brought three different lawsuits 
throughout Tennessee. They have been filed in the 
Tennessee state courts. So that means our lawsuits are a 
little bit different than the vast majority of them across 
the country. Those have been filed primarily in federal 
court or have been moved to federal court. So, we made a 
very, very rational, I think, and determined decision that 
we wanted to keep our cases in state court, and there 
were some reasons for that. We don’t think that a federal 
judge, with all due respect to the federal judiciary in 
Cleveland, Tennessee, where the multi−district litigation 
is, is going to have the same understanding of the real 
day-to-day impact of the opioid crisis. So, we really made 
a point to file our cases in Tennessee.  
So, the first case that we filed is in Sullivan 
County, Tennessee, so up in the very, very top corner in 
the Appalachian region where it is really ground zero to 
the opioid epidemic here in Tennessee. They have the 
number one statistics for births of children that are born 
dependent on opioids, and so those children are classified 
as having neonatal abstinence syndrome, and that was 
the primary reason that we decided to file that first case 
there. Our cases are a little bit different than many of the 
others, because ours has primarily been filed by District 
Attorney Generals, and I think you are going to hear from 
one of our clients a little bit later today. We did that 
because we have a somewhat unique− I say unique, sort 
of− statute in Tennessee called the Drug Dealer Liability 
Act. Now, the Drug Dealer Liability Act initially was put 
together by an organization called ALEC. Has anybody 
heard of ALEC? American Legislative and Exchange 
Council.  
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So, they put together somewhat conservative 
proposed legislation and kind of pushed that legislation 
out throughout the country. I think it was 23 states ended 
up passing various versions of the Drug Dealer Liability 
Act back in the day, and Tennessee was one of them. 
Now, initially the Drug Dealer Liability Act was 
supposed to− I think the thought process at that point 
was, there was a crack cocaine epidemic, and the idea was 
to be able to go after the higher−level drug dealer chain, 
not just the person you’re buying from or the person at 
the drug house, but kind of going up until you get to the 
suppliers and the producers, further and further. So, we 
took that law and decided, well, it kind of seems like the 
same thing for opioids; right? You have the street-level 
dealers. You have the people that they are getting them 
from. You have the pill mill doctors who are supplying 
them, which is often without a legitimate prescription; 
that’s mostly how that happens. They get them from 
various pharmacies, who get them from distributors, who 
ultimately get them from producers. And why is that any 
different than a drug cartel? So that’s why we decided to 
file under the Drug Dealer Liability Act, because, 
truthfully, we think the opioid epidemic and the way that 
it’s impacted Tennesseans and most of the state, it really 
is illegal drug activity; right? That’s really what we’re 
talking about. It may have the veneer of being legal, 
because there are legal uses for opioids, but the legal uses 
of opioids are not what is causing this epidemic and 
causing so many people to die. It’s the illegal uses.  
So, we’re really trying to tackle it from that way. 
Now, the Drug Dealer Liability Act has a lot of benefits 
to it. One of them that we really like is, there’s not that 
level of causation. So, the principles of this law are more 
actually rooted in antitrust, so it’s market participation. 
So, all we have to prove− all we have to prove− is that 
someone or a corporation knowingly participated in the 
illegal drug market, and as you have heard earlier, with 
those numbers, how could you not have known; right? I 
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mean, the diversion is clear, the news stories are clear; 
we simply have to prove that they knowingly participated 
in this illegal drug market. Now, a lot of other causes of 
action shave been filed, a bunch of other different 
lawsuits across the country. They are more of a 
traditional negligent standard, where you would have to 
prove in this context that this individual got this pill from 
this person, there was a duty, there was a breach, and 
you’re going to have to work your way all the up pill by 
pill all the way through. That’s not required under the 
Drug Dealer Liability Act. So that’s why we chose that 
cause of action. The other one that we filed is, we filed 
under common law and statutory nuisance, and you will 
see nuisance showing up in a lot of the lawsuits 
throughout the country. Specifically, for us, our District 
Attorneys typically file nuisance lawsuits. They are the 
ones who file those. They shut down houses of 
prostitution. They shut down crack houses. They do this 
stuff all the time. So, it meshed very well with an 
additional cause that is typically within their purview 
infighting crime. So, the purpose of our lawsuit is to focus 
less kind of on consumer protection, more to really focus 
on the fact that these drugs are now being used illegally 
and everybody knows it. 
 
MR. GROVES: Mr. Stranch, I’ll throw the next 
question to you. Ms. Herzfeld just talked about the state 
law claims that your firm has brought, the Tennessee 
Drug Dealer Liability Act and then the common law and 
statutory public nuisance claims. Some attorneys for the 
opioid manufacturers have argued that federal 
regulations actually preempt any state law claims. So, 
what is your response to that argument? 
 
MR. STRANCH: Those defense lawyers are 
saying anything and everything they can to try to shut 
this litigation down. They are absolutely shameless. They 
are even attacking whether cities and counties have the 
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authority to bring the lawsuit or to hire outside counsel 
to do it. Their entire strategy right now is delay, delay, 
delay as long as possible. I don’t think the federal 
regulations preempt anything in our litigation in 
particular, because we have specific state statutory 
claims that don’t talk, reference or have anything to do 
with federal regulations. One thing that’s clear is, this is 
not a complete preemption area like an ERISA where any 
claim at all would be preempted− field preemption is 
what it’s called. They have not really raised federal 
preemption in our case in the motion to dismiss that we 
already argued. They did throw in the rest of the kitchen 
sink, though. Some of the other cases that are out there 
might have more of a federal preemption issue, 
particularly with the distributors; the McKessons, the 
Cardinals, the AmerisourceBergens, those entities, 
because those claims are often based on− you have this 
federal duty that you have to report when certain key 
things occur, you didn’t report, so now I’ve got a cause of 
action against you, and so you might run into some 
preemption issues on that. We have chosen not to file the 
distributor cases yet until we can get the discovery so we 
can point to exactly what they knew and when they knew 
it so that we can plead around and avoid any possible 
problems with preemption. But, again, it’s not really as 
much of an issue for our case, because we are not trying 
to prove you knew about this through federal regulation. 
We are saying, hey, look, you not only participated in the 
illegal drug market because you continued to ship pills to 
known diversion sources. So, it’s completely outside of 
that realm. And so, we’re a little bit different in what we 
do. But, yes, they are raising any and all defenses that 
they can to delay this as long as possible. 
 
MR. GROVES: Thank you. Ms. Herzfeld, you 
mentioned the remedies that are available for some of 
these causes of action. Can you talk about what kind of 
damages that you are hoping to obtain for the clients that 
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you represent, and are there any procedural or legal 
obstacles that you face in obtaining those damages? 
 
MS. HERZFELD: So, we are hoping to obtain 
really big damages for our clients, huge, huge, and there’s 
a lot of reasons for that, not because anybody is trying to 
get rich; right? When you look at these towns and you 
look at− Sullivan County, Tennessee, is a great example. 
I think someone in the audience said earlier that the 
towns are emptier. They are full of people that can’t get 
jobs, because nobody can pass a drug test, and that’s 
nobody’s fault; right? I mean, it’s not because you decided 
that you were going to become a drug addict and that’s 
how you wanted your world to end up. Nobody intends to 
become a drug addict. But you did have a workplace 
injury because you worked in the coal mines or you 
worked wherever it is, and your doctor gave you these 
drugs. Nobody intends to get addicted. Nobody intends to 
become a drug addict. And the consequences of that are 
just devastating, especially in a small town. We know 
that there are employers that have jobs they can’t fill 
because they cannot find sufficient people to pass a drug 
test. So, our case not only includes damages for the town, 
which I’ll talk about more specifically in a minute, but 
also claims for babies. So I think our case is the only 
casein the country, at least the last time I checked, where 
we have included claims on behalf of particular infants, 
and these are individual children whose identities are 
sealed; I know who they are, but their identities are 
sealed, and they were babies that were born dependent 
on these drugs, so their birth mothers took the drugs 
during pregnancy and at some point gave birth to these 
children who suffered enormously.  
So, I would like to talk about their damages first. 
What we know about the children that are born with 
neonatal abstinence syndrome is actually, pardon the 
pun, in its infancy. It’s not something that has been 
studied for an extraordinary amount of time, but this 
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phenomenon, neonatal abstinence syndrome and opioids, 
hasn’t been around that long. Here’s what we know: 
When these babies are born, they shake, they cry 
uncontrollably, you cannot sooth them. That is the one 
thing you will hear everyone say. They scream and 
scream and scream to the point where their volunteers 
whose only job is to cuddle the babies. They just walk and 
cuddle and rock and walk and cuddle and rock. And why 
is it? Because the children have had a constant supply of 
these highly-addictive medications in utero, and once 
they are born, it’s discontinued. Do you know how they 
treat those babies? Morphine. They have to give those 
babies morphine. In the first days of their life, they are 
given a bit and then they wean them down and they wean 
them down and they wean them down, and so they end 
up in the neonatal intensive unit and they are being 
given controlled doses of morphine to wean them down. 
So that’s the first few weeks, which is crying and shaking 
and rocking and horrible. But then what comes next? You 
have a lifetime of learning disabilities: oppositional 
defiant issues, inability to concentrate, emotional 
outbursts that they don’t understand why that is 
happening; the parents, the grandparents, foster 
parents, no one understands why this child is just not 
behaving in a way that makes sense, and what we’re 
finding, through the studies, is that most of that can be 
taken back to this exposure in utero. Babies are 
developing; there’s stuff that happens there. So, we are 
trying desperately to get damages for those babies. We 
know that they will have a lifetime of medical needs, a 
lifetime of special needs. They need early intervention. 
The educational costs, imagine the educational costs of 
taking a child with needs. We don’t quite understand 
through essentially 20 years. We don’t know what that is 
going to look like. And Tennessee has the highest number 
of babies born with neonatal abstinence syndrome due to 
opioid addiction. 
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MR. STRANCH: It’s a baby born every other day 
dependent on opioids. 
 
MS. HERZFELD: It’s so bad that the Children’s 
Hospital up there had to open up its own wing, its own 
wing with its own beds just for these babies. So, I don’t 
want to lose sight of that. Of course, we’re filing through 
District Attorneys who are seeking truth and justice and 
going to get the bad guys and drug dealers out of their 
districts; right, and that’s true and important and 
amazing, but also, it’s the babies; right? It’s the people 
who are raising the babies. It’s the families that are 
broken and destroyed by the fact that now the 
grandmother or the auntie or the cousin that’s raising 
these babies. And when you take that, and you multiply 
that not just from a one-family perspective, but from an 
entire community, the devastation is extraordinary. So 
what kind of damages are you hoping to get? Well, let’s 
see, prosecutors have to spend more time prosecuting, 
cops have to spend more time arresting, more Narcan, 
more ambulance costs, more emergency room costs, more 
overdose costs, more educational costs. Court system 
costs go up; right? Everything exponentially goes up. 
Those resources might have been used for other things, 
positive things, but instead they are all being diverted to 
deal with this completely overwhelming crisis.  
So, what are the damages? Good question. They 
are enormous. The other thing we have asked for, in 
addition to damages to fix all the stuff that’s happened in 
the past, is, we have asked for injunctive relief going 
forward, and that sounds crazy; right? How do you get 
injunctive relief on a pill epidemic, an illegal pill 
epidemic? But that’s what we want. We want the drug 
manufacturers to stop. That’s just the answer, stop, stop 
doing it. You know what you are doing, you know what 
the harms are, stop putting profits over people, stop. And 
if that means that they have to pay for remediation in 
order to make these things happen, in order to not only 
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make the communities whole for the past damages, but 
to pay for rehab beds, education, different drug courts, 
these types of things going forward to kind of help fix that 
damage, special ed students, all these things, they all 
need to pay that going forward. So, the damages are 
huge, and I think it will probably be a bit challenging to 
figure out exactly how big, because there’s a lot of zeros 
there. 
 
MR. STRANCH: One of the things you need to 
know about that, like in Hawkins County, the sheriff did 
an analysis at the jail. Eighty-eight percent of the jail 
population, which was full, was there because of pills, 
either DUI while high on pills, stealing to buy pills, 
domestic violence while high on pills. It’s all pills. It’s 88 
percent of the jail in Hawkins County. And so, we really 
can’t emphasize enough how bad this is in the 
communities. It’s easy when you’re in a city like 
Knoxville to miss exactly what’s going on in some of these 
smaller communities. 
 
MS. HERZFELD: We missed it. We didn’t know; 
right, until we knew? I mean, we didn’t know until we 
knew. It’s devastating. 
 
MR. GROVES: Professor Buck, we have heard a 
little bit about the suits against these drug 
manufacturers. Just from a broader public health 
perspective, what are the similarities in this type of 
litigation against the drug manufacturers to the 
litigation that occurred against Big Tobacco in the 1990s, 
and are there any differences? 
 
MR. BUCK: Sure. So, focused on manufacturers 
for a minute and talking federal regulations. I think 
there’s one kind of major similarity, and that is, in many 
of these claims that are the federal claims, there is a core 
to them that focuses on some kind of fraudulent 
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advertising. So the drug companies are actually 
advertising these drugs either direct to consumer or in 
doctors’ offices in some way that can be alleged to be 
fraudulent, and in that way we have a similarity with Big 
Tobacco in the 1990s. You know, they’re burying bad 
science, they’re minimizing poor results from clinical 
trials, and they may be actually misbranding these drugs 
through their misleading advertising. But beyond that, 
there are a lot of differences, and in particular there are 
three that I was able to kind of come up with in thinking. 
First, opioids have a lot of regulation around them to 
begin with. They actually are FDA approved to treat 
chronic pain, and we have been talking a lot about misuse 
of opioids and illegal use of opioids, but I think it’s 
important to also recognize that through the last 
generation of health law and policy, there’s been a lot of 
discussions about how chronic pain in this country is 
undertreated and how individuals have a stigma 
attached to them who are facing chronic pain, as well as 
the individuals who prescribe those drugs, and that’s 
complicating the regulation of these drugs in a way that 
never complicated the regulation of tobacco. Tobacco was 
not subject to FDA approval until 2009 in this country. 
Drugs that are sold in this country are approved by the 
FDA, and so we have a regulatory structure in place from 
the federal perspective that is different than tobacco in 
that regard. The second I guess you could say a way that 
these are very different is that these drugs are subject to 
a number of antifraud tools at the federal level when 
we’re talking about manufacturers. So, the most potent, 
you can talk about the False Claims Act.  
The federal government is able to go after 
manufacturers who misbrand their drugs, who advertise 
their drugs to doctors in ways that are untrue, because 
the federal government pays for these drugs through 
Medicare and Medicaid, and these programs allow the 
federal government to empower the Department of 
Justice to go after manufacturing companies who make 
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untrue statements in their advertisement. The problem, 
of course, with this way or this pathway is that there’s 
often a desire to settle these cases, particularly of course 
from the drug companies’ perspective, but also from the 
Department of Justice. There’s been a reliance on 
Corporate Integrity Agreements over the last couple of 
years that are put in place to try to govern drug 
companies’ behaviors going forward and check in every 
quarter on pricing or advertising. And I think the biggest 
challenge here is that misbranding is really profitable for 
these manufacturing companies. So if you’re a 
manufacturing company and you have gotten your drug 
approved for a narrow segment of the population, but you 
can go into a doctor’s office and allegedly talk about an 
off−label use that the FDA has not approved your drug 
for, which is the case in the Purdue case around 
Oxycontin, they were minimizing the addictive effects of 
the drugs to the doctors; that’s the allegation. There’s a 
huge market out there for which you do not have to go 
through the FDA to seek approval. You can get doctors to 
prescribe your drug off label, and often doctors will do so. 
It’s a very profitable thing, if you are a private company 
and you owe a duty to your shareholders to maximize 
profits and you see that you can open up the market by 
eight, nine, ten billion dollars and the statutory penalties 
might only amount to a two or three-billion-dollar 
settlement, that’s a calculation that many drug 
manufacturing companies make. And so, I guess the 
thing that I would say about this is that our enforcement 
and regulatory system here is not potent enough and that 
we settle too much with drug companies in this respect.   
Of course, there’s also a challenge that if you take 
a drug company to trial for one of these cases, what faces 
them, in the event of a bad verdict from their perspective, 
is exclusion from Medicare or Medicaid, and that means 
they can’t basically do any business with anybody related 
to the American healthcare system, to which they make 
the argument to the Department of Justice this is 
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something that will hurt a lot of people. Like the Pfizers 
of the world going to court and saying we do a lot of good, 
so you can’t exclude us because think about all the 
patient harm that will come. And I know I’m blowing that 
out of the perspective there, but that’s the heart of the 
argument from the pharmaceutical company. The final 
thing, the third I think big difference is going back to a 
point that I had made earlier, which is a lot of these 
drugs− and this is what makes this problem so 
complicated and much more complicated than the tobacco 
problem− is that, again, these drugs, some of them are 
indicated, some of them are legitimate. We can’t 
categorize them all in one way or the other. And we built 
the system, at least in this country, around prescription 
drugs that values professional autonomy, and it 
complicates the regulation of prescription. We trust our 
doctors and we give them a lot of authority and discretion 
to make determinations about our drugs. And so, the best 
way I think we can try to go about this problem is to go 
after the manufacturers using the tools I mentioned. I 
think those are the things that complicate the analysis 
when we’re comparing it to tobacco. 
 
MR. GROVES: Mr. Stranch, Professor Buck just 
talked a little bit about the federal government’s 
involvement from a regulatory perspective, but let’s talk 
about what the Justice Department has done just in the 
past year. In August of 2017, the Justice Department 
announced the formation of the Opioid Fraud and Abuse 
Detection Unit, which will temporarily provide financial 
resources to 12 of the 94 U.S. Attorney’s Offices for the 
purposes of prosecuting health care fraud and abuse, and 
the Eastern District of Tennessee U.S. Attorney’s Office 
was selected to participate. So how significant of a 
development is this in your mind, and in general what 
should the role of the federal government be in 
combatting this crisis? 
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MR. STRANCH: I mean, they’re putting drapes on 
a burning house. You’re not going to arrest your way out 
of this problem. It’s way too big. The time to do that was 
25 years ago. And the federal government, there’s been a 
complete failure of the regulatory system to do anything 
about this, both at the state and at the federal level. I can 
tell you, from representing District Attorney Generals, 
that they are absolutely underwater with pill problems. I 
mean, it’s the number one thing they deal with. We have 
even got one DA that we’ve talked with who says, look, if 
I dig hard enough on any case that comes into my office, 
there’s going to be pills in there somewhere, I’ve just got 
to dig deep enough to find it, and I take a little slightly 
view, I say maybe in 99 percent of the cases, but he’s 
adamant it’s a hundred percent. That’s how bad the 
problem is. So, some funding to help find opioid fraud and 
abuse and maybe shutdown a pill mill here or there, it 
will be nice, it will help, but it’s− I mean, you’re standing 
at a breaking dam and you’re sticking your finger in a 
crack. It’s going to take the full weight of the federal 
government, the state government, the court system 
through private litigation and the legislature in changing 
laws if we’re actually going to try to get ahead of this 
problem, because right now we have not even hit the crest 
of the tidal wave. It is still coming. It is still getting 
worse. Every year there’s more babies born dependent on 
opioids. Every year there is a rise in the number of deaths 
due to overdoses. And even in places where we have seen 
the overdose deaths start to level out, what we are seeing 
is a number of overdoses have continued to rise anyway, 
and what it is a reflection of is, now they have Narcan in 
the cop cars, now they have Narcan in the ambulances, 
so they can deploy immediately when something 
happens.  
We have got districts that we’re working with 
where they’re putting it in schools because kids are 
overdosing at school on opioids. So, a couple of million 
bucks from the Department of Justice to put five or six 
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people looking at pill mills is not going to change 
anything. I mean, it’s a window dressing so that someone 
can stand up and say, look, we’re doing something, but 
they are not really doing anything at all. I will speak 
briefly about Purdue for a second. They pled guilty to 
misbranding back in 2006, and they admitted to what I 
call the Holy Trinity of Lies. They said we told people that 
if you have true chronic pain, you will not become 
addicted to our pills. We told doctors and people if you 
have true chronic pain, you won’t develop a tolerance to 
our pills. And we told people if you have true chronic pain, 
you won’t go through withdrawal when the pills are 
taken away. They admitted in their criminal guilty plea 
that those statements were all false and they knew they 
were false at the time they made them, and these are 
statements that they were training their people to go out 
and detail doctors and tell them this over and over and 
over again, and it went on for over a decade before the 
federal government got involved on it. And during that 
time, Oxycontin use went from a mid-eight figure drug to 
a billion dollar drug every single year and created an 
entire generation of doctors that believe these scientific 
facts that are not facts that are in fact false, and it 
created an entire generation of addicts, and despite that 
guilty plea, despite paying $600 million that they paid as 
part of that and agreeing that they’re not going to do that 
and submitting to all these monitoring programs with 
states and the federal government where they’re 
supposed to submit, here’s the list of doctors that are 
prescribing our pills at certain levels, there’s been no 
enforcement action on that at all, and they have 
continued to do the exact same thing. At the time we filed 
our first complaint, they were still pushing OxyContin for 
use in chronic pain, for people that have a history of 
substance abuse and saying they probably would not get 
addicted or less likely to get addicted. This is on web sites 
that they run that they host with their name on them 
that are designed for doctors to answer their questions 
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about the drugs. The regulatory world failed, and they 
have done nothing about it. And having a couple more 
people in the U.S. Attorney’s Office who are focused on 
pill detection and finding street−level drug dealers, it’s 
going to do nothing. 
 
MR. GROVES: In the second half of the discussion 
I want to talk about some legislative policy proposals that 
are percolating in the Tennessee General Assembly, but 
before we get to that, Professor Buck, I’m going to throw 
the ethics question at you. Rule 1.6(c)(1) of the Tennessee 
Rules of Professional Conduct requires lawyers to review 
information relating to the representation of a client to 
the extent the lawyer reasonably believes disclosure is 
necessary to prevent reasonably certain deaths or 
substantial bodily harm. So, what are the implications of 
this rule for attorneys that are representing the 
pharmaceutical companies? 
 
MR. BUCK: Well, I think that the reasonably 
certain deaths or substantial body harm in 1.6(c)(1) 
probably is not as applicable as you might think when 
you take a look at it, because the individual that 1.6 
contemplates is identifiable, and it’s hard to make that 
causal link if you’re representing a pharmaceutical 
company. I think that the ethical question that is perhaps 
more interesting is, what if you find yourself 
representing a pharmaceutical company that wants to 
engage in some kind of activity that you think is 
fraudulent. This happens a lot in the health care world 
when I talk to people who practice, and it’s one of the 
things that keeps them up at night. If our client 
determines that they have gotten overpaid by Medicare 
or if they find that some of their scientific statements 
aren’t defensible, what is my role as the attorney?  
Tennessee’s rules are permissive in that instance, 
so you, as the attorney, have the ability to disclose, it’s 
not required, but it is available to you if you think that 
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you need to in order to prevent an ongoing crime or fraud. 
And withdrawal also is permissible, and so in the event 
that you might find yourself advising a client that’s 
unwilling to reconsider a course of action, the withdrawal 
would be permissive. There are cases in which 
withdrawal is required, and that is when you know that 
your client is using your services to perpetrate a crime, 
so the line between those two standards is pretty blurry, 
but usually there’s a lot of discretion given to the attorney 
to decide what he or she needs to do in that instance, but 
it is not an easy place to be in, and it happens I think 
fairly regularly, so it’s worth thinking about when you’re 
talking about the topic. 
 
MR. GROVES: Now we will make that transition 
and we’re going to talk more about legislative policy 
proposals. As many of you might know, Governor Haslam 
recently announced his Tennessee Together Plan, which 
proposes a host of legislative and regulatory efforts to 
fight this epidemic, and the plan emphasizes three 
different strategies: prevention, treatment and law 
enforcement. So, I want to spend the rest of our time 
talking about this, and then at about 2:00, 2:05 we will 
open it up to audience questions; you can be writing those 
down. So, Ms. Herzfeld, some lawmakers in the General 
Assembly have suggested that one way to prevent future 
opioid addiction is to limit the supply and dosage of opioid 
prescription such as what was mentioned earlier, 
limiting new patients to a five−day supply. Others are 
calling for prevention education in public schools. What 
is your reaction to some of these preventative policy 
proposals? 
 
MS. HERZFELD: I think they are all really good 
ideas, and they are very, very well intentioned, but I 
think as Gerald has made it clear, we are really just kind 
of nipping around the edges at this point. Legislation 
alone isn’t going to fix the problem. I like the 
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three−or−five−day limit on the ability to get those pills. 
That is something that we have noticed is a really big 
deal. The stuff that we have reviewed, I mean, just the 
sheer number of pills that are given to folks, it’s crazy. I 
mean, it’s a crazy amount, when you’re getting a 
30−daysupply and five pills a day and four refills and 
doctors don’t even worry about it; sure, you want another 
refill, no problem. I had my tonsils out a couple years ago 
and they had given me hydrocodone, I think, and of 
course I had taken it for two days. I had my tonsils out; 
right, in my 30s, and it was painful, but after the second 
day, I was like my God, get me off of this stuff, like please.  
When I went for my follow−up a week after, the 
doctor is like do you want more hydrocodone? And I’m 
like oh, my God, no. They just hand it out to you so easily. 
And, again, I don’t think they mean anything by it. I 
think they’re trying to be helpful, at least in some 
circumstances. So, limiting that and limiting who can 
prescribe I think is really another important thing. You 
have a lot of nurse practitioners− and this is not to get 
down on nurse practitioners− but you have a lot of nurse 
practitioners who don’t have sufficient supervision who 
are running things kind of on their own and you are 
seeing an extraordinary number of these pills getting into 
the system that aren’t necessary, they are not medically 
necessary, it’s too much, it’s overkill, and a lot of that is 
coming through nurse practitioners. So, there’s a lot of 
things. There needs to be accountability; what is the 
enforcement mechanism if somebody is violating. There 
needs to be monitoring. There needs to be limitations on 
all that. I don’t think it can just kind of be one thing and 
here’s a little bit of education and we’re going to take the 
pills and make it for five days. It has to be a more 
omnibus kind of gigantic regulatory scheme to even begin 
to make a dent. 
 
MR. GROVES: Mr. Stranch, I was going to ask 
you if you thought $25 million was enough to fund 
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treatment and recovery services, but I think I know your 
answer to that. 
 
MR. STRANCH: Twenty-five million bucks won’t 
even run a quality facility in one area of the state for a 
year. Again, window dressing is all it is. What you need 
to know about addiction when you’re dealing with opioids 
such as this, you actually have multiple levels of addition 
you have to break. You have to break the chemical 
dependency. For many people in Tennessee, that is 
actually broken while they are in jail, because they lose 
the opioids, they go through withdrawal in jail. 
Oftentimes they receive little to no medical care or 
therapy as part of that process. They just literally detox, 
go through the shakes, horrible diarrhea, headaches, 
nausea, throwing up in the jailcell. That’s how it 
normally goes. Once you break the chemical dependency, 
you still have a behavioral dependency that has to be 
broken as well, and your brain won’t go back to the way 
it was before you started taking opioids for 12 to 18 
months after you have broken the chemical dependency, 
and so that’s why you have so many people that relapse 
in that first year, because their brain is still not back to 
normal and they’re feeling depressed, the hormones and 
things inside your brain and the way it works and the 
receptors are not working right again. They’re still not 
back to normal, so it’s easy to slide back to the addiction, 
because that feels good at that point. And so, if you really 
wanted to do this correctly, I mean, you can look at 
programs like the Tennessee Medical Association; they 
have an assistance program for doctors that become 
addicted.  
It’s a multi-year program once you enter it, and 
you lose your medical license if you don’t complete it. 
They have an 85-percent cure rate, but it’s a multi−year 
program. You have to go inpatient depending on the level 
of your addiction. You have regular meetings with people. 
You have regular drug tests. You have therapy on a 
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regular basis, not like 12−step−type stuff, but like sit 
down and talk about what’s going on in your life, what 
are your triggers, help to identify your triggers so you can 
deal with them, and $25 million is not going to let you do 
that for a couple hundred thousand Tennesseans that are 
currently addicted right now. Twenty-five million is not 
going to let you do it for 400 or 500 Tennesseans in one 
small area, and it’s certainly not going to provide the 
aftercare once you break those addictions and you’re 
trying to re-enter society as− as my father would always 
say for me, I just want you to be a taxpayer− try to 
become a taxpayer again. There’s no support services for 
that. Twenty-five million dollars is nothing. 
 
MR. GROVES: Professor Buck, part of the 
Tennessee Together Plan also involves law enforcement, 
and so the question that I have is, how do we enforce 
criminal laws that are already on the books with respect 
to users and distributors while also not re−enforcing the 
negative stigma that is associated with addiction or 
prescribing? 
 
MR. BUCK: I think it’s a very hard question to 
answer, so I’m just going to take up a couple minutes and 
then we can go to the audience. But going back on what 
was previously said, I mean, we don’t think about this as 
a holistic problem, you think about physicians or dentists 
prescribing these drugs and you ask yourself, well, why 
would they? Well, first of all, they are seeking to treat 
some symptom that you might have, but also, they are 
incentivized to do that. We pay them to prescribe in this 
country. Medicare pays more for drugs that are more 
expensive to those doctors. They get a higher cut of the 
cost. And so, until we actually look at our own laws that 
actually create some of this problem in the first place and 
reverse them, we’re not really going to make any dent in 
the problem. In talking about the criminal aspect, I 
mean, these issues that are so interesting find 
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themselves on the line between public health and 
criminal law, and I think part of the challenge is to 
adequately calibrate the response.  
Is it a public health problem or is it a criminal law 
problem? I’m somebody who approaches these issues 
from kind of a health policy perspective, and so I’m much 
more likely to treat them at least on the addict side as a 
public health problem. It reminds me of the case where 
the students, common law students in here or others who 
recently graduated, Ferguson versus the City of 
Charleston that you might do in common law. It becomes 
a Fourth Amendment case, but in that case the issue is a 
hospital is testing the blood of pregnant women who 
comes to the hospital against their consent, and then for 
women who test positive, they are given the option of 
either entering a drug counseling program or going to 
jail. Now, if you think about that and apply a public 
health lens, that’s a terrible program, because not only 
does it penalize people who might need medical 
assistance, but it deters people who need prenatal care 
from coming to the hospital in the first place. So, the first 
thing I would say to the governor is, do no harm, don’t 
have a system in place that deters people from seeking 
help that they need. And so, in that perspective, a public 
health perspective, would say let’s put more money on 
drug rehabilitation centers, let’s expand Medicaid in this 
state, let’s provide care for people who need it who don’t 
have access to these services, but I don’t think that’s the 
total answer. I think the other part of it is, you have got 
to calibrate the penalties for those that have the ability 
to change their behavior, and that’s the manufacturers, 
it’s the drug companies, it’s the distributors, and maybe 
it’s the doctors; maybe we need to change the way we pay 
physicians in this country, and also think about what we 
can do to the regulatory mechanism. Is it really doing 
enough to deter the pharmaceutical companies in this 
country to think twice about advertising their drug in a 
way that they can alleged to be fraudulent, even if it’s the 
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case that they stand to make a lot more money if they do 
so. So, I think we need to think about it from more of a 
holistic perspective. I think you have to be really careful 
that you don’t harm providing care for people who need it 
by leaning too far toward criminality for those who are 
struggling from addiction. 
 
MR. GROVES: We will open it up to questions 
now. I believe we have a couple of microphones that are 
going to be walking around, so if you will just raise your 
hand and I’ll call on you. I think right here in the front. 
 
UNIDENTIFIED SPEAKER: Thank you. As an 
attorney, if I’m working with the DPR and I’m being 
accused of knowingly lying three times with regard to 
relevant facts, even if I’m cooperating and remorseful, I’m 
going to lose my license for some period of time at least, 
and why do the manufacturers not lose their license for 
some period of time at least when they knowingly mislead 
and fraudulently tell things like that? 
 
MR. STRANCH: Because our government is not in 
the business of shutting down big business. They cut a 
deal with them, they take some money, they let them 
move on. I’ll give you an example of how bad it is. In our 
lawsuit, we sent requests for admissions. Each one of the 
facts that they admitted in that criminal guilty plea, we 
asked them just to admit it in our lawsuit, and they 
refused. They denied each one of them, said they are not 
true facts. 
 
UNIDENTIFIED SPEAKER: I was just 
wondering, you had mentioned that there are kids 
overdosing in schools now and I was wondering are those 
primary, middle or high schools? What’s the frequency 
that you all are seeing this now and where in the state, 
which schools, what area is that happening? 
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MR. STRANCH: It’s actually happening across 
the country. It’s showing up in high schools. So, one of the 
big things that’s going on is, school boards are now 
discussing whether they want to deploy Narcan in the 
high schools, because there’s been about a dozen or more 
overdoses that have occurred in high schools where kids 
would go to school, take a couple pills to help float their 
math class and OD. It’s particularly becoming a problem 
with the introduction of fentanyl and carfentanyl, which 
is dangerously potent, and you don’t really know how 
strong it is, because they’re pressing out pills to make it 
look like something, sticking a little fentanyl in it, and 
sometimes you’re getting a dose that’s ten times what you 
think you’re getting. They had an outbreak down in 
Florida recently where I think it was 12 students 
0D’dand died where they were all taking the same pills 
that were supposed to be one strength but were actually 
about 10, 12 times that strength. And so, yeah, it’s 
happening in high schools all over the country. I know 
there’s been a couple of deaths in Ohio. There were the 
deaths in Florida. We have talked to a couple people here 
in Tennessee that are looking into it for their high schools 
as well, as to whether they ought to be deploying Narcan 
for suspected overdoses in the school. It’s a real problem. 
 
MR. GROVES: We have another question down 
here. 
 
UNIDENTIFIED SPEAKER: This might be more 
of a rhetorical statement or rhetorical question. I’m 
thinking somewhat of an analogy to what’s happened 
with the groundswell against the NRA for what 
happened I guess a week and a day ago in Florida where 
at least the kid seemed to be −− there seems to be some 
friction, some impetus to fix. So, here’s my analogy, and 
I’m not sure it works, and I’m wondering what you think 
about it. So if I’m a doctor in Sullivan County, or a 
dentist, and I’m figuring I’ve got, off the top of my head, 
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a hundred colleagues, maybe 50, and I’m going to the 
local county club once a month to meet with them just to 
−− I don’t understand how the doctors in a smaller 
community like that, why there can’t be some 
groundswell from them that would be effective in 
preventing this or something. 
 
MS. HERZFELD: I think with a lot them, there 
actually is. We have talked to an extraordinary number 
of doctors who actually have an incredible amount of 
remorse, who have unwittingly participated in this and 
not realized. We were just talking about −−Gerald and 
our other law partner, Jim, were telling the same story 
about doctors who have said I have prescribed so much 
opioids, I have given all these things, and now I’m looking 
back going, oh, my goodness, how many people did I hook, 
how many people did I harm, and they were talking about 
two different doctors and two completely difference 
conversations, which is wild; right? But it’s not. There’s 
been a million articles− you can Google it− of doctors 
sitting down and saying did I contribute to this, how did 
I do this, and how do I get out of it, because now you have 
patients coming to these doctors, and I’m talking about 
the legitimate ones, I’m not talking about the Fentanyl 
pill mills; that’s a drive−through business. It’s different. 
It’s criminal. But for legitimate doctors, I mean, they are 
now trained to ask what is your pain level; right? When I 
was growing up, nobody asked that. It was how are you 
feeling, what’s your blood pressure, looked at your heart 
rate, blah, blah, blah.  
But now it’s please rate your pain. So, we as a 
society now expect the doctors to keep us out of pain, and 
if you go to your doctor and say I’m in pain and I have got 
this root canal, you haven’t given me enough medication, 
you’re mad at your doctor for keeping you in pain, and 
the truth of the matter is, he’s actually good; right? I 
mean, not all the time and not an extraordinary amount, 
but it is natural. There is a thing about pain. Sometimes 
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you’re going to be in pain. That root canal is going to hurt. 
So, I think that friction between the doctors and the 
patients of I’m expecting you to make me feel better and 
the doctor doesn’t want to give you something but yet 
needs to give you a little something and there’s a dance 
there. There have been some extraordinary things 
written that you can find online where doctors talk about 
that struggle. 
 
MR. STRANCH: By the way, the whole focus on 
pain and how we should never have pain, there’s all these 
groups, Americans Against Pain, the American Society 
for the Prevention of Unnecessary Pain, I mean, they are 
all front organizations that have been funded by the 
opioid manufacturers, and that’s what started this fifth 
vital sign of your pain, because they want to be able to −− 
they have something that they can justify, but it’s 
completely subjective. My grandmother, for example, 
every time she goes to the doctor −−she’s on her fifth bout 
with cancer −− doctor says what’s your pain on a level of 
one to ten. It’s ten. Every time it’s ten. The doctor finally 
says to her, well, it’s always ten. She says, well, yeah, 
either it hurts or it doesn’t. That’s what it is. That’s the 
way she views it. And so, what this pain thing is, it gave 
the doctors the ability to write down in the chart pain of 
eight, oxycodone and give support for it, when it’s just a 
completely subjective measure. There’s nothing objective 
about it. It’s not like your blood pressure or your white 
blood cell count or your temperature. It’s just a complete 
subjective thing that is used to justify prescribing pills. 
And they use these front groups to go in and train and to 
talk to doctors that people should not be feeling pain on 
a day−to−day basis. You should not ever feel pain, pain 
is bad. Well, that was an actual sea change in the way 
doctors view things.  
I blew my knee out playing rugby in the ’90s and 
had to have a knee surgery. When the surgery was done, 
the doctor said to me afterwards, look, I’m going to give 
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you this five-day prescription for pills, but I only want 
you to take them when the pain gets to be too bad. The 
pain is supposed to be your guide. It tells you what you 
can and can’t do with your knee. If it hurts, stop doing 
what you’re doing, because you’re going to over-extend 
and reinjure yourself. That’s what the purpose of the pain 
is. It’s a warning sign to you to don’t do that. And they 
have completely changed that. And the doctor told me you 
should probably only be taking these pills at night, 
because you’re going to be worn out, your knee is going to 
be hurting and it will help you fall asleep. That was it. A 
friend had a very similar surgery last year. He got a 30-
day supply of Oxycontin and the doctor said, "And if you 
feel any pain at all, you call me, and I’ll get you something 
stronger." That’s the change, and it’s this emphasis on 
pain that is not created through the medical community 
by doctors doing largescale studies, blind studies, double 
blind studies, observational studies, longitudinal studies, 
it was created by a bunch of front groups that the opioid 
manufacturers supported, because that’s how they can 
push their pills. 
 
UNIDENTIFIED SPEAKER: The first ten years 
after law school, I did plaintiffs’ asbestos work and so I 
know what’s in front of you and I wish you well. I’m 
interested in causation and damages. Addicted children, 
they don’t all have these horrible effects later in life. Now, 
I’m in family law and I know that. So the test that we 
were stuck with is, if you’re going to say− we were faced 
with this: Okay, yeah, this guy has had all this asbestos 
exposure, he has a much, much higher risk of contracting 
cancer later on, but you have got to prove it’s more likely 
than not that this guy is going to have cancer, so how are 
you going to, A, prove that this baby is going to have 
learning disabilities and obstructive disorder eight, nine, 
ten years from now and there are kids that have learning 
disabilities and obstructive disorder who never were 
exposed to opioids? So, you have got to get over that too, 
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that it’s this and he wouldn’t have just already had it, and 
I can’t imagine how you’re going to do that. So how are 
you going to do that? 
 
MR. STRANCH: For starters, the Drug Dealer 
Liability Act has a specific section that deals with 
assigning claims to babies that are exposed in utero. So, 
they have a specific test already for what you can do, and 
we know for the kids that we filed, they already have 
those problems now. They already have impulse control 
problems now. 
 
UNIDENTIFIED SPEAKER: How old are they? 
 
MR. STRANCH: They range in ages. Most of them 
are close to school age or in school. 
 
UNIDENTIFIED SPEAKER: Some of them will 
graduate from college before you’re through. 
 
MR. STRANCH: More than likely, more than 
likely. But one of the things that what we believe the 
current state of medicine to be on this is, look, if you’re 
exposed to significant amounts of opioids in utero, you’re 
going to have impulse control problems later in life, 
period, full stop, that’s going to happen. The question 
becomes, are you able to deal with it, control it or not, 
which is kind of ironic for someone with impulse control 
problems, but the way it works is, you have to do early 
childhood intervention and you have to work with the 
children from day one and you have to provide them with 
a stable environment so that they cannot have external 
stressors. One of the problems of the opioid epidemic is, 
of these babies that are born with NAS, like 25 percent of 
them end up in foster care within a year. Many of them 
end up bouncing in and out of foster care.  
So, they don’t have a stable environment to start 
with, which only causes to exacerbate the impulse control 
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problems. Now, if a kid gets adopted straight out of 
coming out of the NICU, goes to a stable, loving family 
and they take care of him and they provide all of the early 
childhood intervention, you may see a child that is going 
to graduate and, as my dad said, become a taxpayer. 
Greatest thing you could ever want for your kid is to 
become a taxpayer. But that doesn’t mean that there’s 
not going to be problems and struggles and the 
behavioral therapy and other stuff that’s going to have to 
be done along the way. We also know from another child 
we represented that it can be much more than just 
impulse control problems. It can literally be a question of 
will this child ever be able to be a functioning member of 
society without having to have an adult doing things for 
them and overseeing them. 
 
UNIDENTIFIED SPEAKER: The corporate boys 
are going to say prove that this kid doesn’t need $1,000 
worth of treatment rather than the$500,000 worth of 
treatment that you say he needs ten, 15 years from now. 
 
MR. STRANCH: We’re still struggling to get them 
to admit they’re selling opioids. They’re not admitting 
anything. But we’re going to have our experts that are 
going to go through and that are going to talk about 
what’s facing these kids, what’s going to happen, what 
money is going to have to be spent on them, the problems 
they’re going to have, and they’re going to have their 
experts, like in all cases where you have medical experts, 
who are going to say this kid was never harmed, and if 
there was any harm, it was because the dad had bad 
genetics or the mom had bad genetics and they all 
preexisted and had nothing to do with this, and by the 
way, would you like some opioids?  
I mean, that’s what they’re going to do. And I just 
think our experts are going to be more believable than 
theirs, because we’re going to be putting them in front of 
a jury that is going to be living in a community where 
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they’re seeing this on a day−to−day basis, where they’re 
seeing the disruption in the classroom through their kids 
and their neighbors’ kids. Our first hearing that we went 
to in our case, there was three divorces on the docket, and 
two of them was because the spouse ran off because she 
was addicted to pills. These communities know this, and 
they are not going to be very impressed with a medical 
doctor that comes in and says there’s no long−term harm 
damage from shooting up opioids during pregnancy and 
that these kids are not going to have any problems, and 
if they do, it’s because they didn’t have a stable home life 
beforehand and they’ve got bad genetics. 
 
UNIDENTIFIED SPEAKER: Baby Doe is a very 
sympathetic plaintiff. 
 
MR. GROVES: That’s about all the time that we 
have for this panel of discussion. Join me in thanking our 
panelists for joining us. 
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RESPONDING TO THE IMPACTS OF 
THE OPIOID EPIDEMIC ON 
FAMILIES 
 
Wendy Bach 
Suzanne Weise 
Barry Staubus 
 
MR. ANDREW SCHRACK: Good afternoon, 
everybody, and welcome to our second panel today here 
at “Healing Appalachia.” My name is Andrew Schrack. 
I'm the current Editor in Chief of the Tennessee Journal 
of Law and Policy. It’s my privilege to introduce our next 
panel. On our left here is Professor Wendy Bach, she's an 
Associate Professor of Law here at the University of 
Tennessee’s College of Law. She received her Bachelor's 
and Master’s from the University of Pennsylvania and 
her JD from New York University Law School. She's 
currently involved in research regarding the opioid crisis.  
Sitting next to her is Professor Suzanne Weise. 
She's the Director of the Child and Family Advocacy Law 
Clinic at West Virginia University College of Law. She 
received her Bachelor's from Boston University and her 
JD from West Virginia University College of Law. 
Professor Weise has encountered a lot of the effects of the 
opioid crisis in her Child and Family Advocacy Clinic.  
Finally, on her right is General Barry Staubus. He 
is the District Attorney General of Sullivan County, 
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Tennessee. He received his Bachelor's from East 
Tennessee State University and received his JD from 
Memphis State University Law School. He was appointed 
as Assistant District Attorney in May 1994 and 
appointed to District Attorney General by Governor 
Haslam on July 1st, 2011. He was elected as DA in 
August 2012 and re-elected in August 2014. He is also a 
plaintiff in the lawsuit that was discussed in the previous 
panel. The format for our panel is going to be that each 
one will have an opportunity to talk for about fifteen 
minutes, and then we'll open it up for questions and 
answers at the very end. To start us off, we have 
Professor Bach. 
 
PROFESSOR WENDY BACH: Thank you. I want 
to thank the organizers of this wonderful Symposium and 
everyone that is presenting with me today. It's obviously 
an extremely important topic. As you just heard, I'm here 
today because I’ve been conducting a study, and that 
study is actually about something I'm not going to talk 
about which was the prosecution of women in Tennessee 
for fetal assault. I’m happy to take questions on that. I 
know General Staubus knows a lot about that and would 
be happy to take questions. But what I wanted to do 
today instead is share some information that I've learned 
in the course of doing research. First, I want to talk to 
you about the profound medical complexity in the 
medical and treatment literature about NAS and 
maternal drug use.  
I want to talk to you a little bit about history 
because we've been here in some ways before. And then 
finally, I want to talk to you about the relationship 
between treatment and the courts. One of the things that 
I've done as I’ve conducted this study is, I've read a 
tremendous amount of medical literature, and I've 
spoken and interviewed medical experts about the use of 
opiates during pregnancy which you heard a lot about 
during the video. We're spoken about the effect on 
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children in the short and long-term and the best practices 
in the field for treating both moms and kids. And as I 
mentioned, at the same time that I've looked at history, 
and the last time we focused as a culture on the use of 
drugs during pregnancy during the late '80s and '90s 
during the crack epidemic. So going to today, beginning 
with NAS, I think it’s important that we know precisely 
what the condition is. And you've already heard about 
some of that today. How an infant gets it and what we 
know and don't know right now about the facts. And I just 
wanted you to know that I’m going to respectfully be 
slightly more moderate in what I have to say about the 
effects of NAS on children than you’ve already heard 
today. And that may be me just me not being a litigant or 
in this moment but me being a professor. But I wanted to 
share at least what I've learned. As you've heard, NAS is 
a diagnosis given to infants when they exhibit a defined 
set of symptoms associated with drug withdrawal after 
birth.  
Generally, NAS in particular is generally 
understood in the medical literature to be a short-term 
and treatable condition, the NAS infant. The infants you 
saw on the video were infants who were suffering some of 
the more extreme variations of NAS. But infants who are 
diagnosed with NAS have symptoms that vary 
significantly. So you saw some of the more severe sets of 
symptoms that we do see. On the less severe end, things 
like NAS can be treated without using drugs given to the 
infants, they can be treated with things like swaddling, 
right, comforting the infant, rooming in with their moms, 
if they’re still with their moms, and breastfeeding. And 
the literature says that for those earlier cases, those 
kinds of treatments are appropriate. So I think it's just 
important to know that this is on a spectrum and that 
some of the kids look like that but not all of the kids look 
like that. And this is— my job is to tell you that this is 
complicated. We know, as you heard, that an infant is at 
risk for developing NAS if the mother took opiates during 
the pregnancy. But what I want you to know about this, 
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and this has been referenced a little bit today, is that in 
Tennessee in 2016 over half the cases, 52.5 percent, 
result from the use of opiates that were prescribed and 
lawfully used. So this is a condition that is coming from 
lawful conduct by moms being prescribed. And the reason 
of that, the majority of those 52.5 percent, 86.1 percent of 
that group results from something called medication 
assisted treatment which you've also heard referenced. 
Medication assisted treatment, or MAT, is the use of 
substances, methadone, suboxone, things like that, given 
in this case to pregnant women to treat their addiction. 
Now, this may sound like a strange choice, and it may 
sound counter-intuitive that a doctor would give opiates 
to a pregnant woman knowing that NAS might result. 
But what you should know is that the American College 
of Obstetricians and Gynecologists has long 
recommended MAT as the best practice treatment for 
women who are addicted to opiates. I’ll talk a little bit 
more about that. Some of it is— and some of it is, in fact, 
illegally used. But if 52 percent result from prescription 
drugs, most of that is MAT.  
The others result from an illegal use or a 
combination of legal and illegal use. Illegal use is— and 
you're not going to be surprised by this, because what 
you've seen today is almost entirely the result of 
prescription drug diversion. Something we've already 
heard a lot about, right? So that other big chunk is mostly 
prescription drug diversion or a combination of getting a 
legal prescription and then using drugs illegally that 
you're obtaining from some other source. Only 3.8 percent 
of NAS cases in 2016 were reported to be coming from 
heroin. So this really is what we've been talking about 
today, having to do with the prescription drugs. I already 
said that not all infants who are exposed to opiates are 
going to get NAS. And looking at the medical literature, 
at this point, I can say that we actually don't know a 
whole lot about why some babies get it and some babies 
don't. We do seem to know that MAT as opposed to 
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occasional use, take a couple of pills after knee surgery, 
you're going to be less likely to give birth to an infant 
than if you're on medication assisted treatment or long-
term opiates throughout your pregnancy, that can make 
it a little more likely. We also know, and this is 
important, that exposure to multiple substances not only 
makes it more likely, it appears to make it more likely, 
they could give birth to an infant with NAS, but that the 
NAS is more severe if you take different things as 
opposed to the same thing. That actually leads to an issue 
that a lot of people are talking about, because although I 
told you that the American College of Obstetricians and 
Gynecologists has always— has since the heroin 
epidemics, really, in the '70s, have said that methadone 
is the right thing to do, it might have been later than 
that, actually, but for a long time. There are some early 
research, some of it going on at UT, that says you can 
safely detox moms. And that if you detox moms during 
pregnancy, you will reduce the chance that you give birth 
to an infant with NAS. But this is difficult; right? It's 
difficult to do well.  
And if that mom relapses, as people often do when 
they detox, and then she goes and starts to use street 
drugs, then she's taking multiple substances. So, it's a 
very difficult set of decisions. And, you know, the more I 
got into this literature, the more complexity of this 
problem of what a mom should do when she's pregnant if 
she's an addict, of what she should do in terms of what 
medication she should take or not take, how the infant 
should be treated, are really difficult decisions, and they 
are very specific to that mom and to that baby. And the 
more I thought about this, the more I thought, these are 
decisions that we have to leave between, hopefully 
competent medical professionals— now we've heard a lot 
about not so competent medical professionals today— but 
hopefully good docs and their patients who are helping to 
understand this very complicated field and helping moms 
make the best choices they can make in those 
circumstances. Another thing I've learned a lot about is 
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this data research on the longer-term effects of NAS, and 
this is where I might differ just a tad. It's a very 
complicated question to answer; right? We know what it 
looks like at first, right, we know what it looks like in the 
infants.  
We don’t know who's going to look like that, but 
we do know what it looks like. There are some studies 
that show some developmental delays correlating with 
exposure. There’s lots and lots of stories; right? There's 
lots and lots of anecdotal evidence that the kids are 
suffering. But the studies aren't there yet, and I don't 
know if they're going to get there. And what's interesting 
is, when you look carefully at the medical literature, 
several researchers have suggested that once you account 
for things like socioeconomic status, exposure to violence, 
inadequate nutrition, prenatal and postnatal psychiatric 
stress, alcohol use, maternal education, lots of which we 
call the social determinants of health, it's really unclear, 
right, whether the issues we are seeing are as a result 
just of the opiate exposure or a combination of factors or 
something else. It is true, and this was said before, that 
infants with NAS or with any of those negative social 
determinants of health, are going to do better in stable 
environments with support.  
I promised you I would turn to history. I think it's 
important to look at history and know that we have been 
here as a society before. In the late '80s and early '90s, 
we've labeled a generation of mothers and children crack 
moms and crack babies. At the time— and it’s interesting 
because I've gone back to read the science. And at the 
time, scientists and doctors sounded a lot like the 
scientists and doctors today. They were conducting 
careful studies, they were seeing some early correlations, 
but the majority of those folks were appropriately 
cautious about what their findings meant, not so though 
the press, the public and the courts. The media building 
on the stereotypes of what were then majority poor black 
moms, predicted a generation of destroyed children who 
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would grow up with a whole host of behavioral problems. 
There were crack kids, and the assumption was that this 
would be a lost generation. But here's the thing, that 
turned out not to be true. After following those kids for 
over two decades, we’ve learned a good deal. There are 
effects smaller than predicted in development and 
cognition that are far less severe.  
And one long-term study I think is tremendously 
important. Dr. Hallam Hurt and her team conducted at 
twenty-five year longitudinal study comparing the 
development of infants exposed to crack cocaine to 
similarly situated infants who were not exposed. The 
study was launched in Philadelphia in 1989. Dr. Hurt 
and her team followed two hundred and twenty-four 
babies born between '89 and '92, half had been exposed to 
cocaine in utero and the other half had not been, and they 
were demographically incredibly similar. All the infants 
were born near full-term and were from low income, 
predominantly African American families. And at the 
time Philadelphia— and this is going to sound really 
familiar— was experiencing a drug epidemic similar to 
the opiate epidemic of today, nearly one in six born at the 
time at city hospitals had mothers that tested positive for 
cocaine. What her and her team found after twenty-five 
years were that there were "no significant differences 
between the cocaine exposed children and the controls."  
What they did find, however, was that both groups 
of children, poor kids, predominantly African Americans, 
those who had been exposed to cocaine and those who had 
not, lacked developmental and intellectual measures 
compared to their non-socioeconomically non-racially 
similar compatriots. So, Dr. Hurt started to look at what 
else may be harming those children. They looked at 
environmental factors and found that while being raised 
in a nurturing home led to better outcomes, significant 
proportions of the children by age seven who had been 
exposed to violence, gunshots, witnessing a shooting and 
seeing a dead body, that exposure correlated with 
depression and anxiety and delays. Ultimately, her and 
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her team turned their focus to the effects of the condition 
of poverty on developmental growth and since has gone 
on to focus her research on these issues. I tell you this 
story not because I didn't know whether history is 
repeating itself but as a cautionary tale.  
Those kids and the kids today absolutely need 
enormous support and services. I hope General Staubus 
and his fellow plaintiffs win lots and lots and lots of 
money to put into communities to support kids and 
families. But I think we need to be really cautious about 
labeling these kids and labeling these moms, and 
knowing, right, and be very cautious about the science of 
it, because the last time we did this, we labeled a whole 
generation of kids and we turned out to be wrong largely. 
This leads me to my final point, and that’s about the 
relationship between child welfare cases, family courts, 
criminal courts and treatment. A lot of the focus in the 
conversation has been on turning courts into hubs for 
accessing treatment. Drug courts and other problem-
solving courts explicitly embrace this model, and other 
courts use other staff, probation officers, drug treatment 
coordinators and the like, that helps folks in the system 
access treatment.  
Similarly, the Department of Children’s Services, 
DCS, has a duty to avoid placement, and as part of that 
work, they will often provide folks access to treatment. I 
just want to be clear, I think this is all wonderful and 
really, really important. There's no question that folks in 
those systems need access to treatment. But I do wonder 
if we're going too far, and I’ll tell you why. During my 
study I have talked to lots of folks in the criminal justice 
system across East Tennessee. General Staubus is one of 
them. And during one of the interviews, I interviewed a 
drug treatment coordinator at a rural northeast 
Tennessee court about how she gets folks access to 
treatment. It was clear from the interview done in this 
very small community she was it, she was the one who 
could access treatment. What became clear in the 
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conversation is that it took criminal charges to access her 
services. She explained that if a mom called her and said 
that she wanted to get help for her son or daughter, or 
whoever was needing treatment resources, the first thing 
she would ask is, can you catch him on a little charge, 
because then I can help him. She also explained that she 
had three grants available to her to pay for what is pretty 
much short-term detox treatment, and two of them 
required judicial signoff. So you had to have an open 
criminal case in order to get access to those treatment 
resources in their community. And then I started asking, 
I actually had been asking all along, and every actor in 
the criminal justice system that I have asked this 
question to so far agreed with me when I asked, is it true 
that it's easier to get treatment once you're in court. And 
everybody says, yes, that is how it works, right. That's 
where the caseworkers are, that's where the ones are that 
know how to work with the system. And I think courts 
should have access to treatment resources. But I get 
worried about the zero-sum game. I think if we are 
constantly thinking— and this is what Professor Buck 
was talking about, our public health systems to our child 
welfare and criminal justice systems, we might be 
drawing people into those courts that could be seeking 
help outside of those courts. So I'm going to stop for now. 
I'm happy to take questions. And I'll turn it over to my 
co-panel. 
 
PROFESSOR SUZANNE WEISE: Good 
afternoon. I should never have Power Points, so hopefully 
I will be able to do this correctly. So, I'm coming at this 
from a different angle, because, obviously, I think 
everyone would agree that fighting the opioid epidemic in 
Appalachia must occur on several fronts. So, the primary 
focus of my presentation is the role of family law clinics 
in cases where opioid addiction is the cause of child 
custody disputes in family court. In those cases, our clinic 
has been called upon to16address substance abuse issues 
and the need for the players in custody cases to obtain 
95
et al.: Symposium Issue 2018
Published by Trace: Tennessee Research and Creative Exchange, 2018
TENNESSEE JOURNAL OF LAW AND POLICY 
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION 
 
 
[356] 
treatment for opioid addiction. As you heard earlier from 
Eric Eyre and Pat McGinley, in 2016, West Virginia had 
the highest death rate from opioid overdose. And 
according to the American enterprises, West Virginia's 
economic burden from the opioid crisis amounts to four 
thousand seven hundred and ninety-three dollars per 
resident. Children in foster care, according to the West 
Virginia Department of Health and Human Resources, 
eighty-four percent of the children in foster care in West 
Virginia are in there because of the opioid problems of 
their parents. These children's adverse experiences raise 
their risk of substance abuse as adults. The 2016 report 
of the Surgeon General has recognized that the 
experiences a person has in early childhood and in 
adolescence sets the stage for future substance use and 
sometimes escalation to a substance abuse disorder or 
addiction. Early life stressors, such as the ones that I see 
that the children experience in the cases in which I’m 
involved, involve parents who may have an opioid 
addiction. Maybe it's another family member. They have 
a parent or family member who may be incarcerated on 
drug related charges. There's several factors, but those 
are a lot of what we're seeing happen.  
Research suggests that the stress caused by these 
risk factors may act on the same stress circuits in the 
brain as addictive substances which may explain why 
they increase the addiction rate. And as you've heard 
today, people who are affected by the opioid epidemic 
enter the legal system in many different ways. It may be 
because of drug charges, it may be because of abuse and 
neglect or it may be in family court and child custody 
cases. You usually have counsel appointed in criminal 
cases, at least in West Virginia, and in abuse and neglect 
cases in West Virginia where the party cannot afford 
counsel. However, under the current system, many 
affected by the opioid epidemic cannot afford counsel in 
family court proceedings. These families typically seek 
pro bono representation from Legal Aid and often they 
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will come to law clinics. We only have one law school in 
West Virginia in Morgantown, so we only have one 
university child and family law clinic. So, the WV Child 
and Family Advocacy Clinic that I direct represents 
children and families in custody and education matters 
but also other family related matters. Family courts in 
Monongalia and Preston Counties in West Virginia often 
appoint me and my students to serve as guardian ad 
litem to represent minor children in family custody cases. 
And importantly— and I'll talk about this in a few 
minutes— our clinic partners with Chestnut Ridge 
Center at the West Virginia University psychiatric 
facility and also with WVU Medicine/Pediatrics. And 
what we have is a medical-legal partnership with them, 
which I'll discuss in a minute. So, in the majority of cases 
that my clinic students and I litigate, at least one family 
member of someone involved in the case is suffering from 
some form of abuse, whether it's prescription painkillers, 
heroin. We’re seeing a lot more heroin and meth.  
Also, many of the children we see, they have a 
family member, parent, member of the household— we 
have a lot of mixed households in West Virginia, where 
not everybody is biologically related, they just come 
together because they all need a place to live, so they 
experience that some member of that household may be 
incarcerated. A lot of these children bounce from 
household to household, maybe because a parent can't 
provide shelter, a parent can't keep a job, so these kids 
are shuffled around. And these are the adverse childhood 
experiences that increase the likelihood that the children 
in these situations will also become addicts as a result. 
And I want to give you an example of a couple of cases 
that we're currently working on now as we serve as 
guardian ad litem for the children. In one case, all parties 
have tested positive for drugs at some point in the past 
two years. The biological mother tested positive for 
painkillers at the birth of her child. The biological father 
tested positive for marijuana at the initial court hearing.  
97
et al.: Symposium Issue 2018
Published by Trace: Tennessee Research and Creative Exchange, 2018
TENNESSEE JOURNAL OF LAW AND POLICY 
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION 
 
 
[358] 
And I have to tell you, in family court, testing 
positive for marijuana these days is not that big of a deal. 
The judges aren't as concerned about that because of the 
problems with these other substances. A biological 
parent actually raised this child up until this point, and 
that biological father, along with the fiancée, tested 
positive in court for opiates. There are also allegations 
that the psychological father sells and/or makes meth, 
and all parties have been arrested at some point, but are 
not currently in prison, and the parties have also called 
the police on each other as part of the dispute over child 
custody. So, our role in this case is to try to figure out the 
best interest of the child in every respect. In another case 
where we serve as GAL for the child, the mother 
tragically overdosed and died in 2012. The father claims 
he is recovering from his heroin addiction and wants to 
regain custody. There are allegations that his sister, who 
is the aunt, is selling heroin, and the child is currently 
living with the grandparents.  
So as guardian ad litem in both of these cases, I 
mean we can look at the facts, interview the people, talk 
to their teachers, talk to the healthcare providers, and 
then we can figure out where is the safest place for this 
child to be. At this particular time, what's going to be the 
best nurturing environment, what the options are. But 
resolving that is not going to resolve the drug addiction 
that is the root cause of the family problems, nor does the 
resolution of these issues address the children’s exposure 
to drug addiction and the effect it may have on them. And 
these children need healthy parents.  
When we are representing a client in a custody 
case, and we have some of those right now where the 
other party is struggling with addiction, we have asked 
the family court to make treatment a part of the relief 
given in the case. For example, encouraging the other 
party if you seek treatment for your addiction, this will 
help you with your visitation with your child, we can 
move from supervised visitation to unsupervised, maybe 
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we can move to overnight visits, maybe we can move to a 
weekend, maybe you can regain every other week and if 
you can regain custody. And we’ve asked the court to do 
this. And surprisingly, we've had very mixed results. The 
court, and one judge in particular, has seemed reluctant 
to make that part of the relief granted. In one case, said 
that we were somehow trying to gain an advantage. 
There's no advantage to be gained in these cases. Nobody 
wins. The win would be for the parent who is suffering to 
get the help he or she needs and for the best interest of 
the child. So this has prompted my clinic students and I 
to talk about what is our role. I mean, obviously, we'll be 
in a role as a lawyer. But do we have more of a role, a 
more important role in addition to just helping with— 
you know, with the legal issues that the parties have. So, 
I'm citing the West Virginia Rules for Professional 
Conduct, but ours are based on the Model Rules, and 
they're exactly like the Model Rules. So, under Rule 2.1 
of the Model Rules, "In rendering advice, a lawyer may 
refer not only to the law but to other considerations such 
as moral, economic, social and political factor that may 
be relevant to the child's situation"— or to the "client"—
sorry. And then the comments to that Rule recognizes 
that family matters can involve problems within the 
professional competence of psychiatry, clinical 
psychology or social work, and with consultation with a 
professional in another field is something that a 
competent lawyer would recommend, the lawyer should 
make such recommendations.  
And finally, the Rule also provides that the lawyer 
ordinarily has no duty to initiate an investigation of the 
client's affairs Orto give advice that the client has 
indicated is unwanted. The lawyer may initiate advice to 
a client, but in doing so, appears to be in the client's best 
interest. So how do we help our clinic clients or parties 
involved in the clinic cases get the help that they need? 
And this is where we believe our medical/legal 
partnership comes in to help with the treatment side of 
the opioid epidemic. According to key findings in the 
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Surgeon-general’s 2016 report on addiction, only one in 
ten people suffering from a drug use disorder get 
specialty treatment. And really, the low grade is really 
because of the resources— the lack of resources and 
what's available. And what happens is, because the 
limited resources are so limited, there can be waiting 
periods of weeks or even months just to get help. So 
medical/legal partnerships like the one WVU law has 
with, especially with Chestnut Ridge Center, which is a 
psychiatric facility, may be one way where we can work 
together to help these folks get the treatment that they 
need. And for those of you who don't know what a 
medical/legal partnership is, these are basically doctors 
and lawyers, and we have a memorandum of 
understanding that we’ve entered into, and doctors and 
lawyers are working together to address the 
communities' health-related social needs. Professor Val 
Vojdik established our first MLP at WVU Pediatrics in 
2010, and then she was stolen from us by the University 
of Tennessee. And she is now here. So, when she was 
taken away, I assumed her role as director in 2011. And 
I established our second MLP with Chestnut Ridge 
psychiatric facility in 2016.  
How does it work? The way it initially started 
with these medical/legal partnerships is the healthcare 
providers were referring their patients to us. And so it 
was really basically a one-way street. They were sending 
us their client, their patients to us and we were helping 
with their issues. And also, with the client’s consent, the 
healthcare providers were allowed to be involved with the 
client. And usually, we got the formal consent, but they 
were confiding in them anyway. But to get the formal 
consent for them to do that. And so what our goal is now 
is to now have it a two-way street, so that we’re able to 
consult with healthcare providers through the MLP to 
refer clients either to the Chestnut Ridge programs or to 
the other programs that they feel are more appropriate. 
And the reality is that simply referring the client to a 
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treatment program is not going to solve all the addiction 
issues. They've got to want to be helped. They’ve got to go 
through— most of them through a long process of 
recovering. Unlike drug court where you have the 
incentive, okay, you either go to jail or you're going to 
complete this drug treatment program. So you have the 
incentive, yeah, I don't want to go to jail, I'll complete the 
program. Or in family treatment courts where they say, 
you’re going to lose your kids, we're going to 
terminateyour parental rights if you don't go through the 
treatment program. Those are incentives. You don't have 
that in family court, because the worst thing that can 
happen in family court is that they're no longer the 
primary custodian, maybe they have just now supervised 
visitation or limited visitation or just visitation based on 
what the other parent will allow. And sometimes that 
incentive is not going to be enough. And so we have to 
help encourage them to want to get help for the sake of 
their children and to work with healthcare providers to 
make that happen. So I believe working together that we 
might be able to accomplish this.  
We were talking earlier, what does this long-term 
treatment involve. There are many stages to it, it’s not 
something that you just do in a couple of weeks. The one 
with Chestnut Ridge goes on for at least two years under 
this program. I mean it has stages where they taper off 
and then if they get through, then they can just go to 
meetings, have their follow-ups, and they are also treated 
with suboxone usually. And a law student— I don't think 
he’s here now, but he raised it earlier, and I think he 
raised a really important issue that's a subject for 
another whole another session, is the use of suboxone in 
treatment. Because what we've done, we've replaced, you 
know, the opioid with another drug. And so a lot of folks 
are on this for life.  
Originally, suboxone was used just to taper— the 
original use of it, at least my understanding is, it was just 
to taper a person off of the opioids, and now it's become 
the long-term solution. And I'm not a doctor, and I’m not 
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going to— I know there are cases where they try to take 
them off and other cases where they say it's not possible. 
But I think that's something that we really need to 
examine in the future as well. So a combination of this, I 
think that working together we can do this. But then the 
big question is, who is going to pay for this, which is 
always the question. In West Virginia, Medicaid will 
cover the cost of inpatient or detox partial 
hospitalization, care coordination and case management 
and they'll have prescription drugs like suboxone. We are 
still working in my clinic to try to figure out other 
resources that are available to help pay for these services, 
what services are available. Because just going to a 
suboxone clinic is not going to help you, they need 
counseling. They need somebody working with them to 
find out— you know, people don't just wake up one 
morning and say, oh, I'm going to become an opioid 
addict. There’s something underlying, and it could be 
something as simple as a car accident. We had a client 
that came in addicted as a result of pain resulting from a 
car accident, or some really underlying serious problems.  
We have another case where a woman who had a 
perfectly normal life, hooked up with her old high school 
boyfriend who happened to be a drug dealer and her life 
is a mess now. So there's all these reasons that you have 
to help the person and not just get the suboxone 
treatment but really needs counseling. Another tool to 
combat the opioid addiction in family court is— and I 
think we need to call upon the Bar for a better 
representation by lawyers. Rule 1.6, "Every lawyer has a 
professional responsibility to provide legal services to 
those unable to pay." And this is really an ethical 
commitment that has to be made by every lawyer. So I 
think that we need to call upon members of the Bar to 
step up. I think the family courts need to come up with a 
list of lawyers who are willing to provide pro bono legal 
assistance in family courts to help these folks with their 
custody cases. And finally, as part of the seminar 
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component of our family law clinics, I think we've got to 
start educating our law students about substance abuse 
and its origins so that they may counsel their clients 
where such a role is appropriate. Thank you very much. 
 
GENERAL BARRY STAUBUS: Thank you for 
inviting me. This is my second time here. Actually, I was 
here— The Federalist Society invited me in this very 
room to talk about legalization of drugs. Which we do 
have legalized drugs. All these opioids almost are legally 
given, and we can see what kind of disaster it is. But 
that’s for another day, another topic with another group. 
You all have been here a long time. I'm going to try to be 
short. So I'm going to start off with a clip of a video, and 
it's my appearance on the Today Show. It’s not an— 
making an attempt at self-promotion, but I thought it 
was a well-done video of the clip, segment that the Today 
Show had been doing on opioids. And it's done by Ronan 
Farrow. You may know him. He's the guy who broke the 
Harvey Weinstein story. Also, you may know him as the 
stepson of Woody Allen.  
And secondly, I would say, if I knew he was going 
to say Appalachia, I would have taught him to say it the 
right way. So be forewarned, he says it wrong. And third, 
I never had any physical contact with Matt Lauer during 
the filming and the presentation. So with that, I'm going 
to let them play the video. So I don't want to plow the 
same ground. You've heard from my lawyers who filed 
the lawsuits. I hope I don't repeat what they said. But 
how did I get involved in this thing? Well, the State of 
Tennessee passed a law years ago, Drug Dealers Liability 
Act. I've been a lawyer since 1985. I had never been a 
party to a lawsuit. I had filed some lawsuits for other 
people, and I signed my name on indictments, but I had 
to think long and hard, did I want to do this lawsuit.  
And I got to thinking, it's a good thing that they 
gave the jurisdiction to DAs to file this lawsuit, because I 
feel like as a prosecutor, I have a unique perspective. 
There are a lot of perspectives out here. I see the families 
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of the people that die of the overdoses. I've been to the 
NIC units, and I've seen the babies, I've talked to the 
nurses, I've talked to the doctors, I've talked to the rehab 
people. I've talked to the mothers who gave birth to those 
babies. I have met with the victims of many, many 
crimes. Probably ninety percent of all crimes in Sullivan 
County result in drug abuse. You know, if there's a 
burglary, somebody breaks into a car or a house, a 
building because they're looking for drugs. When they 
break in, they take stuff from people that's not theirs. 
When they shoplift— we have robberies where they don’t 
even ask for the money out of the pharmacy, they just 
want the pills. We have many, many impaired drivers, 
not on alcohol anymore, I see them pilled up, and they 
kill people. They wreck, they harm people, they kill 
people that are minding their own business in a car. I see 
people that are under the influence of drugs when there's 
a domestic violence event. Elder abuse, when older people 
are abused. There’s a number of ways.  
It's sometimes a family member is pilled up and 
they take their money, they take their drugs, they take 
their credit cards, or they neglect them, let them starve, 
put them in perilous condition. I've got one where one 
died. And the mother sat there and watched it happen. I 
attribute that to drug abuse because she was more 
concerned about getting out and getting pilled up every 
day. Almost every identity theft I see, worthless check, 
under the criminal— other crimes like that. Almost all of 
them relate back to people that are addicted to drugs. So 
I see that. Then I saw the pain pills. I don't know if this 
statistic was given, we have a number of pain pill clinics 
in our jurisdiction, and we have thirty-five suboxone 
providers in one single county. And one of the pain clinics 
was prescribing fifty thousand pills per week, fifty 
thousand, and a hundred and fifty thousand 
prescriptions a month in a county that has a hundred and 
fifty-eight thousand people. So I saw that, and I would 
see the people driving from West Virginia down to my 
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county and from southwest Virginia and other parts of 
East Tennessee and getting off the interstates, sitting in 
the parking lot with their kids having fights, eating 
chicken and pizza, playing cards, standing in line on New 
Year's Eve. You know that’s a legitimate doctor. All 
medical providers have people sitting in their parking 
lots from multi states on New Year’s Eve. So I see that, I 
saw that. And I see people going in there and getting 
their suboxone and getting their opioids. I talked to one 
mother who gave birth to a baby. She got opioids because 
she had hepatitis. She got morphine for hepatitis. Now, 
tell me that's a legitimate medical practice. That's the 
kind of things as a prosecutor I’m seeing across the board 
day-in and day-out. And Sullivan County leads the state 
in drug dependent babies. Tennessee is one of the top 
opioid users and abusers. One of the other statistics you 
may have heard, in Sullivan County, forever man, 
woman, and child, there's prescribed 5.5 opioids. Think 
about that. Three Tennesseans die per day by overdose. 
It exceeds the murder rate and car wrecks. And now we're 
flooded with fentanyl and heroin. So a lot of these addicts 
have gone beyond that. I talked to the health department. 
They said, we're on the cusp of a hepatitis C, HIV 
epidemic. Our prison population— our population since 
the '90s, in some cases, I think increased two percent, but 
our jail population seventy percent, almost seventy 
percent.  
You crowd that— you put seven hundred people 
in a five-hundred-person facility filled with drug 
addiction and intravenous drug users and hepatitis and 
you're having another health crisis. So those are the 
things that I see, that I saw, and they're not getting any 
better. I'm seeing it become worse. For the first two 
months, according to March, we’ve had about three 
overdose deaths a week, and almost everyone of them are 
fentanyl and heroin, where we used to see oxycodone and 
a mixture of drugs. And a good book that— I don’t know 
if you've heard about it, but a book that I read several 
years ago that was also a catalyst for me getting involved 
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in this lawsuit was a book called Dreamland by a guy by 
the name of Sam Quinones, and it tells how the first pill 
mills got established in Portsmouth, Ohio. And he 
tracked how everywhere these pill mills come, there's 
heroin right behind it. And when I read the book, we 
weren’t seeing heroin, we weren't seeing fentanyl. We are 
now. And people are dying. We had one provider— you 
may not know this, but nurse practitioners can prescribe 
opioids for pain clinics. We had one nurse practitioner 
who prescribed to at least seven people who have died 
from drug overdose. When I talked to the family of one of 
those people that died, she went personally into the pain 
clinic and said, don't give any more drugs to my daughter, 
please do not. And she says, as long as the law allows me 
to do it, I'll do it. And the mother was right, she predicted 
she would die, and she did. So I hear these stories and I 
see these facts and I see these events, and so I had to 
make a decision, do I want to file this lawsuit or not, do I 
want to stick my neck out. And I was lucky to bring in my 
DA buddies from next door, Tony Clark and Dan 
Armstrong, and we sat down and we had a meeting, and 
I told them I was onboard. And they said, why are you 
doing it?  
And I said, look, I woke up in the middle of the 
night and it just seemed like it was the right thing to do. 
What have I got to lose? And I hope we win, because I 
want a hair transplant. No, I hope we win, and I hope we 
win big, because it has been devastating to our county. 
It's been devastating to our area and outstate. I read that 
there's been a five hundred and forty percent increase in 
the prescribing of opiates. Do you think there's been a five 
hundred and forty percent increase in pain that people 
have? I don't think so. When you see the devastation and 
the death and the babies— and another story I'll tell 
about, and we touched on it, NAS babies. And I'm not 
here for that today, I don't want to really get into that. 
But I know a lady in a place called Stoney Creek, and she 
walked the walk. She adopted one of these babies. And 
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not only did she adopt these babies, but she set up a clinic 
for the women that I met that had drug addiction. And 
she tries to get those women the resources that they need. 
She's a model for what we ought to be doing in West 
Virginia and Tennessee and across the country. But she 
went a step further, she adopted one of those babies. She 
already had raised her kids, had grandkids, she adopted 
one of these babies. So, then she decided, right next door 
to the clinic where I treat the moms, where are they going 
to drop the kids off, next door. So, she has made a facility 
just for these babies for their unique problems that they 
have developmentally. She's designed a little— she's near 
Stoney Creek, which Professor White knows, is next to 
Elizabethton. So, she had a man who volunteered, and 
he’s built a little town, looks like a little speck there. And 
they’ve got a little place where if they get sensory 
overload, they can go. And one of the things— and a lot 
of these kids are freaked out by doctors because they go a 
lot, and stethoscopes and rubber gloves are a big problem. 
So, they have a veterinarian place, so they get to play 
veterinarian, the kids do. When they play veterinarian, 
they want to treat the little Teddy Bears and the dogs. 
They let them wear gloves and stethoscopes, just small 
things like that. They have a restaurant and they have a 
grocery store, so they handle food, because they have a 
lot of weird things about food.  
Those are the kinds of things that need to be done. 
If I win this lawsuit, she's a model for the kind of things 
that need to be done. There are a lot people that could 
help. There’s a lot of people that are helping. There's a lot 
to be done. But these companies, in my opinion, my 
humble opinion, is they created this problem. Now, they 
didn't make anybody take the drugs, I know that. When 
people say, everybody needs treatment. Well, no, if 
somebody is doped up and they run into the back of a car 
with your mom or your wife and your two kids and kill 
them, I'm sorry, I'm not in the mood for rehabilitation 
right then. But there are many, many that do need 
rehabilitation, either in the facility— but they need help, 
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and they need money. And we've seen the devastation. So 
that's what I hope the lawsuit will provide is a statement 
that you push these drugs— and you heard, I'm sure, 
from Mr. Stranch and Ms. Herzfeld, they pushed these 
drugs, miracle drugs that had no side effects. And they 
make lots and lots of money. And I'm not against making 
lots of money, but I am when you're lying to people and 
you're destroying people's lives, and then you claim 
you’re not doing it when you are. So that's why I filed the 
lawsuit. And I guess that's why I'm here today. So, I 
guess I've taken up my fifteen minutes, right. So, in the 
words of Kurt Monagan, thank you for your sweetly faked 
attention. Thank you. 
 
MR. SCHRACK: Thank you. We'll now open it up 
for questions from the audience. We do have two 
microphones available if anyone has any questions. 
 
UNIDENTIFIED SPEAKER: I actually have a 
question for Wendy Bach about one of the things you said 
very early on in your speech. You said that one of the NAS 
treatments that you had run into was breastfeeding, 
which I found very interesting given that we have a 
judicial system that tends to take the children away from 
the mother as soon as they are tested positive for any 
kind of drugs. So, I guess my question would be, is the 
justice system worsening the effects that they have by 
our reaction? 
 
PROFESSOR WENDY BACH: I don't have any 
data. I know what you're saying. I think we have to be— 
I mean one of the points I'm trying to make is, every baby, 
every mom is unique, right? And when you have a policy 
like you just said— and DCS's policy is not every time an 
infant is affected, you take the baby away immediately. 
They do go in and they assess the situation. That's a little 
bit of an overstatement. But I think when we blame the 
moms, we maybe won’t see something like rooming in or 
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breastfeeding as something good if we're worried that the 
mom is the source of the problem or can't do that. And 
that mom may need a lot of support to support that baby. 
But there are good programs where moms and babies can 
be together, and both get the support they need. But I 
think we have to look at this through a public health and 
medical care lens for that circumstance and look at every 
mom and kid and figure out what’s most appropriate and 
just be very mindful about the science of what works and 
what doesn't. 
 
UNIDENTIFIED SPEAKER: Barry, before you 
got here, your lawyers were describing (inaudible) in a 
way I found particularly unflattering and were talking 
about issues such as the doctors all going down to 
Ridgefield County Club and continuing to perpetuate this 
problem. So, my question is, you know, you and I both 
know that area, so how has the community reacted to 
your activism and what, if anything, has the medical 
profession in Sullivan and Washington and Carter 
County done to help you? 
 
GENERAL BARRY STAUBUS: One, I want to say 
that I think the vast majority of doctors are legitimate 
doctors and don't want any part of this. Doctors were put 
in a bad spot in 2001 when the pharmaceutical companies 
pushed for a thing called for "The Retractable Pain Act." 
And it said you've got to do one of two things. If somebody 
comes to you and says, I want a narcotic, you've either got 
to give it to them or send them to somebody else. So, the 
legit doctor said look, I think you're a drug seeker, maybe 
you need rehab, maybe you need to just wait, maybe you 
need an anti-inflammatory. They’re, no, I want it. So 
that's how the drug— most of the pill mills are, to me, 
they're an outlier in the medical community. The medical 
community that I— the people that I’ve talked to, 
particularly the ones that are serving these babies, you 
know, they're as involved as you could be. And I have 
talked to a lot of doctors, and what's the general reaction 
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been? Sullivan County, it's my home, my family has been 
here for generations, and the people there are generous 
and have been generous. And I get a lot of atta-boys for 
doing this. The response has been positive, except for—
when after the Today Show a guy from Iowa called me 
and said, because of you, I can't get my pills. And I said, 
well, move to Tennessee. He said he was reporting me to 
the Board. But my experience with— there are a lot of 
doctors that are in the rehabilitative business and that 
are supportive of what I'm doing, and they've told me 
that. And many of the medical providers said, part of the 
problem was we had this fifth vital sign that you heard 
about that the juvenile judge was talking about. And 
basically, the other thing is, doctors are judged by patient 
satisfaction. Imagine if you were a professor and you 
were graded— your pay increase and your promotions 
were just totally the result of how well the teacher liked 
you. So, what would that do? That would incentivize 
passing everybody, not giving out homework, not being 
critical. So that's what’s happened in the medical 
profession is that— I've talked to ER doctors that said, if 
I don't give them, they fill this out, they'll complain on 
me.  
So, if I'm looking for a promotion or I'm looking for 
a pay raise, and they’re saying, your patient satisfaction 
is low. Well, who’s giving the grade? The dope head, the 
pill heads, the drug seekers, the addicts. So I find that 
the vast majority of the community has been supportive 
of the lawsuit, they want to fight this problem. I think the 
biggest problem I have is that people don't realize the 
magnitude of the problem. I think some people are still 
doubters. And it's easy to understand. It's just like when 
people come and sit in the grand jury thinking, my gosh, 
I didn't know we had this much crime. The only thing 
that gets reported in the paper if you’re in Knoxville, it's 
going to be the murder cases, the sexy cases, I guess you 
would say, high publicity cases. Well, nobody goes to 
sessions court or juvenile court and sees twenty, thirty, 
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forty, fifty thousand cases, depending on the size of the 
municipality. So, my biggest challenge has been people 
who work at Eastman, work at school, they go home, they 
go to ballgames and they go to movies, soccer, church, 
civic groups, and they don't see a lot of it. But that’s 
changing because more and more people are saying, you 
know what, I've got a relative, I've got a friend that had 
a car wreck or— I think of the example you gave, a job-
related injury. We're seeing more and more people get 
addicted because the access is so huge. And doctors have 
over-prescribed. Classic example, I had meniscus 
surgery. When I went in— it's one of those things you go 
in and go out the same day. They gave me a prescription 
for ten Percocets. I took one and it hurt my stomach, I 
threw them away. So, I came back for my ten-day 
checkup, what did they give me, thirty-day supply of 
Percocet. And the new studies that have come out and say 
that if someone takes Percocet drugs for a thirty-day 
period or more, there's almost like a thirty percent chance 
a year later they're going to be taking that drug, which is 
the sign of addiction. So those are the kinds of things 
that— I think that the denial or the misunderstanding or 
the lack of understanding is changing because there's so 
many people across the board. It's not just your 
traditional drug culture people, but now we're seeing 
professionals and nurses diverting, doctors diverting, so 
we're seeing it across the board professionals, middle 
class and lower-class. I hope I answered your question. 
 
UNIDENTIFIED SPEAKER: Can other DAs join 
in, like Bradley County— 
 
GENERAL BARRY STAUBUS: Yes. Sixteen DAs 
have now joined. We started with three, we've gone to 
sixteen— 
 
UNIDENTIFIED SPEAKER: I have to say it was 
an unintended consequence that I'm the sponsor of 
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Senate Bill that set up the Drug Dealer Liability Act in 
the State of Tennessee. 
 
GENERAL BARRY STAUBUS: Congratulations. 
Thank you. 
 
UNIDENTIFIED SPEAKER: Thank you. I have a 
question. I have a question just about your lawsuit. You 
have targeted as defendants the manufacturers. Is that 
because of the Tennessee statute, and why not the 
distributors? 
 
GENERAL BARRY STAUBUS: Well, I think my 
lawyers could be of much more— 
 
UNIDENTIFIED SPEAKER: I don't want you to 
breach your attorney/client privilege. 
 
GENERAL BARRY STAUBUS: Well, we've done 
the manufacturers, but we've also done a pain clinic, 
we've also filed against individuals as well. And the 
reason we feltlike— the center point of our theory right 
now is the manufacturers and the unregistered 
distributors. And that’s why, that we had to focus, we had 
to stick with our theory. And what also makes our lawsuit 
unique, and I’m sure they told you this, but we filed on 
behalf of a drug dependent baby. Nobody else has done 
that, so now other people will. A lot of people have asked 
for copies of our Complaint. But that's one thing that may 
bind me in, it’s not just the DAs, but that baby stands in 
for all the babies that got addicted, for me. It stands there 
as a representative for all these babies that you heard 
about. It’s been estimated that a third or fourth of the 
babies in Sullivan County are born addicted to drugs.  
And I understand what Dr. Bach is saying, we 
don't have the studies in. But common sense will tell you 
this much, that if a woman gives birth to a baby and the 
drugs normally dissipate within forty-eight hours at 
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birth, that tells you that many of these women within two 
to three days of giving birth, on the cusp of a birth, they're 
still taking serious drugs. And you just know that if that 
happens— and usually in bad circumstances where the 
women are under anxiety, they're addicted to drugs, 
they're afraid of crimes, they're afraid of being picked up, 
they're afraid of losing the kids, from pillar to post. They 
may be in an abusive relationship— and I'm sure you see 
a lot of that. You know that's not the ideal circumstances 
to have a baby. So that's why it's so important, I think, 
for that baby to stand in as a plaintiff, because it 
represents the hell that they may have to endure, that 
they did endure just being— the first sensation out of the 
womb is either I'm addicted— either been addicted, high 
or withdrawn, and that's not a good place to be. So, I 
think we have a very strong claim for the baby and all 
babies that it stands for. 
 
MR. SCHRACK: We'll do one more question over 
here. 
 
UNIDENTIFIED SPEAKER: My question is for 
the General too. You talked about suboxone earlier and I 
know you probably have a lot to talk about it. There are 
a lot of people who believe that is the key to fixing this 
problem. And do you know of any known cases of overdose 
that are exclusively to suboxone and no other drugs 
involved? 
 
GENERAL BARRY STAUBUS: No, not 
exclusively. 
 
UNIDENTIFIED SPEAKER: And what are the 
negative effects that you believe suboxone has, and are 
they included in your lawsuit? 
 
GENERAL BARRY STAUBUS: No, suboxone 
dealers are not, the pain clinic is. I'm not a big believer, 
I'll be honest, in suboxone in the way I've seen it used in 
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Sullivan County. I'm not saying it's not a tool, it's not an 
aid. But many of our suboxone clinics, you go in and you 
get your twenty-eight-day supply of suboxone. You come 
back in twenty-eight days and get it. There's no 
individual therapy, there's no counseling, there's no 
really effective drug screening or for risks, there's no 
penalties. You know, if you end up having other drugs in 
your system. There’s no end game. Most of the suboxone 
providers will say, we don't have a game plan to try to get 
this person back to being productive. See, I think the goal 
ought to be— and it may not always happen. But, you 
know, if you’re on suboxone for ten years, there's 
something wrong. I mean you’re either on the same 
amount or you're going higher, and you're having dirty 
drug screens but you're still getting it. And that's not 
right. To me, the goal ought to be, we want to make you 
a productive citizen. Our highest goal is to get you 
completely off of dope of every kind so you can live 
productively. But if we can't, we need to get it to a level 
where you can get a job and you can raise your family and 
you can stay out of trouble.  
I’ll give you another example. Suboxone is a lot 
like methadone except methadone is more highly 
regulated. I had a guy who was committed. He had a 
sentence, and he was on methadone. He had court 
approval to go to Asheville, which is the closest facility to 
get methadone. Of course, if they put him on suboxone, 
he’s going to give it to somebody. This guy comes back, 
he’s been on methadone ten years, and he's still getting 
that substance for his addiction. And he goes to a party, 
and he puts that thing in a glass of Kool-Aid, and his 
buddy drinks it, and he's not used to the power of that, 
methadone, and he had another drug in his system, and 
he lays down on the couch and he goes to sleep, and he 
never wakes up. To me, no one should do that. I guess the 
moral of the story is, nobody should be on methadone for 
ten years. I mean it seems to me— I mean if it's a step-
off drug to productivity, that's the problem. That's what I 
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have the problem with. Suboxone is given out— as 
someone said, it's just another substitute— I'm not 
doing— you know, I’m not on opioids and I'm on 
suboxone. What we find out— and I've talked to the 
toxicologists over at the ETSU Medical Center, and what 
they tell me is, that suboxone is really a bartering drug 
for many people. What that means is, is that you take the 
drug of your choice, and when you need another drug, you 
trade suboxone. When you're jonesing, you know, you're 
coming off of it, you take that as a temporary bridge until 
you can go find a man and get what you need. And the 
man often is, you know, I'm waiting my twenty-eight days 
out, or I'm going to go to heroin. And people say, why 
would anybody go to heroin when you've got these legally, 
you know, regulated drugs of certain purity, because 
they're after the high. And that's why it's so hard to 
combat with just another pill because they're not 
rationally thinking. I mean people will take drugs that 
are fifty to a hundred times more potent, like fentanyl, 
which is so powerful that if a drug dog smells it, it kills 
them. If you touch it and an officer touches it in a wrong 
way, exposed to it, they can overdose from it.  
And you say, well, why would anybody do that 
when they can get it? Because they want more. And I 
think suboxone is the same thing. It's like a temporary 
magic bullet, but it's not a long-term solution, it's not to 
their benefit in the long run. They're not getting off 
drugs, they're just getting a respite from the addiction. 
Now, there are clinics, there are legit clinics that treat 
with suboxone and other methods, there are. But there 
are a lot of them that are just making lots of money. As a 
matter of fact, we convicted one pill mill in Morristown. 
You all probably— Morristown is just a little further east, 
if you don't know where that's at. He pled guilty and he 
paid a fine, he agreed to pay a fine, seven hundred and 
fifty thousand dollars as part of his plea deal. Now, when 
you can crank out— voluntarily pay seven hundred and 
fifty thousand dollars, does that not tell you that it's a 
lucrative business for them? So that's why a lot of people 
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in the suboxone and pain pill business is in it, for money. 
It's a legalized drug dealer. 
 
MR. SCHRACK: Let's thank our panelists for 
coming today. At this time, I would also like to thank our 
Symposium Director, Mr. Michael Deel, for putting this 
together. If you all are interested in this topic, the Baker 
Center across the street will be hosting Mr. Eric Eyre 
tomorrow for another presentation on this. Thank you all 
for coming. 
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I. Introduction 
 
 Opioid addiction fractures entire families and 
leaves children orphaned by overdoses.1 There is no 
stereotypical family of an opioid addict.2 The abuse of 
prescription opioids over the last two decades has grown 
to epidemic proportions reaching every corner of society 
while crossing gender, racial, ethnic, class, and 
geographical lines. As a distraught mother who lost her 
daughter to a prescribed opioid overdose observed, 
“Could be you, could be me.”3 Opioid addiction is a chronic 
                                               
1 Opioid Crisis Strains Foster System as Kids Pried from 
Homes, NBC NEWS (Dec. 12, 2017, 4:53 PM), 
https://www.nbcnews.com/storyline/americas-heroin-epidem 
ic/opioid-crisis-strains-foster-system-kids-pried-homes-n828 
831 [https://perma.cc/7ANS-P7HQ]. 
2 Stephano Dipietrantonio, Exclusive Interview Part I: Parents 
Talk About Daughter’s Drug Overdose Death, WCHS 
EYEWITNESS NEWS (Charleston, W. Va.) (Mar. 31, 2016), 
http://wchstv.com/news/local/exclusive-tv-interview-part-1-
parents-talk-about-daughters-overdose-death [https://per 
ma.cc/FY8R-VW6M]. 
3 Id. (quoting Kate Grubb discussing her daughter’s tragic 
overdose death). Jessie Grubb, daughter of Kate and David 
Grubb, died of an overdose of Oxycodone prescribed following 
surgery by a physician who failed to read her medical chart 
carefully and did not realize that she was a recovering opioid 
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disease requiring long-term treatment. Medical 
specialists in addiction have observed, “Without 
treatment or engagement in recovery activities, addiction 
is progressive and can result in disability or premature 
death.”4  
 
 Nowhere has the impact of the opioid epidemic 
been clearer than in West Virginia.5 According to the 
Center for Disease Control and Prevention, West 
Virginia had the highest percentage of drug overdose 
deaths in 2016.6 Adults aged twenty-five to fifty-four had 
the highest percentage of drug overdose deaths,7 which 
in many cases likely left children deprived of a parent. 
According to the Secretary of the West Virginia 
Department of Health and Human Resources, eighty-
three percent of the children in foster care placed in West 
                                               
addict. Her parents were instrumental in the introduction of a 
bill entitled “Jessie’s Law,” which would require prominent 
display of opioid addiction history in a patient’s medical 
records. Id.; see also Jessie’s Law, S. 581, 115th Cong. (2017) 
(as passed by Senate and referred to H. Subcomm. on Health, 
Aug. 11, 2017). 
4 Am. Soc’y of Addiction Med., Treating Opioid Addiction as a 
Chronic Disease, https://www.asam.org/docs/default-source/  
advocacy/cmm-fact-sheet---11-07-14.pdf [https://perma.cc/Z82 
6-6F5K]. 
5 Eric Eyre, an investigative reporter for The Charleston 
Gazette-Mail, was awarded a Pulitzer Prize for investigative 
journalism. The 2017 Pulitzer Prize Winner in Investigative 
Reporting: Eric Eyre, of Charleston Gazette-Mail, Charleston, 
WV, THE PULITZER PRIZES, http://www.pulitzer.org/winners/ 
eric-eyre [https://perma.cc/ CS49-AQ9R]. Eyre exposed to the 
public for the first time the enormous flood of hundreds of 
millions of doses of prescription opioids flowing into small 
towns in rural West Virginia. 
6 Holly Hedegaard et al., Drug Overdose Deaths in the United 
States, 1999–2016, NCHS DATA BRIEF, No. 294 (Dec. 2017), 
https://www.cdc.gov/nchs/data/databriefs/db294.pdf [https:// 
perma.cc/Q2WD-ECQH]. 
7 Id. 
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Virginia are there because of drug problems within the 
family.8 These adverse experiences increase the 
children’s risks of substance abuse and have an enormous 
impact on their development.9 In addition to exposure to 
                                               
8 Eric Eyre, Opioid Epidemic Costs WV $8.8 Billion Annually, 
Study Says, The Charleston Gazette-Mail (Feb. 6, 2018), 
https:// www.wvgazettemail.com/news/health/opioid-epidemic-
costs-wv-billion-annually-study-says/article_1cd8aaa5-78eb-
5fd5-8619-3a0a1c086e66.html [https://perma.cc/5AHF-RY3E]. 
West Virginia is not the only state where children whose 
parents suffer from opioid addiction have flooded foster care. 
An eight percent increase in foster children occurred in the 
United States from 2011 to 2015: 
In 14 states, from New Hampshire to North 
Dakota, the number of foster kids rose by more 
than a quarter between 2011 and 2015, 
according to data amassed by the Annie E. 
Casey Foundation. In Texas, Florida, Oregon, 
and elsewhere, kids have been forced to sleep 
in state buildings because there were no foster 
homes available, says advocacy group 
Children’s Rights. Federal child welfare money 
has been dwindling for years, leaving state and 
local funding to fill in the gaps.  
Julia Lurie, Children of the Opioid Epidemic Are Flooding 
Foster Homes. America Is Turning a Blind Eye, MOTHER JONES 
(July/Aug. 2017), https://www.motherjones.com/politics/ 
2017/07/children-ohio-opioid-epidemic/ [https://perma.cc/QW 
J5-7EL4]. Some children are more fortunate than others to 
have grandparents who are willing and able to step in. See, e.g., 
Brenda Breslauer & Hannah Rappleye, Opioid Crisis Forces 
Grandparents to Raise Their Kids, NBC NEWS (Oct. 20, 2017, 
5:01 AM), https://www.nbcnews.com/storyline/americas-
heroin-epidemic/opioid-crisis-forces-grand parents-raise-their-
grandkids-n808991 [https://perma.cc/G9TB-PGV8].  
9 The 2016 Report of the Surgeon General has recognized,  
The experiences a person has early in 
childhood and in adolescence can set the stage 
for future substance use and, sometimes, 
escalation to a substance use disorder or 
addiction. Early life stressors can include 
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substance abuse, the Center for Disease Control 
recognizes other childhood experiences that may 
adversely impact child and adolescent development: (1) 
emotional abuse, (2) physical abuse, (3) incarceration of 
a household member, (4) emotional neglect, (5) physical 
neglect, (6) divorced or separated parents, (7) domestic 
violence, (8) depression or mental illness of a family 
household member, and (9) sexual abuse.10 
 Because of the risks associated with adverse 
childhood experiences (“ACEs”), some states have 
enacted statutes acknowledging the impact such 
experiences have on “the development of the brain and 
other major body systems.”11 Recent legislation proposed 
                                               
physical, emotional, and sexual abuse; neglect; 
household instability (such as parental 
substance use and conflict, mental illness, or 
incarceration of household members); and 
poverty.  Research suggests that the stress 
caused by these risk factors may act on the 
same stress circuits in the brain as addictive 
substances, which may explain why they 
increase addiction risk. 
U.S. DEP’T OF HEALTH & HUMAN SERVS., FACING ADDICTION IN 
AMERICA: THE SURGEON GENERAL’S REPORT ON ALCOHOL, 
DRUGS, AND HEALTH, at 2-21 (2016), https:// 
addiction.surgeongeneral.gov/sites/default/files/surgeon-gen 
erals-report.pdf [https://perma.cc/7S2C-VUH2]. 
10 About the CDC-Kaiser ACE Study, CTRS. FOR DISEASE 
CONTROL & PREVENTION (June 14, 2016) https://www.cdc.gov/ 
violenceprevention/acestudy/about.html 
[https://perma.cc/4NNF-2SSJ]. 
11 WASH. REV. CODE § 70.305.010(1) (2014). “Adverse Childhood 
Experiences” are statutorily defined in Washington as follows: 
(1) “Adverse childhood experiences” means the 
following indicators of severe childhood 
stressors and family dysfunction that, when 
experienced in the first eighteen years of life 
and taken together, are proven by public health 
research to be powerful determinants of 
physical, mental, social, and behavioral health 
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in the United States House of Representatives recognized 
that adverse childhood experiences can lead to opioid 
abuse.12 Legislation proposed in Tennessee sought to 
address “the adequacy of resources to assist children and 
youth impacted by the opioid epidemic and adverse 
childhood experiences.”13 An early version of a bill 
recently passed by the Vermont Legislature found that 
“[w]hile much is yet to be learned about the specific 
                                               
across the lifespan: Child physical abuse; child 
sexual abuse; child emotional abuse; child 
emotional or physical neglect; alcohol or other 
substance abuse in the home; mental illness, 
depression, or suicidal behaviors in the home; 
incarceration of a family member; witnessing 
intimate partner violence; and parental divorce 
or separation. Adverse childhood experiences 
have been demonstrated to affect the 
development of the brain and other major body 
systems.  
Id; see also Act of May 22, 2017, 2017 Vt. Acts & Resolves 43 § 
1(1) (“Adversity in childhood has a direct impact on an 
individual’s health outcomes and social functioning. The 
cumulative effects of multiple adverse childhood experiences 
(ACEs) have even more profound public health and societal 
implications. ACEs include physical, emotional, and sexual 
abuse; neglect; food and financial insecurity; living with a 
person experiencing mental illness or substance use disorder, or 
both; experiencing or witnessing domestic violence; and having 
divorced parents or an incarcerated parent.” (emphasis 
added)). 
12 H.R. 3291, 115th Cong. § 2(3) (2017) (“As the number of 
adverse childhood experiences increases so does the risk for . . . 
opioid abuse . . . ”). 
13 H.R. 2580, 110th Gen. Assemb., 2d Reg. Sess. (Tenn. 2017) 
(“On or before January 15, 2019, the commissioner of mental 
health and substance abuse services shall report to the health 
committee of the house of representatives and the senate 
health and welfare committee on the adequacy of resources to 
assist children and youth impacted by the opioid epidemic and 
adverse childhood experiences.”).  
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developmental pathways and predictor variables of 
opioid addiction, programs that reflect the needs of 
people who have suffered from traumatic experiences 
must be part of any comprehensive strategy to attack the 
opioid epidemic.”14 A hearing of the Health, Education, 
Labor, and Pensions Committee of the United States 
Senate recently focused on the opioid epidemic’s impact 
on children. Hearing testimony addressed infants 
experiencing neonatal abstinence syndrome and children 
of opioid-afflicted families now in foster care, as well as 
the remedial actions that need to be taken on the federal, 
state, and local levels.15 
 Going forward, efforts to address the opioid 
epidemic must necessarily occur on numerous fronts.16 
                                               
14 S. 261, 2017—2018 Leg. Sess. (Vt. 2017) (as introduced in 
Vermont Senate, Findings deleted by amendment). 
15 The Senate hearing was held in February 2018 and televised 
on C-Span. The Opioid Crisis Impact on Children and 
Families: Hearing Before the S. Comm. On Health, Educ., 
Labor & Pensions, 115th Cong. (2018), https://www.c-
span.org/video/?440882-1/senate-hear ing-impact-opioid-crisis-
children [https://perma.cc/7C9U-4GNW].  
16 Courts burdened by an increased caseload as a result of the 
opioid epidemic have implemented new programs. For 
example, in Florida, trial courts have established “Early 
Childhood Courts” in response to the increased number of 
dependency court cases:  
This epidemic has influenced Florida’s child 
welfare system and has resulted in an 
increased number of dependency court cases 
throughout the state. Many trial courts have 
established Early Childhood Courts for 
families affected by the opioid epidemic by 
offering a continuum of evidence-based 
services, including Child–Parent 
Psychotherapy—an intervention aimed at 
healing trauma. According to the Florida 
Department of Law Enforcement, Florida 
Medical Examiners Report, in 2016, six of the 
seven Florida counties with the most opioid-
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For example, family treatment drug courts have been 
established throughout the United States to ensure that 
parents immersed in the child welfare system because of 
substance abuse issues receive treatment and are 
reunified with their children.17 The responsibility of 
family drug treatment courts is to address abuse and 
neglect issues by treating underlying drug addictions in 
collaboration with child welfare and substance abuse 
professionals.18  
                                               
related deaths have an Early Childhood Court 
in place. 
In re Certification of Need for Additional Judges, 230 So. 3d 
1164, 1165 (Fla. 2017) (footnotes omitted). 
On the federal level, in September of 2017, the United 
States Department of Justice (“DOJ”) awarded “$58.8 million 
to strengthen drug court programs and address the opioid 
epidemic nationwide.” Press Release, U.S. Dep’t of Justice, 
Department of Justice Awards Nearly $59 Million to Combat 
Opioid Epidemic, Fund Drug Courts (Sept. 22, 2017), 
https://www.justice.gov/opa/pr/department-justice-awards-
nearly-59-million-combat-opioid-epidemic-fund-drug-courts 
[https://perma.cc/S2PR-594F]. DOJ awarded grants to the 
Supreme Court of Ohio, the Colorado Judicial Department, the 
Judiciary Courts for the State of Iowa, and the New York State 
Unified Court System as part of the Family Drug Court 
Statewide System Reform Implementation Program with the 
goal of helping these states improve the outcomes for families 
in the child welfare system who are affected by the opioid 
epidemic. Press Release, Dep’t of Justice, OJJDP FY 2017 
Family Drug Court Statewide System Reform Implementation 
(Sept. 21, 2017), https://ojp.gov/newsroom/ pressreleases/2017/ 
ojp-news-09212017.pdf [https://perma.cc/ A4CQ-PLJ3].  
17 See generally Family Treatment Drug Courts, NAT’L CTR. ON 
SUBSTANCE ABUSE & CHILD WELFARE, https://ncsacw.samhsa. 
gov/resources/resources-drugcourts.aspx [https://perma.cc/7Q 
MX-946M] (information on family treatment courts). 
18 Elizabeth Joanne Gifford, How Does Family Treatment Court 
Participation Affect Child Welfare Outcomes?, 38 CHILD ABUSE 
& NEGLECT 1659 (2014) (citing BUREAU OF JUSTICE 
ASSISTANCE, U.S. DEP’T OF JUSTICE, FAMILY DEPENDENCY 
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 However, in many states, family courts possess 
limited jurisdiction,19 and collaborations with substance 
abuse professionals are rare. Indeed, a family court may 
have authority to order drug testing of parents where 
there is credible evidence of substance abuse and also 
may order a parent to undergo and complete a drug 
treatment program as a condition precedent to being 
allowed to regain custody of her children or to have (or 
increase) visitation with her children. But, typically the 
parent ordered to undergo drug treatment is left to her 
own devices in seeking a treatment program and finding 
                                               
TREATMENT COURTS: ADDRESSING CHILD ABUSE AND NEGLECT 
CASES USING THE DRUG COURT MODEL (2004), 
https://www.ncjrs.gov/pdffiles1/bja/206809.pdf [https://perma. 
cc/P396-X838]), https://www.ncbi.nlm.nih.gov/pmc/articles/P 
MC4194264/ [https://perma.cc/YN9J-ZTB4]. 
19 For example, the Supreme Court of Appeals of West Virginia 
has recognized the limited jurisdiction of family courts in the 
state: 
The power of family courts to exercise 
jurisdiction over various matters is narrowly 
prescribed by the Legislature. “The jurisdiction 
of family courts is limited to only those matters 
specifically authorized by the Legislature, 
while circuit courts have original and general 
jurisdiction and other powers as set forth in 
Article VIII, § 6 of the Constitution of West 
Virginia.” Syl. pt. 5, in part, Lindsie D.L. v. 
Richard W.S., 214 W.Va. 750, 591 S.E.2d 308 
(2003). Accord Syl. Pt. 2, State ex rel. Silver v. 
Wilkes, 213 W.Va. 692, 584 S.E.2d 548 (2003) 
(“‘A family court is a court of limited 
jurisdiction. A family court is a court of record 
only for the purpose of exercising jurisdiction 
in the matters for which the jurisdiction of the 
family court is specifically authorized in this 
section and in chapter forty-eight [§§ 48-1-101 
et seq.] of this code.’ W. Va. Code § 51-2A-2(d) 
(2001), in part.”). 
Deitz v. Deitz, 659 S.E.2d 331, 339 (W. Va. 2008). 
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the means to pay for it.  Given these challenges, this 
article focuses primarily on the evolving roles of family 
law school clinics, medical-legal partnerships, and the 
availability of pro bono lawyers where opioid-affected 
families are entangled in cases litigated in a family court 
system. 
 
II. Treating Opioid Addiction to Resolve 
Custody Issues in Family Court Cases. 
 
A. Family Law School Clinics 
 
 Family law clinics are a staple of the curricula of 
many American law schools, including states with the 
highest rates of opioid overdose fatalities.20  
For example, the West Virginia University 
College of Law Child and Family Advocacy Clinic 
(“CFAC”) has represented children and families in cases 
involving custody, guardianship, education, and domestic 
violence that are litigated in the state’s family courts. In 
addition, family court judges appoint the CFAC to serve 
pro bono as guardian ad litem (“GAL”) in child custody 
cases.  
                                               
20 According to the CDC, the five states with the highest rates 
of death due to drug overdose in 2016 “were West Virginia (52.0 
per 100,000), Ohio (39.1 per 100,000), New Hampshire (39.0 
per 100,000), Pennsylvania (37.9 per 100,000) and []Kentucky 
(33.5 per 100,000).” Drug Overdose Death Data, CTRS. FOR 
DISEASE CONTROL & PREVENTION (Dec. 19, 2017) 
https://www.cdc.gov/drugoverdose/data/statedeaths.html 
[https://perma.cc/695M-V3UC]. All five of these states have law 
schools that are legal partners in a medical-legal partnership: 
University of Louisville Brandeis School of Law, Cleveland-
Marshall College of Law, Case Western Reserve University 
School of Law, University of New Hampshire Law School, 
University of Pittsburgh School of Law, and University of 
Pennsylvania Law School. The Partnerships, NAT’L CTR. FOR 
MEDICAL-LEGAL P’SHIP, http://medical-legalpartnership. 
org/partnerships/ [https://perma.cc/8UWL-LGXC]. 
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 The West Virginia Constitution was amended to 
create “a unified family court system . . . to rule on family 
law and related matters.”21 In addition to many other 
family-related actions, family courts in West Virginia 
have jurisdiction over “actions for the establishment of a 
parenting plan or other allocation of custodial 
responsibility or decision-making responsibility for a 
child[.]”22  
                                               
21 Article 8, section 16 of the West Virginia Constitution 
provides: 
There is hereby created under the general 
supervisory control of the supreme court of 
appeals a unified family court system in the 
state of West Virginia to rule on family law and 
related matters. Family courts shall have 
original jurisdiction in the areas of family law 
and related matters as may hereafter be 
established by law. Family courts may also 
have such further jurisdiction as established by 
law.  
W. VA. CONST. art. VIII, § 16; see also W. VA. CODE ANN. § 51-
2A-2. 
22 W. VA. CODE ANN. § 51-2A-2(a)(6). The West Virginia Code 
enumerates the actions over which family courts have 
jurisdiction:  
(a) The family court shall exercise jurisdiction 
over the following matters: 
(1) All actions for divorce, annulment or 
separate maintenance brought under the 
provisions of article three, four or five, chapter 
forty-eight of this code except as provided in 
subsections (b) and (c) of this section; 
(2) All actions to obtain orders of child support 
brought under the provisions of articles eleven, 
twelve and fourteen, chapter forty-eight of this 
code; 
(3) All actions to establish paternity brought 
under the provisions of article twenty-four, 
chapter forty-eight of this code and any 
dependent claims related to such actions 
regarding child support, parenting plans or 
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other allocation of custodial responsibility or 
decision-making responsibility for a child; 
(4) All actions for grandparent visitation 
brought under the provisions of article ten, 
chapter forty-eight of this code; 
(5) All actions for the interstate enforcement of 
family support brought under article sixteen, 
chapter forty-eight of this code and for the 
interstate enforcement of child custody brought 
under the provisions of article twenty of said 
chapter; 
(6) All actions for the establishment of a 
parenting plan or other allocation of custodial 
responsibility or decision-making re-
sponsibility for a child, including actions 
brought under the Uniform Child Custody 
Jurisdiction and Enforcement Act, as provided 
in article twenty, chapter forty-eight of this 
code; 
(7) All petitions for writs of habeas corpus 
wherein the issue contested is custodial 
responsibility for a child; 
(8) All motions for temporary relief affecting 
parenting plans or other allocation of custodial 
responsibility or decision-making re-
sponsibility for a child, child support, spousal 
support or domestic violence; 
(9) All motions for modification of an order 
providing for a parenting plan or other 
allocation of custodial responsibility or 
decision-making responsibility for a child or for 
child support or spousal support; 
(10) All actions brought, including civil 
contempt proceedings, to enforce an order of 
spousal or child support or to enforce an order 
for a parenting plan or other allocation of 
custodial responsibility or decision-making 
responsibility for a child; 
(11) All actions brought by an obligor to contest 
the enforcement of an order of support through 
the withholding from income of amounts 
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 In approximately eighty percent of the cases 
litigated by the CFAC, at least one family member, or 
someone integrally involved in the case, suffers from 
some form of opioid abuse, including prescription opioids, 
heroin, fentanyl, or other opioid addiction. Also, many of 
the children the CFAC has served as GAL have had a 
parent or parents, family member, or immediate member 
of the household incarcerated on drug-related charges. 
The children in such family circumstances may bounce 
from household to household because the parent is 
unable to hold onto a job or to provide food and/or shelter 
for them. These situations exemplify the types of adverse 
childhood experiences that increase the likelihood 
                                               
payable as support or to contest an affidavit of 
accrued support, filed with the circuit clerk, 
which seeks to collect an arrearage; 
(12) All final hearings in domestic violence 
proceedings; 
(13) Petitions for a change of name, exercising 
concurrent jurisdiction with the circuit court; 
(14) All proceedings for payment of attorney 
fees if the family court judge has jurisdiction of 
the underlying action; 
(15) All proceedings for property distribution 
brought under article seven, chapter forty-
eight of this code; 
(16) All proceedings to obtain spousal support 
brought under article eight, chapter forty-eight 
of this code; 
(17) All proceedings relating to the 
appointment of guardians or curators of minor 
children brought pursuant to sections three, 
four and six, article ten, chapter forty-four of 
this code, exercising concurrent jurisdiction 
with the circuit court; and 
(18) All proceedings relating to petitions for 
sibling visitation. 
Id. § 51-2A-2. 
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children involved will eventually become addicts as 
adults. 
 For example, in one case where the CFAC served 
as GAL, all adult parties tested positive for drugs at some 
point during a two-year period. The biological mother 
tested positive for painkillers at the birth her child, and 
the biological father tested positive for marijuana at the 
initial court hearing. As a consequence of court-ordered 
testing, the psychological father who had raised the child 
and his fiancée were found to be opioid users. The family 
court also was faced with allegations that the 
psychological father sold and/or manufactured 
methamphetamines. All parties had been arrested at 
some point but were not currently incarcerated at the 
time of the CFAC’s involvement. Further complicating 
matters, the parties had also sought police intervention 
against each other as a tactical strategy to gain 
advantage as they sought custody of the child. In another 
case where the CFAC served as GAL for a child, the 
mother of the child died after overdosing on opioids. 
Sadly, the father suffered from heroin addiction, and 
there were allegations that an aunt was selling heroin. 
At the time of the guardianship, the child was living with 
grandparents. 
 As GAL in these cases, the CFAC helped provide 
guidance to the family court as it attempted to decide 
where the children would be safest and receive the best 
care. However, resolving such issues does nothing to 
resolve the underlying drug addiction issues that lie at 
the root of a family crisis, nor does the determination of 
legal issues like custody, divorce, or child abuse and 
neglect address the threat drug addiction poses to the 
children. The optimal solution is for children to have 
physiologically and mentally healthy family members 
who have been able to escape from opioid addiction. 
 In its representation of a parent in a custody case 
where the other parent is struggling with drug addiction, 
the CFAC has sought a family court order making drug 
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treatment part of the relief granted. This request 
envisioned court-imposed treatment as a condition to, 
and an inducement for, the addicted parent to achieve 
increased visitation with his/her children without 
supervision. In this context, the CFAC clinic students 
and staff attorneys considered what, if any, role lawyers 
should play in addressing substance abuse when it is the 
cause of the families’ problems. 
 In order to address opioid issues in family court 
cases, clinic student attorneys and supervising lawyers 
should be recognized as having counseling 
responsibilities beyond the representation of their clients 
regarding only the immediate legal issues.23 Rule 2.1 of 
the Model Rules of Professional Conduct mandates that 
a lawyer representing a client “shall exercise 
independent professional judgment and render candid 
advice.”24 The rule further provides, “In rendering advice, 
a lawyer may refer not only to law but to other 
considerations such as moral, economic, social and 
political factors, that may be relevant to the client’s 
situation.”25   
 The comments to the model rule recognize that 
“[f]amily matters can involve problems within the 
professional competence of psychiatry, clinical 
psychology or social work” and that we should consult 
with persons in these professions when a “competent 
lawyer” would do so.26  While lawyers do not have a “duty 
                                               
23 Numerous articles have addressed a lawyer’s responsibilities 
when a client suffers from addiction. See, e.g., Erin Sparks, 
Comment, Attorney-Client Relationships: Ethical Dilemmas 
with Clients Battling Addiction, 36 J. Legal Prof. 255 (2011); 
Jean Marie Leslie, Understanding Addiction, Helping Clients 
and Colleagues, 69 Ala. Law. 348 (Sept. 2008); Timothy David 
Edwards, The Lawyer as Counselor Representing the Impaired 
Client, GPSolo, Oct./Nov. 2004, at 34.  
24 MODEL RULES OF PROF’L CONDUCT r. 2.1 (AM. BAR ASS’N 
1983). 
25 Id. 
26 The Comment to Rule 2.1 observes: 
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to initiate investigation of a client’s affairs or to give 
advice that the client has indicated is unwanted, . . . a 
lawyer may initiate advice to a client when doing so 
appears to be in the client’s best interests.”27  
 Advising a client to seek treatment for opioid 
addiction is clearly in the client’s best interests, though 
it is acknowledged that the client may not be receptive to 
such counseling. I contend that encouraging a client to 
seek drug addiction treatment falls within an attorney’s 
ethical responsibilities. Helping clients or other parties 
in litigation gain access to needed treatment programs 
and encouraging their completion of these programs is 
also part of the attorney’s ethical responsibilities as a 
                                               
Matters that go beyond strictly legal questions 
may also be in the domain of another 
profession. Family matters can involve 
problems within the professional competence of 
psychiatry, clinical psychology or social work; 
. . . Where consultation with a professional in 
another field is itself something a competent 
lawyer would recommend, the lawyer should 
make such a recommendation. 
MODEL RULES OF PROF’L CONDUCT r. 2.1 cmt. (AM. BAR 
ASS’N 1983). 
27 The Comment to Rule 2.1 also instructs:  
When a lawyer knows that a client proposes a 
course of action that is likely to result in 
substantial adverse legal consequences to the 
client, the lawyer’s duty to the client under 
Rule 1.4 may require that the lawyer offer 
advice if the client’s course of action is related 
to the representation . . . . A lawyer ordinarily 
has no duty to initiate investigation of a client’s 
affairs or to give advice that the client has 
indicated is unwanted, but a lawyer may 
initiate advice to a client when doing so 
appears to be in the client’s best interests. 
Id. 
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counselor.28 Assuming that such counsel is an ethical 
imperative, it must be recognized that the clinical 
lawyer’s efforts can be exceptionally challenging without 
the support provided by relationships with healthcare 
partners who can assist in attaining treatment goals. 
Lawyer-healthcare partner relationships must be 
developed and nurtured to achieve the highest possible 
likelihood of successful treatment. 
 
B. Using Medical-legal Partnerships to       
Assist Clients in Seeking and Receiving 
Treatment of Opioid Addiction.  
 
 Medical Legal Partnerships (“MLPs”) were first 
established in Massachusetts in 1993 at Boston City 
Hospital (now Boston Medical Center).29 The National 
Center for Medical-Legal Partnership was founded in 
2006 and is now housed in the Department of Health 
Policy and Management at the Milken Institute School of 
                                               
28 In helping clients seek and obtain the treatment they need 
for addiction, attorneys also must comply with the provisions 
of Rule 1.14 governing their responsibilities to clients with 
diminished capacities. MODEL RULES OF PROF’L CONDUCT r. 
1.14 (AM. BAR ASS’N 1983). Rule 1.14(b) provides that an 
attorney may take “reasonably necessary protective action” 
when “the lawyer reasonably believes the client has diminished 
capacity.” MODEL RULES OF PROF’L CONDUCT r. 1.14(b). 
Importantly, Rule 1.14(c) provides that “[w]hen taking 
protective action pursuant to paragraph (b), the lawyer is 
impliedly authorized under Rule 1.6(a) to reveal information 
about the client, but only to the extent reasonably necessary to 
protect the client’s interests.” MODEL RULES OF PROF’L 
CONDUCT r. 1.14(c). 
29 Ellen Cohen et al., Medical-Legal Partnership: Collaborating 
with Lawyers to Identify and Address Health Disparities, 25 J. 
GEN. INTERN. MED. 136 (2010). 
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Public Health at the George Washington University.30 
Currently, there are 155 hospitals, 139 health centers, 34 
health schools, 126 legal aid agencies, and 52 law schools 
and pro bono partners operating MLPs to address 
patients’ health-related social needs.31  
 The development of MLPs was based on the 
recognition that many patients suffering from illness also 
face social and legal dilemmas that often impact their 
recovery. In MLPs, healthcare professionals and lawyers 
work together as an integrative team to treat patients 
medically and to meet their legal needs.32 “Patients are 
often able to receive legal assistance in areas such as 
addressing personal safety from exposure to domestic 
violence, gaining access to entitled benefits such as food 
subsidies, disability benefits, or necessary educational 
services, and repairing poor housing conditions through 
MLP services.”33   
 As an example of such collaborations, the CFAC 
has entered into a medical-legal partnership with two 
healthcare providers: Chestnut Ridge Center (“Chestnut 
Ridge”), a West Virginia University Medicine psychiatric 
facility, and with West Virginia University Medicine 
                                               
30 About the National Center, NAT’L CTR. FOR MEDICAL-LEGAL 
P’SHIP, http://medical-legalpartnership.org/about-us/ [https:// 
perma.cc/ 22AF-RV5Z]. 
31 The Partnerships, NAT’L CTR. FOR MEDICAL-LEGAL P’SHIP, 
http://medical-legalpartnership.org/partnerships/ 
[https://perma.cc/8UWL-LGXC]. 
32 Cohen et al., supra note 29, at 136 (“Medical-legal 
partnerships (MLPs) bring together medical professionals and 
lawyers to address social causes of health disparities, including 
access to adequate food, housing and income.”). 
33 TIRSHA BEESON ET AL., NAT’L CTR. FOR MEDICAL-LEGAL 
P’SHIP, MAKING THE CASE FOR MEDICAL-LEGAL PARTNERSHIPS: 
A REVIEW OF THE EVIDENCE (2013), http://www.medical-
legalpartnership.org/wp-content/uploads/2014/03/Medical-
Legal-Partnership-Literature-Review-February-2013.pdf 
[https://perma.cc/42BB-EBK3]. 
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Pediatrics (“WVU Pediatrics”).34 The CFAC’s MLP with 
Chestnut Ridge and WVU Pediatrics allows these 
healthcare providers to refer patients to the family 
advocacy clinic when the stress of legal problems poses a 
threat to the patients’ healing process.  
 Medical-legal partnerships, like the one CFAC 
has established at West Virginia University, present one 
way to assist clients in seeking and obtaining needed 
treatment for opioid addiction.35 This partnership allows 
the CFAC to work with healthcare providers in 
developing a strategy for referring family law clients to 
addiction treatment programs. The goal, of course, is to 
facilitate clinic clients in confronting and overcoming the 
addiction issues that adversely affect their relationships 
with their familial relationships and entangle them in 
legal problems, like child custody and divorce.36 
 According to key findings set forth in the Surgeon 
General’s 2016 report on addiction, only one in ten people 
                                               
34 Partners Across the U.S.: West Virginia, NAT’L CTR. FOR 
MED.-LEGAL PARTNERSHIP, http://medical-legalpartnership. 
org/partnerships/?fwp_states=west-virginia [https://perma.cc/ 
8JC7-RBRM]. 
35 For more information on Medical-Legal Partnerships, see 
Brief: How Medical-Legal Partnership Services Can Help 
Address the Opioid Crisis, NAT’L CTR. FOR MEDICAL-LEGAL 
P’SHIP, http://medical-legalpartnership.org/mlp-resources/ 
opioid-crisis-brief/ [https://perma.cc/HSM2-XDQR]. The 
National Center for Medical-Legal Partnership hosted a 
federal round table in the fall of 2017 to discuss the opioid 
epidemic and the role MLPs can play in helping those afflicted. 
See National Center Convened Federal Agency Roundtable on 
the Opioid Crisis, NAT’L CTR. FOR MEDICAL-LEGAL P’SHIP (Sept. 
27, 2017), http://medical-legalpartnership.org/opioid-round 
table/ [https://perma.cc/GZ4E-BPSN]. 
36 JAY CHAUDHARY ET AL., NAT’L CTR. FOR MEDICAL-LEGAL 
P’SHIP, THE OPIOID CRISIS IN AMERICA & THE ROLE MEDICAL-
LEGAL PARTNERSHIP CAN PLAY IN RECOVERY (2018), 
http://medical-legalpartnership.org/wp-content/uploads/2018/ 
02/MLP-and-the-Opioid-Crisis.pdf [https://perma.cc/3TVN-
PM3V]. 
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suffering from a drug use disorder obtain specialty 
treatment.37 Moreover, a study funded by the National 
Institute on Alcohol Abuse and Alcoholism (“NIAAA”), an 
arm of the National Institutes of Health, reported that 
seventy-five percent of adults in the United States 
suffering from a drug use disorder never receive 
treatment.38 The low rate of treatment is attributed to 
diverse causes such as the “inability to access or afford 
care, fear of shame and discrimination, and lack of 
screening for substance misuse and substance use 
disorders in general health care settings.”39 Moreover, 
many who suffer from drug addiction are not able to 
realize they need treatment or they otherwise reject 
treatment.40  
 Simply referring clients to a treatment programs 
will not solve their addiction issues— clients will have to 
affirmatively desire help and be able to summon the 
                                               
37 U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 4-
2. Of those who did not receive treatment but needed it, “over 
7 million were women and more than 1 million were 
adolescents aged 12 to 17.” Id. at 4-8 (citing CTR. FOR 
BEHAVIORAL HEALTH STATISTICS & QUALITY, SUBSTANCE 
AUBSE & MENTAL HEALTH SERVS. ADMIN., Results from the 2015 
National Survey on Drug Use and Health: Detailed Tables, 
(2016), https://www.samhsa.gov/data/sites/default/files/NSD 
UH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-
2015. pdf [https://perma.cc/JH2V-U9X9]).  
38 10 Percent of US Adults Have Drug Use Disorder at Some 
Point in Their Lives: 75 Percent Report Not Receiving Any Form 
of Treatment, NAT’L INST. OF HEALTH (Nov. 18, 2015), 
https://www.nih.gov/news-events/news-releases/10-percent-
us-adults-have-drug-use-disorder-some-point-their-lives 
[https://perma.cc/2P7V-ZHT4]. 
39Executive Summary of the Surgeon General’s Report on 
Alcohol, Drugs and Health, SURGEON GEN., https://addiction. 
surgeongeneral.gov/executive-summary 
[https://perma.cc/99HC-M5D6].   
40  U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 4-
9. 
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willpower to endure the long process of treatment leading 
to recovery. Some clients may prefer seeking medication 
at Suboxone clinics where treatment drugs are provided 
but counseling is not.41 
 In criminal drug courts, addicts charged with 
crimes face jail time if they do not complete their court-
mandated treatment program. In family treatment 
courts, addicted parents often face termination of their 
parental rights in abuse and neglect cases if they fail to 
finish the treatment program.42 In family court 
proceedings, jail time or termination of parental rights is 
beyond the family court’s jurisdiction if an addicted party 
fails to participate in a substance abuse treatment 
program. Instead, the addicts face loss of their role as the 
primary custodian of their children or are limited to 
supervised visitation. Such sanctions may not provide a 
sufficient incentive for them to persevere to completion of 
the difficult process of treatment and recovery. But, in 
cases where the parents have a strong desire to have 
their children living with them, rather than with a 
grandparent, other family member, or in foster care, 
completing treatment and escaping addiction may be a 
powerful incentive that will help heal the family. 
 Effective treatment requires an active recovery 
program that includes behavioral and cognitive changes. 
For example, Chestnut Ridge, the CFAC’s medical-legal 
partner, has developed a program called the 
Comprehensive Opioid Addiction Treatment (“COAT”) 
                                               
41 Stand-alone Suboxone clinics have emerged as a new 
business to address opioid addiction. In Ohio, where stand-
alone Suboxone clinics are allowed to accept cash only, there is 
a growing concern that these clinics will simply become the 
next “pill mills.” Marty Schladen & Rita Price, Cash-Only 
Suboxone Clinics Fuel Fears of New “Pill Mills”, COLUMBUS 
DISPATCH (Oct. 8, 2017, 5:55 AM), http://www.dispatch. 
com/news/20171008/cash-only-suboxone-clinics-fuel-fears-of-
new-pill-mills/1 [https://perma.cc/QW64-GV92]. 
42 See discussion of family treatment courts, supra pp. 4–6. 
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program.43 This is not a treatment program individual 
addicts can complete in a few weeks. COAT is a long-term 
treatment procedure comprised of stages during which 
the addicted patient is prescribed Suboxone to manage 
his or her withdrawal from opioids.44 Of course, it is 
important to understand that no single treatment 
program will fit every person struggling with addiction.45 
 Treating opioid addiction should begin with a 
healthcare professional’s assessment and diagnosis.46 
This clinical assessment may be based on several 
different models, such as the Addiction Severity Index 
                                               
43 Behavioral Medicine and Psychiatry: Outpatient Programs, 
WVU MED., http://wvumedicine.org/ruby-memorial-hospital/ 
services/wvu-specialty-clinics/behavioral-and-mental-health/ 
chestnut-ridge-center/adult-addiction-services/comprehensive-
opioid-addiction-treatment-coat/ [https://perma.cc/E39P-LCH 
Q]. 
44 Treatment professionals debate how to properly use 
Suboxone as an effective treatment for opioid addiction. When 
it was first introduced, Suboxone was intended to be used only 
during initial detoxification. However, the more prevalent 
treatment process currently followed is to use Suboxone as 
long-term maintenance to suppress an addict’s opioid cravings. 
NAT’L INST. ON DRUG ABUSE, SHORT-TERM OPIOID WITHDRAWAL 
USING BUPRENORPHINE: FINDINGS AND STRATEGIES FROM A 
NIDA CLINICAL TRIALS NETWORK (CTN) STUDY, https://www. 
drugabuse.gov/sites/default/files/files/BupDetox_Factsheet.pdf 
[https://perma.cc/3TF7-R2LC]. 
45 U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 4-
14. 
46 Id. at 4-15. 
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(“ASI”),47 the Substance Abuse Model (“SAM”),48 the 
Global Appraisal of Individual Needs (“GAIN”),49 and the 
Psychiatric Research Interview for Substance and 
Mental Disorders (“PRISM”).50 The Surgeon General’s 
report recommends that a diagnosis of drug abuse be 
based on eleven symptoms of substance abuse disorder 
that are defined in the Fifth Edition of the Diagnostic and 
                                               
47 “The Addiction Severity Index (ASI) is a structured interview 
widely used by substance abuse clinicians and researchers for 
client screening, determining treatment needs, and assessing 
treatment outcomes.” Bertrym E. Stoffelmayr, Brian E. Mavis 
& Rafa M. Kasim, The Longitudinal Stability of the Addiction 
Severity Index, 11 J. SUBSTANCE ABUSE TREATMENT 373, 373 
(1994). The ASI “[a]ddresses seven potential problem areas in 
substance using individuals: medical status, employment and 
support, drug use, alcohol use, legal status, family/social 
status, and psychiatric status.” U.S. DEP’T OF HEALTH & 
HUMAN SERVS., supra note 9, at 4-16. 
48 SAM is “[d]esigned to assess mental disorders as defined by 
the Diagnositic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV).” Id. SAM “[i]ncludes questions about 
when symptoms began and how recent they are, withdrawal 
symptoms, and the physical, social and psychological 
consequences of each substance assessed.” Id.  
49 GAIN is a “[s]eries of measures (screener, standardized 
biopsychosocial intake assessment battery, follow-up 
assessment battery) which integrate research and clinical 
assessment.” Id. GAIN “[c]ontains 99 scales and subscales, that 
are designed to measure the recency, breadth, and frequency 
of problems and service utilization related to substance use 
(including diagnosis and course, treatment motivation, and 
relapse potential), physical health, risk/protective 
involvement, mental health, environment and vocational 
situation.” Id. 
50PRISM is a “[s]emi-structured, clinician-administered 
interview” that “[m]easures the major DSM-IV diagnoses of 
alcohol, drug, and psychiatric disorders” and “[p]rovides clear 
guidelines for differentiating between the effects of 
intoxication and withdrawal, substance-induced disorders, and 
primary disorders.” Id.   
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Statistical Manual of Mental Disorders (DSM-5).51 
Patients may also be assessed in the context of their 
“family environment.”52  
 Once a healthcare provider has completed an 
assessment and diagnosis, an individualized treatment 
plan should be developed taking into consideration the 
person’s specific needs, strengths, weaknesses, financial 
resources, family support, and other physical or mental 
health issues.53 The individualized treatment program 
should also have measures in place to engage and to 
motivate the patient to remain in the program.54 
                                               
51 Id. at 4-15. 
52 Laura Lander, Janie Howsare & Marilyn Byrne, The Impact 
of Substance Use Disorders on Families and Children: From 
Theory to Practice, 28 SOC. WORK PUB. HEALTH 194, 195–205 
(2013) (“Treating the individual without family involvement 
may limit the effectiveness of treatment for two main reasons: 
it ignores the devastating impact of [substance use disorders] 
on the family system leaving family members untreated, and it 
does not recognize the family as a potential system of support 
for change.”). 
53 U.S. DEP’T HEALTH & HUMAN SERVS., supra note 9, at 4-16. 
54 The 2016 Surgeon General’s report observed: 
A typical progression for someone who 
has a severe substance use disorder might start 
with 3 to 7 days in a medically managed 
withdrawal program, followed by a 1- to 3-
month period of intensive rehabilitative care in 
a residential treatment program, followed by 
continuing care, first in an intensive outpatient 
program (2 to 5 days per week for a few 
months) and later in a traditional outpatient 
program that meets 1 to 2 times per month. For 
many patients whose current living situations 
are not conducive to recovery, outpatient 
services should be provided in conjunction with 
recovery-supportive housing.  
In general, patients with serious 
substance use disorders are recommended to 
stay engaged for at least 1 year in the 
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Treatment may include inpatient care, residential care 
outside a hospital setting, “partial hospitalization and 
intensive outpatient care,” and “outpatient services.”55 
Where appropriate, in order to increase the effectiveness 
of treatment, the patient’s family should be involved 
because it can provide “a potential system of support for 
change.”56  
 Treatment programs may involve medication and 
behavioral therapies.57 FDA approved medications might 
                                               
treatment process, which may involve 
participation in three to four different 
programs or services at reduced levels of 
intensity, all of which are ideally designed to 
help the patient prepare for continued self-
management after treatment ends. This 
expected trajectory of care explains why efforts 
to maintain patient motivation and 
engagement are important. 
Id. at 4-18. 
55 Id.  
56 Laura Lander, Janie Howsare & Marilyn Byrne, The Impact 
of Substance Use Disorders on Families and Children: From 
Theory to Practice, 28 SOC. WORK PUB. HEALTH 194, 195 (2013) 
(“Treating the individual without family involvement may 
limit the effectiveness of treatment for two main reasons: it 
ignores the devastating impact of [substance use disorders] on 
the family system leaving family members untreated, and it 
does not recognize the family as a potential system of support 
for change.”). 
57 U.S. DEP’T HEALTH & HUMAN SERVS., supra note 9, at 4-19 to 
-31. 
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include buprenorphine,58 methadone,59 or extended-
release naltrexone60 in treatment programs.61  Suboxone 
and Vivitrol are two frequently prescribed medications 
for treatment of opioid addiction. Suboxone, taken daily, 
contains buprenorphine hydrochloride and naloxone 
hydrochloride,62 while Vivitrol is delivered by an injection 
of naltrexone lasting twenty-eight days. Recent studies 
have found, once started, both medications are equally 
effective treatments for preventing relapse.63 Forty-three 
                                               
58 Following the introduction of buprenorphine, the number of 
opioid treatment programs “offering buprenorphine increased 
from 11 percent [of OTPs] in 2003 [(121 OTPs)] to 58 percent 
[of OTPs] in 2015 [(779 OTPs)].” Cathie E. Alderks, Trends in 
the Use of Methadone, Buphrenorphine, and Extended-Release 
Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 
(Update), SAMHSA: CBHSQ REP. (Substance Abuse & Mental 
Health Serv. Admin., Rockville, Md.) Aug. 22, 2017, 
https://www.samhsa.gov/data/sites/default/files/report_3192/ 
ShortReport-3192.pdf [https://perma.cc/7FD7-AN67]. Only 
about five percent of non-OTP facilities offered buprenorphine 
treatment in 2003; however, that number grew to twenty-one 
percent (2625 facilities) by 2015. Id.   
59 The Substance Abuse and Mental Health Services 
Administration has found that the number of patients who 
receive methadone treatment has “steadily increased from 
about 227,000 in 2003 to 356,843 in 2015” and “accounted for 
approximately 21 to 25 percent of all substance abuse 
treatment clients each year.” Id. 
60 “In 2013, 359 clients in facilities with OTPs and 3,422 clients 
in facilities without OTPs received extended-release, injectable 
naltrexone services, and in 2015, a total of 712 clients in 
facilities with OTPs and 6,323 clients in facilities without 
OTPs received these services.” Id. 
61 Spencer Bujarski et al., Prevalence, Causes, and Treatment 
of Substance Use Disorders, Judges J., Winter 2018, at 10, 14. 
62 Buprenorphine is an opioid that treats withdrawal 
symptoms, while naloxone is an opioid antagonist used to 
reverse opioid overdose. Id. 
63 See Joshua D. Lee et al., Comparative Effectiveness of 
Extended-Release Naltrexone Versus Buprenorphine-Naloxone 
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states limit daily total milligram dosages of 
buprenorphine and buprenorphine/naloxone combination 
drugs,64 while seven do not.65 
 Opioid treatment plans should be expected to 
include behavioral therapies that may involve only the 
individual; other plans may include family or group 
sessions.66 Therapies such as Cognitive Behavioral 
                                               
For Opioid Relapse Prevention (X:BOT): A Multicentre, Open-
Label, Randomised Controlled Trial, 391 THE LANCET 309, 317 
(2018); Lars Tatum et al., Effectiveness of Injectable Extended-
Release Naltrexone vs. Daily Buprenorphine-Naloxone for 
Opioid Dependence: A Randomized Clinical Noninferiority 
Trial, 74 JAMA PSYCHIATRY 1197 (2017).  
64 The following states have limits in place: AK, AL, AR, CA, 
CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, 
ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NV, NY, OH, 
OK, PA, TN, TX, UT, VA, VT, WA, WV, WY.CTR. FOR MEDICAID 
& CHIP SERVS., MEDICAID DRUG UTILIZATION REVIEW STATE 
COMPARISON/SUMMARY REPORT FFY 2016 ANNUAL REPORT: 
PRESCRIPTION DRUG FEE FOR SERVICE PROGRAMS 49 (2017), 
https://www.medicaid.gov/medicaid-chip-program-
information/by-topics/prescription-drugs/downloads/2016-dur-
summary-report.pdf [https://perma.cc/MM7V-BX2C]. 
65 The following seven states do not have these limits: HI, NM, 
OR, RI, SC, SD, WI. Id. 
66 U.S. DEP’T HEALTH & HUMAN SERVS., supra note 9, at 4-26. 
143
et al.: Symposium Issue 2018
Published by Trace: Tennessee Research and Creative Exchange, 2018
TENNESSEE JOURNAL OF LAW AND POLICY 
VOLUME 13 | SUMMER 2018 | SPECIAL EDITION 
 
 
[404] 
Therapy (“CBT”),67 Contingency Management (“CM”),68 
Community Reinforcement Approach (“CRA”),69 
                                               
67 The Surgeon General’s 2016 report explained CBT as follows: 
The theoretical foundation for Cognitive-
Behavioral Therapy (CBT) is that substance 
use disorders develop, in part, as a result of 
maladaptive behavior patterns and 
dysfunctional thoughts. CBT treatments thus 
involve techniques to modify such behaviors 
and improve coping skills by emphasizing the 
identification and modification of dysfunctional 
thinking. CBT is a short-term approach, 
usually involving 12 to 24 weekly individual 
sessions. These sessions typically explore the 
positive and negative consequences of 
substance use, and they use self-monitoring as 
a mechanism to recognize cravings and other 
situations that may lead the individual to 
relapse. They also help the individual develop 
coping strategies. 
Id. (citing H.D. KLEBER ET AL., PRACTICE GUIDELINE FOR THE 
TREATMENT OF PATIENTS WITH SUBSTANCE USE DISORDERS 42 
(2006)). 
68 Contingency Management involves awarding tangible items 
to patients to reinforce positive behavioral changes. Id. at 4-27 
(citing NAT’L INST. ON DRUG ABUSE, PRINCIPLES OF DRUG 
ADDICTION TREATMENT: A RESEARCH-BASED GUIDE (3d ed. 
2012)) (“In this therapy, patients receive a voucher with 
monetary value that can be exchanged for food items, healthy 
recreational options (e.g., movies), or other sought-after goods 
or services when they exhibit desired behavior such as drug-
free urine tests or participation in treatment activities.”).  
69 The Surgeon General 2016 report explained CRA as follows: 
Community Reinforcement Approach (CRA) 
Plus Vouchers is an intensive 24-week 
outpatient program that uses incentives and 
reinforcers to reward individuals who reduce 
their substance use. Individuals are required to 
attend one to two counseling sessions each 
week that emphasize improving relations, 
acquiring skills to minimize substance use, and 
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Motivational Enhancement Therapy (“MET”),70 the 
Matrix Model,71 Twelve-Step Facilitation therapy 
(“TSF”),72 and family therapies may be employed 
                                               
reconstructing social activities and networks to 
support recovery. Individuals receiving this 
treatment are eligible to receive vouchers with 
monetary value if they provide drug-free urine 
tests several times per week. 
Id. at 4-27 (endnotes omitted) (citing NAT’L INST. ON DRUG 
ABUSE, supra note 68). 
70 This counseling approach “uses motivational interviewing 
techniques to help individuals resolve any uncertainties they 
have about stopping their substance use. MET works by 
promoting empathy, developing patient awareness of the 
discrepancy between their goals and their unhealthy behavior, 
avoiding argument and confrontation, addressing resistance, 
and supporting self-efficacy to encourage motivation and 
change.” Id. at 4-28 (endnote omitted) (citing CTR. FOR 
SUBSTANCE ABUSE TREATMENT, TREATMENT IMPROVEMENT 
PROTOCOL SER. 35, ENHANCING MOTIVATION FOR CHANGE IN 
SUBSTANCE ABUSE TREATMENT, ch. 3 (1999)). 
71 The surgeon general’s 2016 report explained the Matrix 
Model:  
The Matrix Model is a structured, multi-
component behavioral treatment that consists 
of evidence-based practices, including relapse 
prevention, family therapy, group therapy, 
drug education, and self-help, delivered in a 
sequential and clinically coordinated manner. 
The model consists of 16 weeks of group 
sessions held three times per week, which 
combine CBT, family education, social support, 
individual counseling, and urine drug testing. 
Id. (endnote omitted) (citing NAT’L INST. ON DRUG ABUSE, supra 
note 68). 
72 TSF is “an individual therapy typically delivered in 12 
weekly sessions” and “designed to prepare individuals to 
understand, accept, and become engaged in . . . Narcotics 
Anonymous (NA), or similar 12-step programs.” Id. (citing 
Kimberly S. Walitzer et al., Facilitating Involvement in 
Alcoholics Anonymous During Outpatient Treatment: A 
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depending upon the individual and the severity and 
duration of the addiction.73  
 The Substance Abuse and Mental Health Services 
Administration (“SAMHSA”) is “the agency within the 
U.S. Department of Health and Human Services that 
leads public health efforts to advance the behavioral 
health of the nation” in order “to reduce the impact of 
substance abuse and mental illness on America’s 
communities.”74 The number of opioid treatment 
programs regulated by SAMHSA “increased from 
approximately 1,100 in 2003 to almost 1,500 by the end 
of 2016.”75  SAMHSA has compiled a National Directory 
of Drug and Alcohol Abuse Facilities that contains 
information on “federal, state, and local government 
facilities and private facilities that provide substance 
abuse treatment services,” including “codes that 
represent the services offered” by each facility listed.76 
                                               
Randomized Clinical Trial, 104 ADDICTION 391 (2009); L.A. 
Kaskutas et al., Effectiveness of Making Alcoholics Anonymous 
Easier: A Group Format 12-Step Facilitation Approach, 37 J. 
SUBSTANCE ABUSE TREATMENT 228 (2009)). 
73 Family therapies include family behavior therapy (“FBT”), 
which “is a therapeutic approach used for both adolescents and 
adults that addresses not only substance use but other issues 
the family may also be experiencing, such as mental disorders 
and family conflict. FBT includes up to 20 treatment sessions 
that focus on developing skills and setting behavioral goals.” 
Id. at 4-30 (endnote omitted) (citing NAT’L INST. ON DRUG 
ABUSE, supra note 68). 
74 About Us, SUBSTANCE ABUSE AND MENTAL HEALTH SERVICE 
ADMINISTRATION, https://www.samhsa.gov/about-us [https:// 
perma.cc/DLG3-KUWR]. 
75 Alderks, supra note 58. 
76 SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., 
BEHAVIORAL HEALTH SERVICES INFORMATION SERIES: 
NATIONAL DIRECTORY OF DRUG AND ALCOHOL ABUSE 
TREATMENT FACILITIES 2017, at iv (2017), https:// 
www.samhsa.gov/data/sites/default/files/2017%20SA%20Direc
tory.pdf [https://perma.cc/2U4Y-4SLV]. 
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SAMHSA also tracks the number of state admissions of 
patients for opioid treatment.77  
 For example, in 2011 in West Virginia, SAMHSA 
reported that 1,294 male and female patients over the 
age of twelve were admitted for treatment for opioid 
abuse.78 Of those West Virginia patients admitted for 
opioid abuse, ninety-nine percent were white, and eighty-
nine percent were between the ages of twenty to forty-
four.79 
 Obviously, before referring their clients to any 
treatment program, clinical law students and their 
supervising attorneys should know the applicable law as 
well as the rules, regulations, and requirements of each 
program. They also should identify and be aware of the 
recovery services each program provides as well as 
program treatment success and failure rates. In addition 
to connecting their clients with treatment programs 
                                               
77 Treatment Episode Data Set, SUBSTANCE ABUSE AND MENTAL 
HEALTH SERVICE ADMINISTRATION, CLIENT LEVEL DATA / 
TREATMENT EPISODE DATA SET, https://www.samhsa.gov/data/ 
data-we-collect/teds-treatment-episode-data-set [https://per 
ma.cc/ASZ6-K6DB]. 
78 SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., 
TREATMENT EPISODE DATA SET (TEDS) 2001–2011: STATE 
ADMISSIONS TO SUBSTANCE ABUSE TREATMENT SERVICES 134 
(2013), https://www.samhsa.gov/ data/sites/default/files/TE 
DS2011St_Web/TEDS2011St_Web/TEDS2011St_Web.pdf 
[https://perma.cc/Y6VZ-ARMX]. This number includes 158 
patients admitted for treatment of heroin addiction and 1,136 
for treatment for “other opiates.” Id. It is noteworthy that the 
total number of admissions for treatment for opioid abuse in 
Tennessee was more than triple of the admissions in West 
Virginia. In Tennessee, a total of 4,121 patients over the age of 
twelve were admitted for treatment of opioids in 2011, the 
substantial majority of which were white. Id. at 128. 
79 Id. The exclusive treatment of white people by West Virginia 
is problematic. It strongly suggests a need to analyze 
treatment programs to determine if barriers to access exist, 
and if they exist, whether they may be rooted in racial 
discrimination, poverty, racial preference or other factors. 
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through an MLP, the clinic’s supervising attorneys, law 
students, and staff also should be able to connect clients 
to community recovery support services that provide 
ongoing support during and after treatment. The 
students and their supervisors may consider obtaining a 
medical release from the client to enable them to consult 
with healthcare providers and to receive treatment 
updates that would allow them to support the client 
through the treatment and recovery process. 
 Opioid treatment programs work when the 
patients recognize they have a substance abuse problem 
and desire to overcome their addiction. For example, one 
CFAC client became addicted to prescription pain 
medication after she was injured in a car accident. As 
part of her treatment after the accident, the doctor 
prescribed pain medication as part of her treatment. She 
subsequently recognized that she had developed an 
opioid dependence and sought treatment for the sake of 
her children. She completed her treatment plan and 
continues to attend counseling sessions. She also 
continues to take Suboxone and will be medically 
evaluated to determine whether and when she should 
taper off of the drug.80 
 Thus, beyond their role of advising on legal 
strategy and litigating on behalf of their clients, law 
school clinics with established MLPs should work with 
their healthcare partners to ensure that— if available—
their clients will have access to treatment and will have 
                                               
80 As noted earlier, healthcare professionals debate whether 
recovering opioid addicts will need to take medications like 
Suboxone for life. Suboxone was originally proposed for short-
term use during the detoxification process. See NAT’L INST. ON 
DRUG ABUSE, supra note 44. However, Suboxone is also 
regarded as an opioid treatment with a “dark side” because of 
the health complications it can cause and because it is subject 
to abuse like other drugs. Deborah Sontag, Addiction 
Treatment With a Dark Side,  N.Y. TIMES, Nov. 17, 2013, at A1. 
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support to complete the program and the recovery 
process. 
 
C. Helping Clients and Other Party 
Litigants Cover the Cost of Treatment 
 
 Beyond these challenges of supporting addicted 
clients in seeking and obtaining treatment, the client will 
need assistance in identifying sources of financing 
treatment. Treatment costs vary based on a number of 
factors, but likely are expensive. Law school clinics like 
the CFAC represent clients who, because of their socio-
economic status, cannot afford to pay attorney fees; the 
financial ability to pay for addiction treatment programs 
is likely well beyond their reach.  
 Like the CFAC clients, the great majority of law 
school clinic clients probably have no private health 
insurance. Indeed, one study reported that in 2015 
almost “441,000 non-elderly adults with opioid addiction 
were uninsured.”81 That number likely understates the 
level of non-elderly uninsured opioid addicted patients. 
 The medications used for treating opioid addiction 
alone are costly. For example, the United States 
Department of Defense estimated that a patient 
receiving treatment in a certified opioid treatment 
                                               
81 Julia Zur, 6 Things to Know About Uninsured Adults with 
Opioid Addiction, KAISER FAMILY FOUND., https://www.kff.org/ 
uninsured/fact-sheet/6-things-to-know-about-uninsured-
adults-with-opioid-addiction/ [https://perma.cc/7T6H-AXMX]. 
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program82 using buprenorphine83 and requiring twice-
weekly visits could incur costs of “$115 per week or $5980 
per year.”84 Patients receiving treatment in a certified 
opioid treatment program using naltrexone and receiving 
related services could incur costs of “$1,176.50 per month 
or $14,112.00 per year.”85  
 State Medicaid programs have and hopefully will 
continue to play a key role in supporting opioid addiction 
treatment for those who cannot afford it.86 The most 
recent data from the Agency for Healthcare Research and 
Quality indicates that Medicaid expansion under the 
Affordable Care Act (“ACA”) significantly increased 
                                               
82 Certification of opioid treatment programs is governed by 
federal regulations. 42 C.F.R. § 8.1 (2016). Certified opioid 
treatment programs are overseen by SAMHSA’s Division of 
Pharmacologic Therapies. See generally Certification of Opioid 
Treatment Programs (OTPs), SUBSTANCE ABUSE & MENTAL 
HEALTH SERVS. ADMIN., https://www.samhsa.gov/medication-
assisted-treatment/opioid-treatment-programs 
[https://perma.cc/TX2M-EDUX]. 
83 Over a billion dollars’ worth of Suboxone are sold annually. 
In re Suboxone (Buprenorphine Hydrochloride and Naloxone) 
Antitrust Litig., 64 F. Supp. 2d 665, 673 (E.D. Pa. 2014). 
84 How Much Does Opioid Treatment Cost?, NAT’L INST. ON 
DRUG ABUSE, https://www.drugabuse.gov/publications/ 
research-reports/medications-to-treat-opioid-addiction/how-
much-does-opioid-treatment-cost [https://perma.cc/86GS-
6QX5] (citing TRICARE, Mental Health and Substance Use 
Disorder Treatment, 81 Fed. Reg. 61,068 (Sept. 2, 2016) 
(codified at 32 C.F.R. pt. 199),  https://www.federalregister.gov/ 
documents/2016/09/02/2016-21125/tricare-mental-health-and-
substance-use-disorder-treatment [https://perma.cc/4TQ8-
4YDX]). 
85 Id. 
86 Medicaid’s Role in Addressing the Opioid Epidemic, KAISER 
FAMILY FOUND., https://www.kff.org/infographic/medicaids-
role-in-addressing-opioid-epidemic/ [https://perma.cc/HZ9P-
FRK9]. 
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access to and coverage for opioid treatment.87 Medicaid 
expansion under the ACA now provides coverage for 
adults in some states who are suffering from opioid 
addiction that were not eligible for treatment under the 
previous state programs.88 According to data collected by 
the Kaiser Family Foundation, Medicaid covers four in 
ten “nonelderly adults with opioid addiction.”89 
 Under the expansion in West Virginia,90 Medicaid 
will cover inpatient or detox treatment, partial 
hospitalization, care coordination and case management, 
and prescription drugs like Suboxone.91 Starting in 
January of 2018, Medicaid expansion in West Virginia 
included “a new screening tool to identify treatment 
                                               
87 Matt Broaddus, Peggy Bailey, & Aviva Aron-Dine, Medicaid 
Expansion Dramatically Increased Coverage for People with 
Opioid-Use Disorders, Latest Data Show, CTR. ON BUDGET & 
POLICY PRIORITIES, https://www.cbpp.org/research/health/ 
medicaid-expansion-dramatically-increased-coverage-for-
people-with-opioid-use [https://perma.cc/RG5X-BGMB]. 
88 Id. 
89 Zur, supra note 81. The report recognizes “[t]hat number 
may become substantially larger as a result of the GOP’s 
efforts to restructure the Medicaid program through the 
American Health Care Act, which may decrease eligibility and 
coverage, setting back states’ efforts to address the epidemic.” 
Id. 
90 In October of 2017, the Centers for Medicare & Medicaid 
Services approved a waiver for West Virginia to help the state 
cover substance abuse treatment for more people. Press 
Release, W. Va. Dep’t of Health & Human Res., DHHR’s 
Medicaid Program to Expand Substance Use Treatment and 
Services (Oct. 10, 2017), https://dhhr.wv.gov/News/2017/Pages/ 
DHHR’s-Medicaid-Program-to-Expand-Substance-Use-Treat 
ment-and-Services.aspx [https://perma.cc/8QYR-7KTQ]. 
91 Press Release, W. Va. Dep’t Health & Human Res., DHHR 
Receives CMS Approval for Neonatal Abstinence Syndrome 
Treatment Services (Feb. 13, 2018),  https://dhhr.wv.gov/News/ 
2018/Pages/DHHR-Receives-CMS-approval-for-Neonatal-
Abstinence-Syndrome-Treatment-Services.aspx [https://per 
ma.cc/5XYF-HRUW]. 
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needs and Medicaid coverage for providing methadone for 
opioid addiction withdrawal.”92 The Medicaid expansion 
will also “allow West Virginia to cover methadone, 
naloxone, peer recovery support, withdrawal 
management, and short-term residential services to all 
Medicaid enrollees.”93   
 Significantly, West Virginia’s Medicaid will also 
cover the treatment costs of infants who are born to 
addicted mothers.94 The West Virginia Department of 
Health and Human Resources announced on February 
13, 2018, that its Bureau for Medical Services had 
received “approval from the U.S. Centers for Medicare 
and Medicaid Services (“CMS”) to offer Neonatal 
Abstinence Syndrome (“NAS”) treatment services. West 
Virginia is the first state in the nation to receive such an 
approval.”95 To treat their opioid withdrawal symptoms, 
the program will allow NAS babies to receive (1) a 
“[c]omprehensive assessment to determine a plan of 
care”; (2) “[l]ow or reduced stimulus environment, slow 
introduction to sensory stimulation (both site and 
sound)”; (3) “Pharmaceutical Withdrawal Management, 
with tapering protocol as referenced by the American 
Academy of Pediatrics”; and (4) Monitoring Withdrawal 
                                               
92 Associated Press, West Virginia Expands Medicaid Drug 
Treatment, WHSV (Harrisonburg, Va.), http://www.whsv.com/ 
content/news/West-Virginia-expands-Medicaid-drug-treat 
ment-469605873.html [https://perma.cc/NS3U-B57Q] (“The 
program waiver from the U.S. Centers for Medicare and 
Medicaid Services is more than 80 percent federally funded.”) 
93 W. Va. Dep’t of Health & Human Res., supra note 90.  
94 Associated Press, West Virginia Medicaid Will Now Cover 
Babies in Drug Rehab, MODERN HEALTHCARE (Feb. 14, 2018), 
http://www.modernhealthcare.com/article/20180214/NEWS/ 
180219963 [https://perma.cc/4L29-M232] (“The Centers for 
Disease Control and Prevention says the rate of babies born 
dependent on drugs in West Virginia was 33.4 per 1,000 
hospital births in 2013, the latest year available, compared 
with the national average of 5.8.”) 
95 W. Va. Dep’t Health & Human Res., supra note 91. 
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Objective Assessment, at least twice, daily.”96 In 
addition, the babies will receive non-pharmaceutical 
interventions such as “[t]herapeutic swaddling,” 
“[v]estibular stimulation/vertical rocking,” “C-position,” 
“[h]ead-to-toe movements,” “[c]lapping,” “[e]xercise to 
relieve gas discomfort,” and “[n]ewborn massage.”97 
 However, unlike West Virginia, access to 
treatment in other states is not increasing. The American 
Society of Addiction Medicine conducted a benefits 
survey of states, receiving responses from thirty-seven 
states.98 The survey revealed that “[c]overage for 
[Medically-Assisted Treatment] clearly depends on which 
state Medicaid agency, which medication and which 
official is involved, whether or not counseling and 
medical monitoring is covered and required.”99 Another 
study found “several clusters of counties with higher than 
average rates of opioid use disorder (OUD) and lower 
than average treatment admissions among [opioid 
treatment programs] that accept Medicaid . . . [in] 
Arkansas, Kentucky, Louisiana, Mississippi, and 
Tennessee.”100 
 Some states have sought and obtained grants to 
increase access to treatment services.101 Three-year grant 
                                               
96 Id. 
97 Id. 
98 AM. SOC’Y OF ADDICTION MED., ADVANCING ACCESS TO 
ADDICTION MEDICATIONS: IMPLICATIONS FOR OPIOID ADDICTION 
TREATMENT 21 (2013), http://www.asam.org/docs/advocacy/ 
implications-for-opioid-addiction-treatment [https://perma.cc/ 
YLR7-Y5WB]. 
99 Id. at 36. 
100 Amanda J. Abraham et al., Geographic Disparities in 
Availability of Opioid Use Disorder Treatment for Medicaid 
Enrollees, 53 HEALTH SERVS. RES. 389, 389 (2017). 
101 For example, Arkansas has obtained a grant from the 
SAMHSA Center for Substance Abuse Treatment to fund the 
Arkansas Access to Recovery Program: 
The initiative provides vouchers through the 
Arkansas Department of Human Services for 
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programs are available to “states with high rates of 
primary treatment admissions for heroin and opioids per 
capita.”102 SAMHSA has compiled state-by-state 
abstracts of “State Targeted Response to the Opioid 
Crisis (Opioid STR) Grant Awards.”103  
 Types of treatment programs available vary in 
each state that provides affordable or free treatment 
                                               
patients to purchase treatment for substance 
use disorders and for support services. The 
program's goal is to `expand capacity, support 
client choice, and increase the array of faith-
based and community-based providers for 
clinical treatment and recovery support 
services.’ Currently, the program provides 
vouchers that patients use to obtain treatment 
and support services in thirteen counties, 
including Benton, Craighead, Crawford, 
Faulkner, Garland, Independence, Jefferson, 
Lonoke, Pulaski, Saline, Sebastian, 
Washington, and White counties. A Care 
Coordinator assists each patient in obtaining 
the services needed. The funds support medical 
care, dental care, addiction treatment, mental 
health treatment, childcare, drug-free housing, 
life-skills training, peer coaching, and some 
other recovery services. 
Frankie M. Griffen, Prescription Opioids in Arkansas: Finding 
a Legislative Balance, 68 ARK. L. REV. 913, 952–53 (2016). 
102 State Grant Programs, SUBSTANCE ABUSE & MENTAL 
HEALTH SERVS. ADMIN., https://www.samhsa.gov/programs-
campaigns/medicat ion-assisted-treatment/training-materials-
resources/state-grant-programs#mat-pdoa [https://perma.cc/U 
B5R-TBXF]. 
103 State Targeted Response to the Opioid Crisis (Opioid STR) 
Grant Awards, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. 
ADMIN., https://www.samhsa.gov/sites/default/files/grants/.../ 
ti-17-014-opioid-str-abstracts.pdf [https://perma.cc/4NE7-
AWDC]. 
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services.104 Some programs provide “sliding scale 
treatment” where the fees charged are based upon a 
patient’s income and ability to pay. There are also non-
profit treatment centers that are able to provide free 
treatment or lower cost treatment because of their non-
profit status. Faith-based treatment programs are 
another alternative that may be a source of free 
treatment or may offer payment assistance for those who 
cannot afford treatment as part of their ministry 
services.105 Treatment programs are also available to 
veterans for free or at lower costs.106 Finally, most larger 
treatment programs offer payment assistance based 
upon need.  
 
D. Pro bono Representation by Clinical Law 
Students and Members of the Bar in Family 
Court.  
 
  People affected by the opioid epidemic enter the 
legal system in different ways. They may face criminal 
drug charges, allegations of abuse and neglect, or the loss 
of primary custody of their children by family court order.  
 Counsel is usually appointed in criminal cases 
and in abuse and neglect cases where the party cannot 
                                               
104 SAMHSA has a free national hotline that provides 
treatment referral and information services for families facing 
opioid addiction issues. The hotline refers those who have no 
insurance or are underinsured to state offices “responsible for 
state-funded treatment.” The hotline can also refer callers to 
treatment programs that charge on a sliding scale or that 
accept Medicaid and Medicare. National Helpline, SUBSTANCE 
ABUSE & MENTAL HEALTH SERVS. ADMIN., https://www. 
samhsa.gov/find-help/national-helpline [https://perma.cc/F5 
HH-HEUR]. 
105 See Griffen, supra note 101. 
106 See Substance Use Disorder (SUD) Program Locator, U.S. 
DEP’T OF VETERAN AFFAIRS, https://www.va.gov/directory/ 
guide/sud.asp [https://perma.cc/S3KM-8Q4B]. 
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afford counsel.107 Under the present system, many people 
affected by the opioid epidemic cannot afford the 
                                               
107 For example, criminal defendants in West Virginia may be 
eligible for court-appointed counsel: 
“A court of record may appoint counsel to assist 
an accused in criminal cases at any time upon 
request . . . In every case where the court 
appoints counsel for the accused and the 
accused presents an affidavit showing that he 
cannot pay therefor, the attorney so appointed 
shall be paid for his services and expenses in 
accordance with the provisions of article 
twenty-one, chapter twenty-nine of this Code.”  
W. Va. Code Ann. § 62-3-1 (2015). In addition, respondents in 
abuse and neglect cases in West Virginia have a right to 
counsel if they cannot afford one:  
(f) Right to counsel. – 
(1) In any proceeding under this article, the 
child, his or her parents and his or her legally 
established custodian or other persons 
standing in loco parentis to him or her has the 
right to be represented by counsel at every 
stage of the proceedings and shall be informed 
by the court of their right to be so represented 
and that if they cannot pay for the services of 
counsel, that counsel will be appointed. 
(2) Counsel shall be appointed in the initial 
order. For parents, legal guardians, and other 
persons standing in loco parentis, the 
representation may only continue after the 
first appearance if the parent or other persons 
standing in loco parentis cannot pay for the 
services of counsel. 
(3) Counsel for other parties shall only be 
appointed upon request for appointment of 
counsel. If the requesting parties have not 
retained counsel and cannot pay for the 
services of counsel, the court shall, by order 
entered of record, appoint an attorney or 
attorneys to represent the other party or 
parties and so inform the parties. 
156
Tennessee Journal of Law and Policy, Vol. 13, Iss. 3 [2018], Art. 1
https://trace.tennessee.edu/tjlp/vol13/iss3/1
DEFINING THE ROLE  
13 TENN. J.L. & POL’Y 377 (2018) 
 
 
[417] 
assistance of legal counsel when they become involved in 
family court proceedings, and there is no constitutionally 
or statutorily-based right to court-appointed counsel in 
family court custody cases. Therefore, if the adults in 
these family court matters desire the assistance of 
lawyers, they generally have no alternative but to seek 
pro bono legal services from legal aid and law school 
clinics. 
 It is axiomatic that the best interests of children 
in family court cases are served when parents suffering 
from addiction are connected with treatment services and 
are provided legal representation in their custody 
matters. Under Rule 6.1 of the Model Rules of 
Professional Conduct, the family court could and should 
call upon private-sector attorneys to undertake pro bono 
representation of individuals struggling with opioid 
addiction who face losing visitation rights or custody of 
their children in family court.108 Rule 6.1 of the Model 
Rules of Professional Conduct recognizes that “[e]very 
lawyer has a professional responsibility to provide legal 
services to those unable to pay.”109 To fulfill their ethical 
responsibilities, law school clinicians, clinical law 
students, and members of the bar in private practice 
should be strongly encouraged to provide legal services to 
persons of limited means in such family court cases 
where addiction lies at the root of a family’s legal 
problems.  
 For lawyers who are not schooled in family court 
issues or otherwise unable to provide pro bono 
representation to clients for practical reasons, Rule 6.1 
provides that they can participate “in activities for 
improving the law [or] the legal system” as it relates to 
                                               
W. VA. CODE ANN. § 49-4-601(f) (2015). 
108 MODEL RULES OF PROF’L CONDUCT r. 6.1 (AM. BAR ASS’N 
1983).  
109 Id.   
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opioid addiction and treatment.110 “Because the provision 
of pro bono services is a professional responsibility, it is 
the individual ethical commitment of each lawyer.”111 
Despite this “ethical commitment,” the provision of pro 
bono services has only been mandated in one state.112 
 Many lawyers may be hesitant to commit to pro 
bono representation in cases involving parties or clients 
suffering from opioid addiction because it may prove 
difficult and/or require prolonged services. A lawyer 
volunteering to represent a client experiencing addiction 
to opioids undertakes what is a difficult, but exceedingly 
important assignment. She should be fully aware of the 
potential difficulties that such representation may 
present: the client may have an underlying untreated 
psychiatric disorder that led to the addiction; the client 
may be in denial about his addiction and the impact it is 
having on the family; the client may not be able to 
comprehend the severity of the situation he faces; and the 
client’s addiction may impair his ability to participate 
effectively in the case. Lawyering in such circumstances 
can present considerable challenges not faced by many in 
private civil practice, but such work is honorable and 
provides a vital public service. 
 Legal aid lawyers and clinical law students 
already provide pro bono legal services in family court 
                                               
110 Id. One author has described this provision as a “loophole to 
excuse them from doing pro bono work.” Spencer Rand, A 
Poverty of Representation: The Attorney’s Role to Advocate for 
the Powerless, 13 TEX. WESLEYAN L. REV. 545, 565 (2007). 
111 Id. at cmt. 9. 
112 Only New Jersey requires practitioners to perform some 
form of pro bono work. Lydia Chan, New York’s New Rule: A 
Novel Approach to Closing the Access to Justice Gap, 26 GEO. 
J. LEGAL ETHICS 597, 600, 610 (2013) (citing Deborah L. Rhode, 
Cultures of Commitment: Pro Bono for Lawyers and Law 
Students, 67 FORDHAM L. REV. 2415, 2418 (1999)). See also 
Cory H. Morris, Access to Justice, Observations and Thoughts 
from the Incubator—A New York State of Mind, 83 UMKC L. 
Rev. 883, 884 (2015).  
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cases involving substance abuse issues. Moreover, many 
state bars, as in West Virginia, have established pro bono 
assistance projects.113 However, because the opioid 
epidemic is fracturing families and increasing caseloads, 
family courts should identify and compile a list of 
attorneys who are willing to work pro bono specifically in 
family court cases where addiction and custody are at 
issue.114 Recognition is needed for a specialized bar of pro 
bono attorneys who are willing to take on cases where the 
need to help the addiction-afflicted family is great, the 
                                               
113 For example, West Virginia has established the Pro Bono 
Referral Project.  
The State Bar approved an aspirational goal 
for each active practicing lawyer in West 
Virginia to provide 20 hours of legal work to 
assist our low-income men, women and 
children. The legal aid programs at that time—
there were four of them— agreed to work with 
the State Bar in setting up the program. The 
legal aid offices would determine the financial 
eligibility of our citizens, ascertain if the legal 
case was a priority matter and match a 
volunteer lawyer with the case to handle the 
legal responsibilities. The Pro Bono Referral 
Project was born.  
Thomas R. Tinder, The Tinder Box: A Case in Point, W. VA. 
LAW., Sept./Oct. 2005, at 46, 46. The American Bar Association 
has an online state-by-state directory of pro bono legal 
programs:  https://www.americanbar.org/portals/public_re 
sources/aba_home_front/directory_programs.html [https://per 
ma.cc/YB5M-RG2L]. 
114 Attorneys who volunteer for such pro bono representation 
would have to be those that the family court can rely upon to 
provide the same quality of representation that they give their 
paying clients. See Barbara Graves-Poller, Is Pro Bono Practice 
in Legal “Backwaters” Beyond the Scope of the Model Rules?, 13 
U.N.H. L. REV. 1, 5–6 (2015). 
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work is challenging, and the attainability of the goals is 
uncertain.115  
 
E. Educating Law Students About 
Counseling Clients with Substance Abuse 
Issues and About Educating Themselves. 
 
 Finally, as part of the seminar component of 
family law clinics, students should be educated about 
substance abuse and its origins so that they may counsel 
their clients where such a role is appropriate. Students 
can be trained by attending live or videotaped lectures 
and presentations on substance abuse treatment offered 
by their medical-legal partners, like Chestnut Ridge and 
WVU Pediatrics referenced above. As part of such 
training, clinicians should assign students research 
projects on treatment options and programs, as well as 
identification of funding for treatment of clients who 
cannot otherwise afford it. 
 Typically, at the beginning of the first semester of 
the clinic’s training component, students should learn the 
skills necessary to effectively interview clients who are 
addicts or are affected by addiction in the context of their 
family. As part of this process, students should also learn 
how to ask the right questions to gauge whether and to 
what extent substance abuse is an issue. Further, 
students should be sensitive to their potential clients’ 
responses, family situation, and needs.  
 Clinic law students should communicate with 
community programs helping those with substance abuse 
disorders and develop working relationships with 
programs providing recovery services. Additionally, 
                                               
115 This would not be the first occasion for a specialized pro 
bono bar to be created to meet a crucial need. See, e.g., Barbara 
Hart, DV and the Law: Creating a DV Bar, NAT’L BULL. ON 
DOMESTIC VIOLENCE PREVENTION, Feb. 2017, at 4; Chandlee 
Johnson Kuhn, Pro Bono Work in the Family Court, 23 DEL. 
LAW. 28, 28 (2005).  
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students should develop a list of local treatment facilities 
and community programs, become familiar with the 
services they provide, and update the list each year. 
Students should also have information available to 
provide to their clients regarding programs such as 
Alcoholics Anonymous and Narcotics Anonymous. Of 
course, it goes without saying that clinical faculty should 
supervise such tasks assigned to law students. 
 As part of the clinical law seminar, clinicians can 
invite guest speakers, including drug court and family 
court judges, healthcare professionals, and community 
service providers to speak with their students and engage 
them in a dialogue about mutual professional 
responsibilities to the families who are the focus of 
clinical efforts. 
 Clinical law students also could organize 
continuing legal education seminars for practitioners and 
other law students to educate them on state-of-the-art 
treatment, developing trends in the family court system 
for addressing opioid addiction, as well as information 
relating to clients’ access to treatment while they help 
them resolve their legal issues.116 
 Drug courts may also have a need for pro bono 
assistance by clinical law students.117 To determine 
                                               
116 For example, clinical law students could organize a 
continuing legal education seminar on representing impaired 
clients. See Annemarie E. Kill, Representing Impaired Clients: 
Challenge and Opportunity, THE CATALYST, Mar. 2009, at 10 
https://www.isba.org/committees/women/newsletter/2009/03/ 
representingimpairedclientschalleng [https://perma.cc/9GLA-
Z7X R]. 
117 Law schools have externship programs where law students 
are exposed to drug courts. See, e.g., Gregory Baker & Jennifer 
Zawid, The Birth of a Therapeutic Courts Externship Program: 
Hard Labor but Worth the Effort, 17 ST. THOMAS L. REV. 711 
(2005). Some clinical law programs represent clients in drug 
court. See, e.g., Tamar M. Meekins, Risky Business: Criminal 
Specialty Courts and the Ethical Obligations of the Zealous 
Criminal Defender, 12 BERKELEY J. CRIM. L. 75, 75 n.2 (2007). 
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whether the need exists, clinical law supervisors could 
obtain approval from judges to allow students to observe 
juvenile drug and adult drug court.118 Because of their 
closer proximity in age, clinical law students may be 
uniquely able to help youth entangled in juvenile drug 
court,119 many of whom have been subjected to adverse 
childhood experiences.120 Should the court determine a 
                                               
118 Incarceration alone is not the solution to drug-addicted 
offenders. There is evidence that in-prison treatment for those 
who are not diverted to drug court can decrease opioid abuse 
and “reduce associated criminal behavior.” Redonna K. 
Chandler, Bennett W. Fletcher & Nora D. Volkov, Treating 
Drug Abuse and Addiction in the Criminal Justice System: 
Improving Public Health and Safety, 301 JAMA 183 (2009), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681083/ 
[https://perma.cc/BM2X-5PVG]; see also Catherine D. McKay, 
Steven T. Davis & Adam Taylor, Confronting Delaware’s 
Heroin Epidemic: In-Prison Treatment, Methadone 
Maintenance and Providing Post-Release Support and 
Counseling Can Reduce Recidivism and Discourage a Return to 
Addiction, DEL. LAW.,  Spring2015, at 14. 
119 In addition to helping resolve their legal issues, law 
students could serve as positive adult role models and help 
these youthful offenders recognize their potential and set goals 
for the future. See generally SCOTT BERNARD PETERSON, 
TEEN/YOUTH COURT PROGRAMS AND MENTORING: THE 
REFERRAL STAGE (2018), 
https://www.globalyouthjustice.org/wp-content/uploads/sites/ 
19/2018/01/Teen_Court_and_Mentoring_TA.pdf [https://per 
ma.cc/N3ZZ-46NP]. 
120 The Office of Juvenile Justice and Delinquency Prevention 
conducted a study examining the prevalence of adverse 
childhood experiences and their negative repercussions among 
youth involved with the juvenile justice system in Florida. 
Michael Baglivio et al., The Prevalence of Adverse Childhood 
Experiences (ACE) in the Lives of Juvenile Offenders, J. JUV. 
JUST., Spring 2014, at 1, https:// www.researchgate.net/ 
publication/284889607_The_prevalence_of_Adverse_Childhoo
d_Experiences_ACE_in_the_lives_of_juvenile_offenders 
[https://perma.cc/Y6FT-7R7B]. The study found that the 
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need, clinical law students could supplement the list of 
pro bono attorneys volunteering their time. This 
representation should include encouraging and helping 
youth obtain treatment and counseling to address their 
drug abuse and the ACEs that may have led them to 
experiment with opioids in the first place. 
 
III. Conclusion 
 
 Clearly, children’s best interests are not served 
when they are in the care of parents impaired by opioid 
addiction. Few would dispute that parents’ opioid 
addiction can lead to custody disputes that cause scarring 
adverse childhood experiences for the children in their 
care. Nor would many disagree the proposition that 
medication-assisted treatment, behavior counseling, and 
community support for opioid-affected families can help 
them ultimately remain together in a healthy home 
environment. Legal and healthcare partners who 
collaborate in medical-legal partnerships hopefully 
would agree that combining their resources and working 
together to provide access to treatment and recovery can 
lead to positive, long-term outcomes for clients and 
patients. Moreover, attorneys should appreciate and 
embrace the ethical and moral dimensions attendant 
providing wise counsel and legal assistance to opioid-
impaired clients who seek treatment and long-term 
recovery. 
 Clinical law students and pro bono family court 
attorneys have the opportunity to identify resources 
available to clients for treatment and counseling and to 
identify programs that clients can afford that will 
motivate them to engage in the long-term process of 
recovery. As a practical matter, clients in family court 
will have to desire treatment if they are to have a realistic 
hope of recovery. While the availability of affordable 
                                               
number of ACEs of youths in the juvenile justice system in 
Florida is higher than the general youth population. Id. 
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treatment and counseling will present serious challenges 
to client and attorney alike, the greatest challenge is 
likely to be the ability of the parents or other addicted 
caregivers to summon their inner strength and resolve to 
overcome their opioid affliction for the sake of their 
children and families. 
 The Rules of Professional Conduct should, in my 
view, be interpreted as imposing an ethical responsibility 
on student attorneys and their supervisors to counsel and 
assist clients who are struggling with addiction but 
willing to do what is necessary to heal their children and 
their families. Notwithstanding whether such a formal 
ethical duty flows from the Rules of Professional 
Conduct, it surely is a higher calling for clinical law 
programs to explore all available options within their 
charters to add their professional expertise to the 
exceedingly important struggle to bring the nationwide 
opioid epidemic under control. Helping to restore families 
shattered by the opioid-fed crisis and protecting innocent 
children ensnared as the collateral damage of addiction 
can be empowering to law students and their institutions 
and bring honor to our profession. 
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distributors. In those cases, the State plaintiff had sought 
damages for the drug companies’ alleged complicity in the 
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public disclosure of DEA prescription opioid distribution 
information contained in sealed court records. Using this 
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overdose death rates in the country.” 
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Abstract 
 
The U.S. Center for Disease Control reports that 
from 1999–2016 more than 350,000 people died from 
overdoses involving prescription and/or illicit opioids. In 
2016 alone, deaths from prescription opioids and illegal 
opioids like heroin and illicitly manufactured fentanyl 
totaled almost 42,000. The number of overdose deaths 
involving opioids was 5 times higher in 2016 than in 
1999. On average, 115 Americans die every day from an 
opioid overdose. In this article, Professor McGinley 
examines the evolution of the nationwide opioid epidemic 
over the last two decades focusing on the role played by 
drug manufacturers, drug distributors and the U.S. Drug 
Enforcement Administration in the flood of literally 
billions of “legal” prescription opioid pills inundating 
communities across the nation. 
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